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Endothelial dysfunction plays a pivotal role in the development and progression of 
atherosclerosis. Atherogenic risk factors harbor the potential to injure the endothelial layer by 
promoting apoptosis, preceded by an inflammatory reaction in the vessel wall. The 
maintenance of the endothelial layer is therefore crucial to ensure its integrity. More recent 
studies suggest an important role of endothelial progenitor cells (EPCs) in contributing 
towards reendothelialization after vascular injury. These EPCs home to sites of hypoxia or 
ischemia and take part in vascular repair. Recent studies have shown that a rare population of 
EPCs called endothelial colony forming cells or ECFCs can be derived from peripheral and 
cord blood and can be transplanted into immunodeficient mice that have demonstrated the 
ability to form chimeric blood vessels. Hyperoxia has been shown to be a model of mild 
oxidative stress, and this oxidative stress is characterized by an increase in reactive oxygen 
species (ROS) levels that can lead to a wide range of chemical reactions resulting in cellular 
necrosis and apoptosis through lipid peroxidation and DNA damage. We therefore proposed 
that by growing endothelial cells in vitro in hyperoxic conditions can in turn lead to cellular 
damage and activation of pro inflammatory markers in these cells. PGC-1α belongs to a small 
family of transcriptional coactivators which have been shown to regulate reactive oxygen 
species generation and apoptosis in mature endothelial cells. The mechanisms through which 
PGC-1α activates gene expression are poorly understood. This study aims at identifying a 
molecular signature of human endothelial progenitor cells (ECFCs) so that they can be 
distinguished from mature endothelial cells (HUVEC) and identifying the role of PGC-1α 
and its downstream targets when these endothelial progenitors and mature endothelial cells 
are exposed to oxidative stress. In order to achieve that goal we isolated endothelial colony 
forming cells and mature endothelial cells from the same donor. This was followed by their 
molecular profiling at mRNA level using qPCR and at protein level using 
immunofluorescence and FACS analysis. Cells were grown till late passages to study the 
growth kinetics of ECFCs and HUVEC in normoxia and hyperoxia. Telomerase activity was 
measured using TRAP assay and telomere length measurement was done using flow FISH. 
Low density array was carried out in order to distinguish between ECFCs and HUVEC in 
terms of gene expression analysis. The results showed that ECFCs were distinguished from 
early EPCs and HUVEC. PGC-1 alpha levels were up regulated in ECFCs when exposed to 
hyperoxia and this in turn activated several other genes that are involved in angiogenesis, 
oxidative phosphorylation and electron transport chain. ECFCs and HUVEC have shown to 
behave differently under conditions of oxidative stress and we found ECFCs to be more 
resistant to stress than HUVEC as shown in their growth kinetics. 
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Chapter 1. Introduction 
 
1.1 Origin of the human vascular system  
The formation of a human vascular network can occur through vasculogenesis or 
angiogenesis, which are two mutually non-exclusive processes (Jain, 2003). Angiogenesis 
refers to sprouting of vessels from pre-existing vessels and plays a vital role in wide variety 
of pathological and physiological conditions in post natal life (Folkman, 1995; Morin and 
Tranquillo, 2013). This process is crucial to the maintenance of many physiological and 
pathological phenomenon that includes development of an embryo, carcinogenesis, wound 
healing, diabetes and several ocular disorders (Carmeliet and Jain, 2000; Carmeliet, 2005; 
Carmeliet and Jain, 2011; Zheng et al., 2013). These newly formed capillaries lead to the 
formation of a complex vascular network that eventually penetrates the tissue and provides 
direct oxygen and nutrient supply. Angiogenesis is characterized by three successive events 
before blood supply to the tissue ensues. These include initiation, extension and maturation, 
(Mantzaris et al., 2004) a brief description of which is presented below.  
In fully mature blood vessels, endothelial cells (ECs) are encapsulated by mural cells that 
include pericytes. These ECs are maintained in a resting state by continuous secretion of 
angiopoietin-1 (Augustin et al., 2009). In pathological conditions such as vascular injury this 
quiescent state is subjected to alteration by cell surface binding of proangiogenic growth 
factors mainly vascular endothelial growth factor (VEGF). This binding of VEGF results in 
production and release of angiopoietin-2 which in turn leads to activation of endothelial cells 
by detachment of mural cells so that they can move towards source of VEGF (Hegen et al., 
2004; Matsushita et al., 2005; Jang et al., 2009).  
Endothelial cells migrate through the extra cellular matrix (ECM) and remain attached to 
each other forming a new capillary bed. The tip cells perform the function of extending the 
capillary, while the stalk cells continue to proliferate adding cells to the growing sprout 
(Gerhardt et al., 2003). Endothelial cell migration and proliferation are therefore considered 
to be two of the most important steps in capillary extension (De Smet et al., 2009). 
Endothelial cells release platelet derived growth factor-B (PDGF-B) during advanced stages 
of vascular development that leads to the proliferation of pericytes and their migration 
(Gaengel et al., 2009). This is followed by pericyte production of angiopoetin-1 and  as a 
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result of that, ECs switch back towards the resting state and the capillary is stabilized 
(Augustin et al., 2009).     
On the other hand, vasculogenesis is the process in which primitive vascular networks are 
formed from angioblasts or endothelial progenitor cells (EPCs) that differentiate and give rise 
to endothelial cells (Jain 2003). During embryonic development, haematopoietic stem cells 
(HSCs) form blood whereas the endothelial progenitor cells form blood vessels in a highly 
coordinated manner. There is strong evidence shown in mammals, as shown in figure 1.1, 
that HSCs originate from a common precursor, the hemangioblast or from hemogenic 
endothelium by a process termed as endothelial-haematopoietic transition (Tavian et al., 
1996; Kattman et al., 2006; Eilken et al., 2009; Lancrin et al., 2009; Bertrand et al., 2010; 
Boisset et al., 2010; Kissa and Herbomel, 2010). Despite extensive studies, the steps involved 
in lineage development from endothelial progenitor cells to mature endothelial cells and their 
site of origin in humans postnatally still remain less well-defined (Yoder and Ingram, 2009). 
EPCs are found in umbilical cord blood, peripheral blood, bone marrow and vessel walls. 
Umbilical cord blood is known to be a rich source of these cells, and show high levels of 
CD133 and CD34 positive cells, same as in the peripheral blood of adults (Ingram et al., 
2004).                                                 
 
Figure1.1. Illustrating the proposed development programme of endothelial cells. Endothelial and 
hematopoietic stem cells originating from a common precursor, the hemangioblast.  
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1.2 Postnatal vasculogenesis in humans  
Postnatal vasculogenesis was always believed to occur by angiogenesis, until this dogma was 
challenged by Asahara and colleagues (1997). They showed for the first time that peripheral 
blood mononuclear cells (PBMNCs) could be differentiated into potential endothelial cells 
and can become incorporated at neovascularisation sites in ischemic animal models. After 
this, several studies indicated that these putative human EPCs could be differentiated in vitro 
into endothelial cells and could be incorporated at sites of active angiogenesis in NOD/SCID 
bone marrow transplantation models (Kalka et al., 2000a). These human EPCs were also 
shown to be mobilized in to the peripheral blood in response to ischemia by cytokines 
(Takahashi et al., 1999). Lin et al. showed that in allogeneic bone marrow-transplanted 
patients, the CD14ˉ cell population led to the production of late-outgrowth endothelial cell 
colonies in culture and proposed that EPCs could originate from existing vessel walls or may 
be from transplanted marrow itself (Lin et al., 2000). Endothelial precursor cells derived from 
bone marrow that were positive for Tie-2 showed postnatal induction of revascularization in 
an in vivo graded model of ischemia (Tepper et al., 2005). This proposed that cells of 
monocytic lineage could be the source of endothelial progenitors or of proangiogenic cells 
that were named as circulating angiogenic cells (CACs). 
Hill et al. proposed a clonogenic colony- forming unit „endothelial cell‟ (CFU-EC or CFU-
Hill) assay and demonstrated that there exists an inverse relationship between cardiovascular 
risk factors and number of CFU-Hill in human peripheral blood (Hill et al., 2003). But these 
cells again were classified as EPCs on the basis of expression of biomarkers such as CD31, 
CD105, CD144, CD146, CD309 and vWF, which are not specific for endothelial cell lineage. 
For instance, CD144 shows expression on foetal HSCs in both mouse and human (Fleming, 
2005; Oberlin et al., 2010). Recently, it has been shown that CD34
+
 CD45
+
 CD144
+
 cells in 
human foetal liver were able to produce hematopoietic cells but failed to give rise to 
endothelial cells (Oberlin et al. 2010). The EPCs derived by the Hill method also showed the 
expression of specific hematopoietic markers like CD14 and CD45, and demonstrated the 
uptake of AcLDL (acetylated low-density lipoprotein), a known function of macrophages and 
some endothelial cells (Yoder et al., 2007). These human cells did not form secondary 
colonies on replating and did not form chimeric vessels when transplanted into mice. They 
were shown to be clonally distinct from the endothelial colony forming cells (ECFCs) as 
shown by JAK-2 mutational analysis of cell sets (Yoder et al. 2007). Several recent studies 
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have confirmed that CFU-Hill derived cells are of monocytic/hematopoietic origin, and might 
also contain T cells (Critser and Yoder, 2010; Steinmetz et al., 2010).  
Elsheikh et al. proposed that a common monocytic-endothelial progenitor might exist. They 
identified a subset of CD14 and CD309/VEGF-2 expressing human peripheral blood 
monocytes (2% of CD14 expressing cells) and showed that they could contribute to 
revascularization in an in vivo tissue damage model (Elsheikh et al., 2005). Similarly, 
CD202b/Tie-2 and VEGF-2 expressing cells in monocytes of the peripheral blood were 
identified as proangiogenic cells and were recruited to tumours, where they lead to 
enhancement of vessel growth in these tumours but failed to differentiate in to endothelial 
cells (De Palma et al., 2007; Venneri et al., 2007; Patel et al., 2013). In summary, bone 
marrow derived monocytic subsets of cells that express biomarkers found on endothelial cells 
can promote neovascularisation, but their transcriptomic and proteomic analysis clusters them 
more with the monocytic cells, and they or their myeloid progenitors can never differentiate 
towards endothelial lineage (Watt and Fox, 2005; Rohde et al., 2006; Purhonen et al., 2008; 
Pearson, 2009; Critser and Yoder, 2010; Fantin et al., 2010; Medina et al., 2010b). 
 
 
1.3 Human endothelial progenitor cells (EPCs) 
Endothelial progenitor cells (EPCs) are progenitor cells that are considered to be unipotent 
cells, in contrast to other stem cells that are usually pluripotent. EPCs have been a matter of 
debate for a long time, and their role in postnatal vasculogenesis and angiogenesis still 
remains controversial, simply because of discrepancies in their identification. To this date, 
there is no unique marker that can identify EPCs, and it has been widely recognized now that 
the bio-markers that have been used over the years for characterizing EPCs have not been 
exclusive to the endothelium and have shown expression on other cell lineages (Crister and 
Yoder 2010). 
There has always been some controversy regarding the nomenclature used to define EPCs. 
Richardson and Yoder have recently suggested a revised terminology for different types of 
cells based on the expression or absence of certain well known markers that have been used 
to define endothelial cells (Richardson and Yoder, 2011). A brief description of these cell 
types along with the revised nomenclature is described below. 
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1.3.1 Isolation of proangiogenic or early endothelial progenitor cells (EPCs) 
Human circulating endothelial progenitor cells called CECs, CACs or CEPs or collectively as 
EPCs mainly represent the mature non-proliferative endothelial cells that in response to tissue 
damage are sloughed-off from the blood vessels (CECs) or proangiogenic cells of myeloid or 
monocytic lineage (CACs, CEPs, EPC). Both these varieties of cells are not considered the 
true EPCs and are mostly considered to be part of hematopoietic lineage. CECs have been 
reported to be increased in blood of patients with burns or cancers (Duda et al., 2007; Fox et 
al., 2008b; Lowndes et al., 2008; Strijbos et al., 2009). Phenotypically they are supposed to 
be similar to ECFCs, but they are non-proliferative mature viable endothelial cells. They 
express CD34, CD31, CD105, and CD146 and are negative for CD45 (Mancuso and 
Bertolini, 2010). Similarly, proangiogenic haemopoietic cells are defined as those that are 
positive for CD34, CD31, VEGF2, Tie2, CD45 and AcLDL uptake, but negative for CD14 
(Hirschi et al., 2008). They represent the cells for which the term EPC has been used before 
by several groups (Asahara et al. 1998; Kalka et al 2000). They also include previously 
described CFU-Hill cells that are positive for CD31, VEGF2 and Tie2, formed myeloid 
colonies in vitro and could be distinguished from ECFCs by lack of expression of BMP2 and 
BMP4 (Hill et al., 2003; Smadja et al., 2008). Similarly, cells expressing CD34, CD45, 
CD133 and CD31 have been shown to belong to hematopoietic lineage, and most likely 
represent the cells previously classified as CACs (Estes et al. 2010). 
 
1.3.2 Isolation of human endothelial colony forming cells (ECFCs) 
Endothelial colony forming cells (ECFCs) represent EPCs with differing proliferative 
potential, and although they are believed to be synonymous with the late outgrowth 
endothelial cells, their relationship with endothelial stem cells still remains unclear. Yoder et 
al. (2007) were the first group to analyse the proliferative potential of human ECFCs in 
clonogenic assays in vitro. This assay included plating of ECFCs in collagen-coated plates 
and the number of colonies developed over 14 days were enumerated. The developing cells 
displayed a typical cobblestone morphology shown in figure 1.2, and showed differing 
proliferative potential, with high proliferative potential colony-forming cells (HPP-ECFCs) 
giving rise to low proliferative potential colony-forming cells (LPP-ECFCs) and finally to 
mature non-dividing endothelial cells. The LPP-ECFCs formed colonies of less than 2000 
cells, and failed to form colonies on replating, whereas HPP-ECFCs formed colonies 
containing greater than 2000 cells and formed at least secondary colonies. Those forming 
tertiary colonies were proposed to have much higher proliferative potential (Melero-Martin et 
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al., 2007; Melero-Martin et al., 2008; Reinisch et al., 2009; Melero-Martin et al., 2010). The 
cells that showed high proliferative potential possessed the ability to form vascular tubes in 
vitro (Zhang et al., 2009a) had high levels of telomerase activity (Yoder et al. 2007) and 
could be incorporated in to the vascular endothelium or in matrigel in vivo immunodeficient 
vasculogenic models (Kung et al., 2008; Yoder and Ingram, 2009). Several phenotypic 
studies combined with culture assays have indicated that ECFC levels are several fold higher 
in human umbilical cord blood at birth than in adult peripheral blood from a normal donor, 
suggesting the former to be a much richer source of ECFCs (Watt et al., 1980; Estes et al., 
2010). According to the revised criteria ECFCs are now classified as cells that are 
proliferative and form day 14 endothelial colonies with more than 50 cells and are positive 
for CD34, CD31, CD105, CD146 and negative for CD133, CD45, CD14, CD41a and 
CD235a (Richardson and Yoder  2010).  
 
 
Figure 1.2. Schematic representation of different approaches used to isolate EPCs. Adapted from 
(Prater et al., 2007). 
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1.4 Role of EPCs and angiogenic factors in neovascularization in humans 
It has been shown that human blood consists of a small proportion of circulating 
hematopoietic stem cells (HSCs) and much more hematopoietic progenitor cells which are 
already committed to erythroid lineage (Ho et al., 1998; Cheung et al., 2007). It has been 
proposed that these circulating hematopoietic progenitors are remnants of stem/progenitor 
cell pool formed during embryonic development. Another view is that these circulating 
progenitors have the ability to rapidly enter the tissues or bone marrow in response to 
haematological stress, thereby allowing their maturation leading to oxygen delivery to tissues 
when required (Watt et al., 2010). Similarly, human non hematopoietic stem/progenitor cells 
including endothelial colony forming cells (ECFCs) and mesenchymal stem cells (MSCs) are 
found in adult peripheral blood in low counts under homeostatic conditions (He et al., 2007; 
Salem and Thiemermann, 2010; Yoder, 2010). It has also been shown that these ECFCs 
along with MSCs and HSCs reside in the bone marrow postnatally and are associated with 
vascular niche and can be released into the blood in response to ischemia or under the 
influence of angiogenic growth factors (Ergün et al., 2007; Watt and Forde, 2008; 
Campagnolo et al., 2010; Klein et al., 2010; Lymperi et al., 2010).  
 
 
1.5 Proangiogenic factors and their role in vascular inflammation  
One of the most important angiogenic factors that play a vital role in angiogenesis is vascular 
endothelial growth factor (VEGF). It has been shown that patients with coronary artery 
bypass grafting and burn injuries show an increased level of VEGF in plasma for 6-12 hr 
which is linked with a concomitant mobilization of proangiogenic cells in the blood stream 
along with circulating late out growth endothelial cells (Watt et al., 2010). It has recently 
been demonstrated that in normal adult blood, levels of proangiogenic growth factors 
including CXCL-12 (also known as stromal derived factor-1)  and VEGF which are ligands 
for the chemokine receptors CXCR-7 and CXCR-4 respectively, are proportional to the 
number of proangiogenic cells (Smythe et al., 2008; Thelen and Thelen, 2008; Watt and 
Forde, 2008). 
The release of VEGF in the plasma of burns patients is associated with an increase in mRNA 
level of expression of endothelial specific genes mainly ECSM2 which is also related to the 
severity of burns in terms of total surface area of the patient (Fox et al., 2008a; Fox et al., 
2008b). ECSM2 which is also referred to as endothelial restricted cell surface receptor 
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(ECSCR) is known to increase the sensitivity of VEGF during vasculogenesis (Verma et al., 
2010; Kilari et al., 2013). This suggests that in response to vascular injury and an increase in 
VEGF and CXCCL-12 circulating levels, both proangiogenic and endothelial progenitor cells 
are mobilized into the blood. As expected there is also an increase in pro- inflammatory 
markers as a result of vessel injury that include  MCP-1, MIP-1α, IL4, IL6, IL8, IL10, IL13, 
IL15, IL17 and IFN-γ (Finnerty et al., 2008). The relationships between these factors and 
ECFCs and proangiogenic levels in the blood have still not been studied in great detail. It has 
been shown that IL-8 is a cytokine that is found in abundance in ECFCs but not in HUVEC 
and could act in a paracrine manner to promote angiogenic activity of these cells as shown by 
enhanced capillary tube formation (He et al., 2005; Nagano et al., 2007). 
  
 
1.6 Angiogenic growth factors and related cardiovascular disorders 
There has been considerable amount of work done on studying the role of mobilizing factors 
and their role in cardiovascular disorders, but till now it has been a challenge to distinguish 
between the ECFCs, circulating mature endothelial cells and proangiogenic cells. The term 
EPCs has been used widely to describe these mobilizing cells collectively. First evidence for 
a relationship between cardiovascular diseases and EPCs was demonstrated by Hill et al. 
They showed that patients who are at risk of developing cardiovascular diseases have a low 
EPC (CFU-Hill) count in their circulation and the number of these cells was inversely 
proportional to the Framingham cardiovascular risk score (Hill et al., 2003). There have been 
differences in the number of cells in patients with coronary artery diseases and conflicting 
data has been demonstrated (Leone et al., 2009). As earlier documented with severe burn 
injuries, acute myocardial infarction (AMI) can also lead to mobilization of these EPCs 
(Proangiogenic cells) into the circulation with a concomitant increase in circulating 
angiogenic factors. Enhanced VEGF levels have been shown in patients with post MI 
(Shintani et al., 2001).  This is in correlation with an increase in circulating levels of cells that 
can be identified as either circulating angiogenic cells (CACs), circulating endothelial cells 
(CECs) or endothelial colony forming cells (ECFCs). However, there was no significant 
change in expression levels of IL-3, IL-6, GM-CSF, G-CSF and b FGF in these patients post-
MI,  measured for a period of over 4 weeks (Shintani et al., 2001). Other studies have shown 
a rapid increase in circulating levels of proangiogenic cells post-MI that reached a peak at 
around 7 days and the levels then gradually declined over a period of two months (Massa et 
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al., 2005). This increase in level of progenitor cells was linked with an increase in VEGF 
levels but no significant change was seen in the plasma levels of CXCL-12 and SCF. Some 
studies have reported an increase in VEGF, CXCL-12 and G-CSF in patients after MI (Leone 
et al., 2009). It has been suggested that VEGF shows two peaks during MI, the first in acute 
phase which is within 48hrs and the other is in the sub-acute phase which is within 7 days, 
although this requires further investigation (Pannitteri et al., 2006). Similarly, in patients with 
heart failure, cells with proangiogenic capacity and forming CFU-Hill were found to be 
increased in number along with an increase in VEGF and CXCL-12 at early stages of heart 
failure (NYHA I and II) and reduced in number during later stages of heart failure, (NYHA 
III and IV) (Valgimigli et al., 2004). It has also been shown that endothelial colony forming 
cells (ECFCs) have increased levels in peripheral blood following myocardial infarction (MI) 
and they are correlated with the number of CD34
+
 CD45ˉ and CD34+ VEGFR-2+ cells, but 
are not related to CD133
+ 
CD34
+
  cell population in the blood (Massa et al., 2009). Finally, 
apart from above mentioned factors angiopoeitins, PDGF, IGF-1 and some cell surface 
receptors such as CD146, N-cadherin, Notch, VEGFR-2 and EphB4 are involved in 
endothelial cell proliferation and control the mobilization of proangiogenic cells in to the 
circulation (Al Haj Zen and Madeddu, 2009; Leone et al., 2009; Azam et al., 2010; Harhouri 
et al., 2010; Kebir et al., 2010; Padfield et al., 2010; Saharinen et al., 2010; Sheldon et al., 
2010). This further confirms that following an acute cardiovascular insult both circulating 
angiogenic cells (CACs) and ECFCs are mobilized in to the peripheral blood and play their 
respective roles.  
 
1.7 Diagnostic and therapeutic potential of EPCs 
Endothelial damage following vascular injury or tissue damage requires wound healing, 
which is divided in to four phases. It starts with haemostasis which involves deposition of 
extracellular matrix followed by inflammation and proliferation in which blood vessel 
formation takes place (Nguyen et al., 2009). The remodelling phase is also known as cellular 
phase which involves proangiogenic cells including fibroblasts and monocyte/macrophages 
and smooth muscle cells. Many studies have recently focused on demonstrating the 
relationship between circulating angiogenic cells, angiogenic growth factors and progression 
of diseases and clinical outcomes. It has been suggested by Estes et al, that a ratio between 
circulating proangiogenic cells and non-angiogenic cells of less than 1 is indicative of 
vascular disorders in humans (Estes et al., 2010). On the other hand, ECFCs are present in 
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human blood in low numbers and are not as easily identified as their proangiogenic and non-
angiogenic counterparts which are readily detected. Very few studies have been reported that 
have analysed these recently identified subsets in the blood of patients suffering from 
vascular injury and therefore their importance as diagnostic tools to predict vascular disease 
requires more patient groups. Studies from various groups have shown that the levels of 
circulating endothelial cells or circulating endothelial progenitors change in several cancers 
and in response to chemotherapy (Strijbos et al., 2008). Proangiogenic hematopoietic cells 
and CACs levels in peripheral blood can be used as a diagnostic tool as certain advanced 
cancers show increased levels of these cells which are reduced to normal with cancer therapy. 
Similarly, higher CAC levels in blood of breast cancer patients which were undergoing 
chemotherapy was a positive  predictor of increased survival rate, and these CAC levels have 
been used as markers for anti-angiogenic drug therapy and for detecting vascular toxicity 
following long term chemotherapy (Bertolini, 2009; Watt et al., 2010).  
 
1.8 Cell therapies for cardiovascular repair 
Several studies in animal models have shown that blood or bone marrow derived endothelial 
progenitor cells can be used for vascular repair. This was instrumental in rapid translation of 
this research into clinical scenario and clinical research settings (Watt et al., 2010). These 
included use of mononuclear cells or CD34
+
/CD133
+
 selected cells from peripheral blood or 
bone marrow. Several groups have carried out randomized clinical cellular therapy trials for 
treating acute myocardial infarction and ischemia performing intracoronary or 
intramyocardial infusion of mononuclear cells (Brunskill et al., 2009; Martin-Rendon et al., 
2009). In a more recent study it was shown that late outgrowth endothelial cells were much 
more effective than mesenchymal stem cells (MSCs) in cardiac revascularization in a swine 
model of AMI (Stevens et al., 2009; Dubois et al., 2010). Other strategies that have been 
employed  include application of induced pluripotent stem (iPS) and ES-derived cells in 
scaffolds, or use of drugs to assess the effects on vascular repair and cardiac revascularization 
(Jujo et al., 2010; Kong et al., 2010a; Maltais et al., 2010; Qian and Srivastava, 2010; 
Shrivastava et al., 2010; Evans et al., 2013). 
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1.8.1 Clinical trials for cardiovascular disorders using EPCs  
Several randomized clinical trials targeting cellular therapy for acute myocardial infarction 
and ischemic heart diseases have been carried out recently. These trials were limited to intra- 
coronary or intra- myocardial infusion of MNCs derived from peripheral blood or bone 
marrow. This resulted in an improvement in left ventricular ejection fraction (LVEF) 
particularly in those cases where ≥ 108 cells were infused into the heart. This requires further 
follow up in patients to study the persistence of this positive effect over a longer period of 
time (Martin-Rendon et al., 2008a; Martin-Rendon et al., 2008b; Brunskill et al., 2009; 
Assmus et al., 2010; Chavakis et al., 2010). In another study, intracoronary cellular therapy 
after percutaneous coronary intervention for acute myocardial infarction showed signs of 
improvement in patients (Lipinski et al., 2007). In cases of non-randomized clinical trials 
some adverse effects of the cellular therapy have been observed. High number of cases with 
in-stent restenosis or denovo stenosis following intracoronary infusion of  granulocyte colony 
stimulating factor (G-CSF) mobilized MNCs or CD133
+
  progenitor cell population derived 
from bone marrow suggested an increased risk of progression of atherosclerosis (Bartunek et 
al., 2005; Mansour et al., 2006). Therefore, further analysis of randomized clinical trials is 
required to assess the efficiency of these therapies. One of the consequences of 
atherosclerosis which affects lower extremities and often referred to as peripheral artery 
occlusive disease (PAD) has been attempted to treat with these cellular therapies using 
mobilized PBMNCs and bone marrow derived cells and applying them directly to the injured 
site (Martin-Rendon et al., 2009).  
 
1.8.2 Limitations of cell therapies used for cardiovascular repair  
These studies have been carried out in non-randomized clinical trials and long term pain 
relief along with some adverse effects being reported. Randomized clinical trials, along with 
well-defined and sorted cell populations are needed to confirm the safety and efficacy of 
these therapies for PAD. All these cell therapies that have been attempted so far have some 
limitations. The trials that have been conducted in animal models of MI indicate that some of 
the cell populations derived from bone marrow such as mesenchymal stem cells do not 
remain in the heart and the improvement that occurs is due to hormonal or paracrine effects 
that limit inflammation and also prevents scar formation. This effect is also responsible for 
increased neovascularization and promoting the proliferation of stem/progenitor cells 
(Stuckey et al., 2006; Carr et al., 2008; Martin-Rendon et al., 2008c; Quevedo et al., 2009; 
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Sato et al., 2010). It has also been shown that ECFCs contributed more towards 
neovascularization than mesenchymal stem cells (MSCs) in a swine model of acute 
myocardial infarction (Dubois et al., 2010).  
1.9 Clinical applications of ECFCs 
There are three strategies that can be used once ECFCs are successfully isolated from either 
peripheral or umbilical cord blood. 
 
1.9.1 ECFCs as neovascularizing agents for cell therapy  
The first strategy involves using ECFCs as neovascularization agents for cellular therapy, 
which in a clinical scenario can be implicated for the promotion of wound healing or rescuing 
of critical ischemia in patients or may be as a source for delivering angiogenic factors. 
Intracoronary infusion of VEGF and bFGF (basic fibroblast growth factor) has been 
attempted that led to an improved blood flow but the effects were transient and patients 
presented with hypotension (Al Haj and Madeddu 2009). Gene therapy techniques have also 
been tested to deliver angiogenic factors. Adenoviral vector encoding VEGF injected in to 
ischemic tissue led to an increase in systemic VEGF. Similarly gene transfer of naked DNA 
encoding VEGF resulted in improved lower extremity blood flow demonstrated by magnetic 
angiography (Isner and Asahara, 1999; Critser and Yoder, 2010; Dubois et al., 2010; Medina 
et al., 2010a). Conversely, an anti-angiogenic strategy to suppress excess proliferation of 
endothelial cells as required in some ocular diseases has been attempted successfully 
(Anderson et al., 2010; Rajappa et al., 2010). Cells can also be used as vehicles for gene 
delivery. It has been shown that retrovirally induced myoblasts resulted in VEGF productions 
which in turn lead to 30 fold increase in the capillary density with in few days (Padfield et al., 
2010). It has been suggested that the cells involved in vascular regeneration including 
proangiogenic and mesenchymal cells can be used for controlled delivery of growth factors 
(Padfield et al., 2013). 
 
1.9.2 ECFCs as progenitor cells for vascular repair 
The second strategy involves using capacity of colony derived cells/ECFCs to differentiate 
into endothelial cells that can be used as a tool to re-endothelialize damaged blood vessels 
and maintain an intact endothelium. Prosthetic vascular grafts or stents that are coated with 
endothelial cells have been proposed as an approach to decrease the incident of neointimal 
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formation and premature graft failure and drug-eluting stents have shown to be more 
effective in that regard (Padfield et al., 2010). The implantation with cells of  left ventricular 
assist devices and grafts in human and animal models have been reported recently (Yoder, 
2010). As shown earlier, it has been suggested that proangiogenic cells that are mobilized 
from bone marrow in response to vascular injury also promote the mobilization of ECFCs 
and their proliferation and re-endothelialization of stents (Watt et al., 2010). This 
endothelialization can also be enhanced by use of proangiogenic factors that can mobilize 
these cells from bone marrow and peripheral blood and include statins, G-CSF and 
peroxisome proliferator activator antagonists. Cellular therapies involving infusion of ECFCs 
and proangiogenic cells directly to the affected area and stent-based treatments have been 
tested before and include VEGF gene-eluting stents and CD34 cell capture stents (Padfield et 
al., 2010; Watt et al., 2010). 
 
1.9.3 ECFCs for tissue engineering applications  
Third strategy involves using the ECFCs for tissue engineering applications, and as a source 
of endothelium in forming a microvasculature. The scarcity of transplantable tissues and 
organs has led researchers to think in terms of creating an organ or a tissue that can be a 
suitable replacement for human transplantation. For this to happen, a source of vascular 
supply is the most important issue along with specific progenitor cells, since in vivo, oxygen 
and nutrient supply is essential for maintaining a three-dimensional tissue construct. In an in 
vitro system various attempts have been made to form a vasculature which mainly involved 
culturing endothelial cells in collagen gels, which formed tubular structures spontaneously. 
Similarly, human umbilical vein endothelial cells have been co-cultured with fibroblasts and 
keratinocytes resulting in a graft containing properly developed capillaries with a basement 
membrane (Black et al., 1998). Endothelial cells, when cultured together with mesenchymal 
cells have been shown to play a role in stabilizing the micro vessels by recruiting pericytes to 
their luminal surface. Human umbilical vein endothelial cells have also been used after 
transfection with bcl2 in fibrinogen or collagen gels in order to achieve long term survival 
with the formation of HUVEC lined micro vessels (Zheng et al., 2004). Human umbilical 
vein endothelial cells have also been cultured together with mouse myoblasts along with 
embryonic fibroblasts to produce skeletal muscle constructs in an in vitro system. This 
construct was implanted  in vivo and it was observed that the developed vasculature was 
successfully maintained (Levenberg et al., 2005). It has been reported that HUVECs along 
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with 10T1/2 mesenchymal progenitors when seeded in fibronectin type I collagen gel and 
implanted in to SCID (severe combined immunodeficiency) mice resulted in the formation of 
blood vessels that became connected to the circulation and survived in vivo for more than a 
year (Koike et al., 2004). The use of human bone marrow derived mesenchymal stem cells 
(hMSCs) and EPCs have been attempted by Au and colleagues who showed that these cells 
(MSCs)  can be successfully used as vascular progenitors and played an important role in 
stabilizing newly formed blood vessels by functioning as perivascular progenitors (Au et al., 
2008b). The blood vessels formed remained stable in vivo for more than four months. More 
recently, it has been shown that blood derived ECFCs and human dermal fibroblasts can lead 
to the formation of micro vessels in dermal substitutes in vitro (Hendrickx et al., 2010). They 
further extended this study to produce an in vivo model of wound healing (Hendrickx et al., 
2010; Watt et al., 2010). ECFCs and hMSCs have been shown to be cultured in animal serum 
free cultures in an in vitro system producing a microvasculature in immunodeficient mice 
(Reinisch et al., 2009). More recently, it has been shown that human cord blood derived 
ECFCs when administered together with MSCs resulted in an increase in in vivo 
vasculogenic response and ECFCs were found to be incorporated into neovessels  (Schwarz 
et al., 2012).  
 
1.9.4 Limitations in using ECFCs for vascular repair  
As reviewed by kirton and Xu most of the studies conducted so far for vascular repair have 
been conducted in animal models or have used ECFCs in human clinical trials which have 
been difficult to obtain in large numbers (Kirton and Xu, 2010). This is important in the 
context that cellular therapies for cardiovascular repair that have used blood or bone marrow 
derived mononuclear cells, and CD34
+ 
and CD133
+
 cells have resulted in very low level of 
improvement in left ventricular ejection fraction (Martin-Rendon et al., 2009). This is 
therefore essential to study in detail the source of origin of ECFCs. As till now, this is unclear 
whether ECFCs that reside within vessel wall and close to the damaged vasculature take part 
in the repair or the cells that are mobilized from the bone marrow in response to vascular 
injury and home into sites of damaged endothelium take part in this process. 
One of the approaches that have been suggested are to use autologous ECFCs and support 
proangiogenic cells with or without scaffolds to promote neovascularization, as this will 
decrease the risk of transplant rejections by overcoming human leukocyte antigen systems. 
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Another challenge is that the ECFCs occur in low counts postnatally, and it is important to 
generate sufficient proliferating ECFCs in vitro. These ECFCs have been expanded in 
specialized and defined protein conditions and have maintained their phenotypic 
characteristics. More recently, an exciting attempt with varying degree of success has been 
made to generate endothelial cells from induced pluripotent cells (Taura et al., 2009). These 
cells and factors that are involved in the regulation of revascularization and maintenance of 
an intact endothelium can be used as a future source of autologous cell therapy or in drug 
discovery. Grafting of a human donor trachea that was precolonized with chondrogenic and 
epithelial cells in to a patient suffering from tuberculosis has been shown to produce a 
functional trachea that was vascularized by patients own cells (Hollander et al., 2009). 
 
1.10 The role of oxidative stress and endothelial progenitor cells  
Oxidative stress has been shown to be involved in wide range of pathogenic diseases due to 
weakened antioxidative mechanisms or overproduction of free radicals that overcome body 
scavenging mechanisms. To study cardiovascular diseases mainly atherosclerosis several 
experimental models have been proposed that support the fact that reactive oxygen and 
nitrogen species play a role in atherosclerosis and other vascular diseases. The main models 
that have been used include using extracellular sources of superoxide (O2
-
) and hydrogen 
peroxide (H2O2), normobaric hyperoxia (elevated oxygen levels) and oxidized low-density 
lipoprotein induction. All these methods have been used to induce oxidative stress in cell 
culture systems. Induction of oxidative stress can be achieved by two different approaches, 
either by increasing the free radical load or by disrupting anti oxidative defence mechanism.  
Hydrogen peroxide can be added directly to the culture medium that results in rapidly 
decreasing concentration of H2O2. It is mainly stable in most culture systems but in the 
presence of cells its concentration declines quickly depending upon cell density and presence 
of catalase enzyme. Its main advantage is that it readily penetrates the cellular envelope. 
Superoxide can also be added directly in the culture medium in the form of potassium 
superoxide. It also leads to rapidly decreasing concentrations but is converted to hydrogen 
peroxide by enzymatic reaction which can also produce hydroxyl ion. The effects are similar 
to hydrogen peroxide but it does not readily penetrate the cellular envelope. Also, catalase 
needs to be added to the media in order to avoid hydrogen peroxide and subsequent hydroxyl 
formation. Exposure to hyperoxia is mainly performed by incubating cells for several days 
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and the main effect is produced by direct interaction of oxygen with the cells instead of 
oxygen reacting with the media producing substances that can affect the cells. The main 
difference between extracellular hydrogen peroxide and superoxide in comparison to 
hyperoxia is that the later requires prolonged exposure. We, therefore chose hyperoxia as we 
required to grow cells for long term culture and with hydrogen peroxide there is this issue of 
rapid decrease in concentration. 
It has been shown recently that endothelial progenitor cells play an important role in postnatal 
neovascularization and are involved in re-endothelialization of disrupted endothelium 
(Asahara et al., 1999; Griese et al., 2003; Zampetaki et al., 2008; Wang et al., 2013). These 
EPCs have been isolated from several sources that include bone marrow, peripheral blood 
and cord blood derived mononuclear cells (Murohara et al., 2000; Kawamoto et al., 2001). 
Animal models of hind limb ischemia and myocardial infarction have shown improved blood 
flow as a result of endogenous mobilization of EPCs (Takahashi et al., 1999; Kawamoto et 
al., 2003). Several clinical studies have mentioned that EPC numbers have been affected by 
various risk factors that also account for coronary artery diseases thus causing a challenge for 
promotion of neovascularization by these EPCs (Vasa et al., 2001; Taniyama and Griendling, 
2003; Werner and Nickenig, 2006). It has been proposed and shown that oxidative stress that 
leads to an increase in reactive oxygen species (ROS) production and a decrease in 
antioxidant enzyme expression, can promote vascular senescence and is considered to be one 
of the main factors involved in coronary artery disease (CAD) along with smoking, aging, 
diabetes and hypertension (Cai and Harrison, 2000).  Oxidative stress has been implicated in 
a wide range of vascular disorders leading to DNA damage, decreased nitric oxide (NO) 
availability and change in redox state as a result of increased ROS production (Sugamura and 
Keaney Jr, 2011; Higgins et al., 2012; Williamson et al., 2012). Oxidative stress has been 
shown to be involved in the progression of atherosclerosis as ROS has shown to directly 
result in endothelial dysfunction (Cai and Harrison, 2000; Taniyama and Griendling, 2003; 
Touyz, 2004). It is suggested that ROS plays a key role in the progression of atherosclerosis, 
as oxidative stress affects EPC survival and mobilization (Torsney et al., 2005; Yao et al., 
2006). ROS has been shown to directly affect the endothelium and increased superoxide 
accumulation decreases EPC activity and survival (Griendling and FitzGerald, 2003a; Thum 
et al., 2007). Treatment of EPCs with high levels of hydrogen peroxide has shown induced 
oxidative stress and progression towards apoptosis and reduced EPC count (Kao et al., 2001; 
Hung et al., 2003; Urbich et al., 2005). In an animal model of myocardial infarction, 
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increased ROS production has been associated with reduced EPC level (Thum et al., 2006). 
Oxidative stress has also led to the mobilization of dysfunctional EPCs which has reduced 
capacity to migrate and home to sites of vascular injury   (Schatteman et al., 2000; Tepper et 
al., 2002). This oxidative damage can be linked to vascular aging, as this cellular damage due 
to increased aging can reduce EPC function resulting in an increased risk of vascular 
pathologies. It has been shown that both early and late EPCs are more resistant to this 
oxidative stress than mature endothelial cells (HUVEC) as they express higher level of 
antioxidant enzymes (Dernbach et al., 2004; He et al., 2004a; Cai et al., 2006; Williamson et 
al., 2012). This suggested that these EPCs can be more efficient cells involved in vascular 
repair as a result of an ischemic insult, owing to this improved resistance to oxidative stress. 
However, it has been shown recently that early EPCs or circulating angiogenic cells (CACs) 
are cells of myeloid origin and express certain monocyte-macrophage lineage markers 
including CD45, CD14 and CD115 and are proangiogenic but do not take part in vascular 
repair directly, whereas late EPCs or endothelial colony forming cells (ECFCs) have been 
shown to be the EPCs involved in vascular repair although they themselves are not shown to 
be completely resistant to oxidative stress, but are better suited to these conditions as 
compared to mature endothelial cells (Ingram et al., 2007; Yoder et al., 2007). Hydrogen 
peroxide induced oxidative stress has shown to impair EPC function although they are known 
to have better equipped intracellular mechanisms to combat oxidative stress but they are still 
not resistant to this stress (Dernbach et al., 2004; He et al., 2004a; Ingram et al., 2007).  
However, this antioxidative capacity of EPCs has been shown to diminish with aging, and 
early EPCs isolated from young subjects have shown higher levels of antioxidant enzyme 
glutathione peroxidase (GPx-1) as compared to old ones (He et al., 2009) and were found to 
be more resistant to stress induced apoptosis. There has been some conflicting data in terms 
of effect of oxidative stress on EPCs, but it is mainly due to the fact that these EPCs are better 
classified as early and late EPCs depending upon their appearance in an in vitro culture 
system. These two EPC types are different from each other morphologically and in terms of 
clonogenic and proliferative capacity (Hur et al., 2004; Deschaseaux et al., 2007). These 
early and late EPCs have been used by researchers for testing the effect of oxidative stress by 
exposing these cells to hydrogen peroxide after culturing in an in vitro system. It has been 
reported that early EPCs have shown to express both endothelial and monocyte/macrophage 
cell surface antigens and were found to be tolerant to oxidative stress, whereas late EPCs or 
ECFCs have shown to be sensitive to oxidative stimuli, do not express monocyte/macrophage 
markers and show much higher proliferative potential (Dernbach et al., 2004; Ingram et al., 
 18 
 
2004; Ingram et al., 2007). In a more recent study, late EPCs have been used to test the effect 
of hydrogen peroxide induced oxidative stress and it has been shown that it leads to a 
decrease in cell survival and causes increased apoptosis which was dependent  on hydrogen 
peroxide dosage (Wang et al., 2013). 
Aging also leads to an up regulation of Angiotensin II which is known to promote 
atherosclerosis by enhancing ROS production and associated cell death (Baylis et al., 1997; 
Wang et al., 2003; Imanishi et al., 2005). Similarly, it has been shown recently that EPC 
number was increased in a coronary artery disease patient when treated with an angiotensin II 
receptor antagonist (Endtmann et al., 2011). It has been shown that forkhead hemeobox type 
O (FoxO) family of transcription factors 1, 3a and 4 are involved in apoptosis and cell 
survival (Puig and Mattila, 2011). The activity of foxOs is mainly dependent on their nuclear 
localization and are phosphorylated by Akt kinase in the presence of serum and growth 
factors leading to their nuclear removal and deactivation (Accili and Arden, 2004; Zhang et 
al., 2011). However, in the presence of oxidative stress localization of the foxOs to the 
nucleus occurs resulting in activation of foxO target genes that include a pro-apoptotic gene 
Bim that promotes apoptosis (Dijkers et al., 2000; Storz, 2011). More recently, role of 
foxO3a has been studied and it has been shown that oxidative stress reduces tube forming 
ability of EPCs and this occurs through a foxO3 dependent mechanism (Wang et al., 2013). It 
has been shown that in mammals all three above mentioned foxO proteins are present in 
EPCs performing different functions (Potente et al., 2005; Marchetti et al., 2006; Spinetti et 
al., 2013). There have been studies that reported insights into mechanisms involving 
oxidative stress induced EPC dysfunction and revealed that foxOs transcription factors 
mainly work by inhibition of cell growth eventually leading to apoptosis (Dejana et al., 
2007). 
 
1.11 Redox control mechanisms and angiogenesis 
Redox control and signalling remains a topical area in vascular research. Endothelial cells 
mediate ROS production in the form of superoxide and hydrogen peroxide which act as 
messengers leading to a growth factor dependent response,  promoting angiogenesis (Case et 
al., 2008). NADPH oxidase is considered to be the most important source of ROS in 
vasculature (Griendling et al., 2000; Lassègue et al., 2012). NADPH oxidase (NOX) derived 
ROS has been shown to be implicated in several cardiovascular diseases and increased ROS 
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levels have been found in both human and animal models (Lacy et al., 2000; Touyz and 
Schiffrin, 2001; Álvarez et al., 2008; Brandes et al., 2010; Lassègue and Griendling, 2010). 
Interestingly, it has been shown that two important angiogenic factors vascular endothelial 
growth factor (VEGF) and angiopoeitin-1(ANG1) promote endothelial cell migration via 
activation of NOX2 expressing NADPH oxidase (Ushio-Fukai et al., 2002; Harfouche et al., 
2005). It has been shown that increased expression of Nox2 is linked with enhanced 
production of ROS in murine angiogenic models of hind limb ischemia and retinopathy (Al-
Shabrawey et al., 2005; Tojo et al., 2005). Similarly, Nox2 null mice have shown inhibition 
of angiogenesis in response to ischemia and VEGF signalling.  
ASK1 protein is another important regulator of angiogenesis that is controlled by redox 
signalling. This protein belongs to the family of mitogen-activated protein kinase (MAP 
kinases) and is involved in activation of P38 kinase pathway. ASK1 is known to play a role in 
regulating oxidative stress induced apoptosis and cellular senescence (Tobiume et al., 2001). 
ASK1 is also involved in cytokinesis and proliferation and a hyperglycaemia induced ASK1 
activation leads to cell senescence in endothelial cells (Izumi et al., 2003; Matsuzawa et al., 
2005; Yokoi et al., 2006). ASK1 is also involved in activation of plasminogen activator 
inhibitor-1 (PAI-1) expression in endothelial cells. PAI-1 is an important protein involved in 
fibrinolysis and aging-related thrombosis (Juhan-Vague et al., 1989). ASK1 deficient mice 
has  also been shown to be involved in endothelial dysfunction caused by nitric oxide (NO) 
deficiency (Yamashita et al., 2007). ASK1 is therefore, proposed to be a therapeutic target in 
patients to combat vascular aging (Case et al., 2008). 
Glutathione peroxidase 1 (GPx-1) is another important protein involved in redox signalling 
that plays a role in vascular homeostasis. GPx-1 has been shown to play a protective role in 
preventing oxidative damage to the endothelium by reducing both lipid peroxides and 
hydrogen peroxide (Raes et al., 1987; Maiorino et al., 1995). Vascular injury has been 
demonstrated to be linked with a reduction in GPx-1 activity and atherosclerotic plaques 
isolated from carotid arteries have shown decreased expression of GPx-1 (Lapenna et al., 
1998). More importantly, over expression lead to restoration of endothelial function in 
endothelial cells treated with high levels of homocysteine (Weiss et al., 2001). Several mice 
studies have demonstrated that loss of GPx-1 is implicated in endothelial dysfunction and 
several other vascular abnormalities and renders them vulnerable to ischemic insult (Forgione 
et al., 2002a; Forgione et al., 2002b). 
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1.12 Tumour angiogenesis and its role in carcinogenesis 
Tumour progression requires orchestration of a micro vascular network and in order to 
achieve that goal tumour cells secrete wide range of cytokines and angiogenic growth factors 
thus promoting angiogenesis and in turn tumorigenesis (Folkman, 1971; Hanahan and 
Folkman, 1996; Nör and Polverini, 1999; Naumov et al., 2006). There are several signalling 
pathways and growth factors that are involved in coordinating and regulating this complex 
process, but three main growth factor/receptor systems play a central role that include 
VEGF/VEGFR2, ANG1/TIE2 and PDGF-B/PDGFR-β (Cébe-Suarez et al., 2006; Naumov et 
al., 2006; Augustin et al., 2009; Gaengel et al., 2009). Role of VEGF as an angiogenic 
growth factor is well documented as it is expressed by most tumour cell types and has shown 
to promote endothelial cell migration and proliferation (Dvorak, 2002; Ferrara, 2005). VEGF 
has also shown involvement in EC survival by up regulation of Bcl-2 expression mediated 
through its receptor VEGFR-2 (Gerber et al., 1998). VEGF along with angiopoeitins (1 and 
2) seem to play a coordinated and complementary role in the development of blood vessels. 
The ANG/TIE2  pathway is considered to be  the gateway of angiogenesis, as the endothelial 
cell phenotype is determined by regulation of the balance between ANG1 and ANG2 
expression (Tait and Jones, 2004). When ANG1 levels are increased with respect to ANG2 
endothelial cells shift to quiescent state and maturation and stabilization of blood vessels take 
place along with promotion of interaction between endothelial cells and supportive cells 
mainly pericytes (Zheng et al., 2013). On the other hand, overexpression of ANG2 relative to 
ANG1 leads to active migration and proliferation of ECs in the presence of VEGF. Pericytes 
are mural cells that play a supportive role in angiogenesis by extending cytoplasmic 
projections over ECs surface so that they become interconnected. This interaction between 
pericytes and endothelial cells is essential for the maturation and remodelling of the vascular 
system. PDGF-B is involved in proliferation of pericytes and also acts as a chemotactic factor 
that promotes the migration of pericytes to the site of blood vessel formation (Gaengel et al., 
2009).  
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1.13 Hallmarks of aging 
Aging is normally defined as a gradual and time-dependent decline in body functions 
associated with cellular damage that affects every living organism (Kirkwood, 2005; Vijg and 
Campisi, 2008; Gems and Partridge, 2013). In addition to cancer, there are several clinically 
important pathologies including vascular inflammation and atherosclerosis which manifest 
themselves as age-related diseases and are characterized by uncontrolled cell growth and 
hyperactivity (Blagosklonny, 2008). More recently, effort has been attempted at 
characterizing the molecular and cellular hallmarks of aging and nine candidate processes 
have been categorized as contributors towards aging. These include  as shown in figure 1.3, 
genomic instability, telomere dysfunction, epigenetic modifications, stem cell exhaustion, 
altered intercellular communications, cellular senescence, mitochondrial dysfunction, 
abnormal nutrient regulation and loss of proteostasis (López-Otín et al., 2013). The processes 
which have been relevant to our area of research are discussed in detail below. 
 
 
      Figure 1.3. Schematic representation of hallmarks of aging. Adapted from (López-Otín et al., 2013). 
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1.13.1 Telomere attrition and dysfunction 
There is strong evidence that aging encompasses genomic damage and factors that promote 
this damage can lead to accelerated aging. It has been shown recently that enhancement of 
chromosomal segregation can lead to extended longevity in mammals (Baker et al., 2013). In 
cases of progerias which are linked nuclear defects there is enough evidence to show that 
treatments can prevent premature aging (Fong et al., 2006; Varela et al., 2008; Gregg et al., 
2012; Kane et al., 2013). This suggests that exploring ways to stabilize nuclear and 
mitochondrial genome by having a better control on  aspects that govern them such as DNA 
repair mechanisms can have a positive effect on normal aging (López-Otín et al., 2013). 
DNA damage that accumulates with normal aging seems to affect the genome randomly, but 
there are specific region known as telomeres that are more susceptible to these age-related 
changes (Blackburn et al., 2006).  
DNA polymerases do not have the capacity to completely replicate the terminal ends of the 
linear DNA molecule, and this function is the characteristic of a specialized DNA polymerase 
known as telomerase. The telomerase is however, not expressed by most mammalian somatic 
cells causing gradual loss of telomere-protective sequences from chromosome ends. This 
explains the phenomena of replicative senescence, which allows limited proliferative 
potential of cells grown in an in vitro culture system, also termed as Hayflick limit (Hayflick 
and Moorhead, 1961; Olovnikov, 1996). Overexpression of telomerase has been shown to 
confer immortality to cells without even leading to oncogenic transformation (Bodnar et al., 
1998). Telomere shortening is therefore considered as a part of normal aging process in both 
mice and humans (Blasco, 2007). Telomeres are bound by a multiprotein complex known as 
shelterin which prevents the access of DNA repair proteins to them and blocks the repair of 
telomeres when DNA stands break, resulting in fusion of chromosomes (Palm and De Lange, 
2008). As a result of this restricted DNA repair, when telomeres are succumbed to DNA 
damage, this usually is persistent and leads to senescence and apoptosis (Fumagalli et al., 
2012; Hewitt et al., 2012).  Human telomerase deficiency is associated with premature 
disease progression, mainly in pulmonary fibrosis, dyskeratosis congenita  and also aplastic 
anaemia all of which are related to reduced regenerative capacity of the tissues (Armanios 
and Blackburn, 2012).  
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1.13.2 Mitochondrial dysfunction and reactive oxygen species (ROS) 
 
The relationship between mitochondrial dysfunction and aging has been discussed and 
studied for a long time but still most aspects are not well understood. It has been proposed 
that as cells undergo aging, the respiratory chain loses its efficiency and leads to electron 
leakage causing reduced ATP production (Green et al., 2011). These findings stem from the 
mitochondrial free radical theory of aging, first proposed by Harman et al.1965. In the recent 
past, there has been a lot of development in re-evaluating this free radical theory and 
considerable amount of work has been done to investigate the links between ROS and 
mitochondrial damage (Hekimi et al., 2011). Several studies have come up in last few years 
that have reported interesting but conflicting data in terms of the effect of ROS production 
and aging in different species. This includes the observation that increased ROS production 
plays a role in prolonging the life span of yeast and C. elegans (Doonan et al., 2008; Van 
Raamsdonk and Hekimi, 2009; Mesquita et al., 2010). In mice however, genetic alterations 
causing an increase in ROS production and subsequent mitochondrial damage did not prevent 
aging (Van Remmen et al., 2004; Zhang et al., 2009b). Similarly, an increase in antioxidative 
defence mechanisms did not cause an extension of life span in mice (Pérez et al., 2009) and 
interestingly, genetic alterations that damaged mitochondrial activity but did not increase 
ROS levels lead to accelerated aging (Trifunovic et al., 2004; Kujoth et al., 2005; Vermulst et 
al., 2008; Edgar et al., 2009; Hiona et al., 2010). These studies have resulted in researchers 
moving towards re-evaluating the role of ROS in aging and several studies have recently 
reported that intracellular signalling mechanisms have shown enough evidence that ROS  
activation  occurs in response to physiological stress and result in cell proliferation and 
survival (Ristow and Schmeisser, 2011; Sena and Chandel, 2012). Hekimi et al, 2011 have 
recently proposed a conceptual framework to redefine the role of ROS in aging. According to 
this hypothesis, as the chronological age increases the cellular stress and damage increases as 
well and ROS functions to balance this damage in order to maintain the survival. This is 
referred to as a compensatory homeostatic response, but after reaching a certain limit this 
counteracting mechanism becomes weak and instead of preventing this damage it causes 
aggravation of this   age-associated destruction (Hekimi et al., 2011).  
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 Figure 1.4. Mitochondrial life cycle involving biogenesis and mitophagy. Adapted from (Kluge et al., 
2013). 
 
It has been shown recently that in DNA polymerase γ deficient mice, mitochondrial 
dysfunction can accelerate the aging process on its own and independently of any damage 
caused by ROS production (Edgar et al., 2009; Hiona et al., 2010). Several mechanisms have 
been proposed for this to occur which include disrupted apoptotic signalling due to 
mitochondrial dysfunction resulting in permeabilization of mitochondria in response to 
physiological stress (Kroemer et al., 2007) and promoting inflammatory response by 
triggering ROS or permeabilization mediated  activation of inflammatory cytokines (Green et 
al., 2011). Another implication of mitochondrial dysfunction is its impact on cell signalling 
pathways by affecting the links between endoplasmic reticulum and outer mitochondrial 
membrane (Raffaello and Rizzuto, 2011). Telomere dysfunction in telomerase deficient mice 
has been shown to be a consequence of p53-mediated reduction in the expression of PGC-1α 
and β resulting in repression of mitochondrial biogenesis (Sahin and DePinho, 2012). This 
mitochondrial compromise also occurs in physiological aging but can be partially reversed by 
activation of telomerase, as shown recently in wild type mice (Bernardes de Jesus et al., 
2012). The NAD
+
-dependent histone deacetylase SIRT1, which is the human ortholog of Sir2 
(Silent information regulator), has a potential role in longevity and metabolic functions in 
mammals and  interacts with PGC-1α and deacetylates it at 13 lysines in different domains of 
the protein (Rodgers et al., 2005). SIRT1 has also been shown to play a role in modulation of 
mitochondrial biogenesis through regulation of this transcriptional coactivator, PGC-1α and 
is also involved in regulating autophagy that removes degraded mitochondria (Rodgers et al., 
2005; Lee et al., 2010). Similarly, SIRT3 which is a recently identified downstream target of 
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PGC-1 alpha (Kong et al., 2010b) is a mitochondrial deacetylase (In et al., 2008) that targets 
several important enzymes which play a key role in energy metabolism (Lombard et al., 
2007). SIRT3 has been shown to be involved in regulating enzymes that form part of the 
respiratory chain, β oxidation of fatty acids, TCA cycle and ketogenesis (Giralt and 
Villarroya, 2012). More importantly, SIRT3 is involved in controlling the rate of ROS 
production by deacetylating an important antioxidative enzyme MnSOD in response to stress 
(Qiu et al., 2010; Tao et al., 2010). This suggests that telomeres along with sirtuins are 
involved in regulation of age associated diseases by controlling mitochondrial function. 
Mitochondrial biogenesis and metabolism can also be altered by various other mechanisms 
that include mtDNA mutations, mitochondrial protein oxidation, derangement of respiratory 
chain complexes and alterations in mitochondrial membrane lipid composition and defective 
functioning due to improperly managed fission and fusion events (Wang and Klionsky, 
2011). Defective mitophagy also leads to impaired mitochondrial biogenetics resulting in low 
mitochondrial turn over contributing towards aging, although it has recently been shown that 
alternate day fasting can improve health by reducing mitochondrial degradation (Castello et 
al., 2011; Safdar et al., 2011). It is interesting to note that this increase in health span occurs 
in part due to activation of autophagy which is triggered by fasting and endurance training  
(Rubinsztein et al., 2011). Activation of autophagy however, is not the only pathway that can 
improve health span and counteract aging and additional mechanisms promoting longevity 
play a role (Kenyon, 2010). More recently a concept has evolved that has gained wide 
interest explaining mitochondrial dysfunction during aging process termed as mitohormesis. 
This suggests that toxic treatments trigger a beneficial compensatory  response and this 
overcomes the existing mitochondrial damage and over repairs the organelle leading to 
improvement in overall cellular fitness much more than that of the predamaged condition  
(Calabrese et al., 2011). This further explains the earlier observation that mild respiratory 
deficiencies can help in improving the lifespan of an individual if they do not lead to severe 
mitochondrial damage that can be pathogenic (Haigis and Yankner, 2010). As shown in C. 
elegans these hormetic responses can ensue this defence mechanism in tissues that have 
defective mitochondria as well as in those distant tissues which do not have this 
mitochondrial dysfunction (Durieux et al., 2011). There is strong evidence that compounds 
such as resveratrol and metformin act as triggers leading to mild mitochondrial damage 
causing low energy state by activation of AMPK and increasing adenosine 
monophosphate(AMP) levels (Hawley et al., 2010). Metformin has shown to increase the 
lifespan in C. elegans by activation of AMPK mediated compensatory stress response that 
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proved to be beneficial and also involved antioxidant regulator NRF2, which is considered to 
be an important player in regulating and combating oxidative stress (Onken and Driscoll, 
2010). More recently, it has been shown that metformin promotes longevity in worms by 
inhibiting methionine and folate metabolism of their intestinal flora (Cabreiro et al., 2013). 
Regarding the effects and impact of metformin usage in mammals not a lot has been shown in 
terms of life span improvement, although early administration of metformin has been 
reported to extend the life span in mice (Anisimov et al., 2011). Resveratrol and an important 
sirtuin activator SRT1720 have been shown to activate PGC-1 alpha and improve 
mitochondrial function and prevent the metabolic damage (Baur et al., 2006; Lagouge et al., 
2006; Feige et al., 2008; Minor et al., 2011). Resveratrol unlike metformin has shown to have 
no effect in promoting longevity in mice under normal dietary conditions (Pearson et al., 
2008; Strong et al., 2013). The role of PGC-1 alpha in improving mitochondrial activity has 
further been confirmed, as PGC-1 alpha overexpression leads to an extension of life span in 
Drosophila (Rera et al., 2011). Increase in lifespan of flies and mice has also been achieved 
recently by chemical administration of uncoupler 2-4- dinitrophenol and by genetically 
engineered overexpression of potent uncoupler protein UCP1 (Gates et al., 2007; Caldeira Da 
Silva et al., 2008; Fridell et al., 2009; Mookerjee et al., 2010). Finally, this has now been 
confirmed by several studies that there exists an important relationship between 
mitochondrial activity and aging and mitochondrial damage can lead to acceleration in the 
progression of aging. This still remains to be seen if  by improving mitochondrial activity, an 
extension in the lifespan of mammals can be achieved successfully and already several 
evidence exists that provide a link to that possibility (Trifunovic et al., 2004; Kujoth et al., 
2005; Vermulst et al., 2008; Ristow and Schmeisser, 2011; Ivanova and Yankova, 2013). 
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Figure 1.5. Illustration of mitochondrial contents in endothelial cells. Electron transport chain 
complexes are shown in relation to reactive oxygen species generation. Adapted from (Kluge et al., 
2013).  
            
 
1.13.3 Cellular senescence and age progression  
 
Cell senescence is simply referred to as the cell cycle arrest which is linked to well defined 
phenotypic changes (Campisi and D'Adda Di Fagagna, 2007; Collado et al., 2007; Kuilman 
et al., 2010; López-Otín et al., 2013). This term was first coined by Hayflick who cultured 
human fibroblasts in vitro for several passages (Hayflick and Moorhead, 1961). It has now 
been shown that this senescence occurs as result of telomere shortening (Bodnar et al., 1998). 
More recently, it has been suggested that apart from telomere shortening there are other 
factors that promote cell senescence that include non telomeric DNA damage and 
derepression of INK4/ARF  loci both of which are key players involved in chronological 
aging and induce aging (Collado et al., 2007). DNA damage is a good indicator of 
accumulation of senescent cells in tissues undergoing aging process and several studies have 
shown that these cells can be identified using senescence-associated β-galactosidase (SABG) 
staining that  has been confirmed in young and old mice liver (Dimri et al., 1995; Wang et 
al., 2009). Several other tissues showed similar result patterns with staining for senescent 
cells including lung, spleen and skin and involved detailed quantification of DNA damage 
and β-gal staining showing high percentage of senescent cells in old mice as compared to 
young ones (Wang et al., 2009). It was interesting to note that no change was observed in 
heart, muscle and kidney tissues suggesting that cell senescence is not a feature of all aged 
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tissues and as shown in tumour senescent cells, an extremely efficient immune system 
regulates removal of senescent cells regularly by phagocytosis (Wang et al., 2009; Hoenicke 
and Zender, 2012). It has been proposed for a long time that as the number of senescent cells 
keeps on increasing with advancing age there has to be some relationship between aging and 
cell senescence. This could be due to a decrease in rate of elimination of senescent cells as a 
result of attenuated immune system, a consequence of aging  or due to an increase in 
generation of senescent cells because of aging (Xue et al., 2007; Kang et al., 2011). More 
recently it has been suggested that as senescence mainly serves the purpose of preventing the 
propagation and promoting the clearance of damaged cells by maintaining a strict 
surveillance of immune system, an efficient cell replacement system is required that 
eliminates senescent cells and at the same time mobilizes progenitor cells to compensate for 
the number of lost senescent cells and re-establishing the cell count (Kuilman et al., 2010; 
Rodier and Campisi, 2011). It has recently been shown that senescent cells acquire a specific 
type of secretome which is a mixture of proinflammatory cytokines and metalloproteinase    
referred to as senescence-associated secretory phenotype and promotes aging process 
(Kuilman et al., 2010; Rodier and Campisi, 2011). Apart from DNA damage there are several 
other important factors that can lead to senescence, and mitogenic signalling is one such 
factor that plays a vital role in progression of senescence (Gorgoulis and Halazonetis, 2010). 
A recent study has mentioned that more than fifty oncogenes and mitogens can induce cell 
senescence as a result of the compensatory response to this form of stress and mainly involve 
on of these two pathways namely p16INK4a/Rb and p19ARF/p53 (Serrano et al., 1997). 
These two important pathways that are involved in aging are related to the chronological age 
of tissues as shown in humans and in mice (Krishnamurthy et al., 2004). Levels of p16
INK4a
 
and p19
ARF
 have been used to assess the age of tissues in both mice and humans (Ressler et 
al., 2006). To date there has not been any other gene or protein identified that is so closely 
associated with chronological aging as these two genes. This relationship has been so robust 
that it has been tested across species and tissues and proves to be the most validated means to 
distinguish between young and old cells (Jeck et al., 2012). Both these genes are encoded by 
the same locus which is INK4a/ARF locus and a recent analysis has revealed that genome 
wide association study of more than 300 has identified this locus to be genetically linked and 
involved in several important age-associated pathologies namely Alzheimer‟s disease, 
diabetes mellitus and most of  the cardiovascular  diseases (Jeck et al., 2012). This confirms 
the status of this gene as the most well documented gene locus that is involved in regulation 
of human aging and associated age-related human pathologies. The role of p16
INK4a
 and p53 
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in promoting senescence has been studied in detail and it has been proposed that senescence 
induced due to these two can lead to physiological aging. In several mouse models, mutant 
mice that show signs of premature aging due to persistent cell damage undergo further 
deterioration when either p16
INK4a
 or p53 are eliminated (Varela et al., 2005). Similar results 
have been obtained with mice having chromosomal aberration due to BubR1 mutation (Baker 
et al., 2011). It has been shown that overexpression of either p16
INK4a
, p19
ARF
, or p53 in mice 
can lead to extended longevity (Matheu et al., 2007; Matheu et al., 2009). Similarly, 
amelioration of progeroid phenotypes have been observed in mice that are p53 deficient 
(Calderwood et al., 2009; Ruzankina et al., 2009). To summarize this, the induction of p53 
and INK4a/ARF occurs as a compensatory response to prevent accumulation of damaged 
cells and progression of aging and cancer, but this can in certain advance conditions  exhaust 
tissue regenerative capacity and might result in accelerated aging (Matheu et al., 2007; 
Matheu et al., 2009; Baker et al., 2011).   
 
 
1.13.4 Energy sensing network and role of AMPK and sirtuins  
 
Growth hormone (GH) produced from anterior pituitary gland is the main somatotrophic axis 
in mammals and its most important mediator is insulin like growth factor-1(IGF-1) which is 
secreted in response to different cell types, most specifically by hepatocytes in the liver. As 
the name suggests IGF-1 acts in the same manner as insulin and uses the same intercellular 
signalling pathway informing cells of the presence of glucose. Due to this reason, insulin and 
insulin like growth factor-1signalling is collectively known as “insulin and IGF-1 signalling 
(IIS) pathway” (Kluge et al., 2013). This IIS pathway is considered to be the most important 
and evolutionary conserved aging-controlling pathway and mainly targets two of the aging 
associated complexes including FOXO family of transcription factors and mTOR complexes   
(Fontana et al., 2010; Kenyon, 2010; Barzilai et al., 2012). It has been interesting to note that 
genetic mutations or polymorphisms that affect growth hormone (GH) or its mediator IGF-1 
and any of its downstream targets including Akt, FOXO or mTOR  results in longevity, and 
again emphasizing the impact of energy pathways on extension of life span (Colman et al., 
2009; Fontana et al., 2010; Mattison et al., 2012). As deranged nutrient signalling is 
considered to be a sign of aging, dietary restriction has therefore shown to have a positive 
impact on health and life span of all eukaryotes from yeast to humans (Fontana et al., 2010). 
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Genetic alterations that affect the IIS signalling pathway at different levels has been 
consistently shown to improve longevity in worms, flies and mice and the most important 
effector system has been FOXO signalling (Kenyon et al., 1993; Slack et al., 2011). In mice, 
FOXO1 is responsible for carrying out the tumour suppressive effect of dietary restriction, 
but if this effect leads to the extension of life span still remains to be seen (Yamaza et al., 
2010). It has been shown recently that mice that are treated with tumour suppressor PTEN 
have undergone down regulation of IIS pathway and show an increase in oxidative 
metabolism with enhanced activity of brown adipose tissue (Garcia-Cao et al., 2012; Ortega-
Molina et al., 2012). Increased lifespan has been observed in these PTEN-induced mice 
coupled with decreased IIS activity. Similar results have been reported with hypomorphic 
PI3K mice (Ortega-Molina et al., 2012; Foukas et al., 2013). Growth hormone and IGF-1 
levels are known to decline as part of normal aging as well as in mouse progeroid models, 
therefore decreased activity of IIS is considered to be a hallmark of both physiologic and 
accelerated aging and extends lifespan (Garinis et al., 2008; Schumacher et al., 2008). When 
IIS activity declines to an extremely low level it can become lethal as has been reported in 
cases of mice with null mutations of PI3K and Akt kinases, and alternatively supplementation 
with IGF-1 has shown to improve symptoms of premature aging (Renner and Carnero, 2009; 
Mariño et al., 2010).  
 
 
Figure 1.6. Schematic representation of energy sensing network. A) Showing nutrient regulation mechanisms 
involving mTOR, AMPK and Sirtuins. Adapted from (López-Otín et al., 2013). 
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Apart from IIS pathway which mainly focuses on glucose sensing mechanisms, there are 
three important nutrient sensing pathways. Increased amino acid levels are instantly detected 
by mTOR signalling, whereas low energy states which mainly manifest as high AMP 
concentrations are detected by AMPK signalling mechanisms and finally sirtuins, which 
sense low energy status by high NAD
+
 levels (Houtkooper et al., 2010; Houtkooper et al., 
2012).  
The mTOR kinases are involved in the regulation of anabolism and consists of two protein 
complexes, namely mTORC1 and mTORC2 (Laplante and Sabatini, 2012). Genetic 
mutations resulting in down regulation of mTORC1activity has shown to increase lifespan of 
worms, flies and mice (Johnson et al., 2013). Rapamycin treatment in mice which involves 
binding to mTORC1complex has shown to extend longevity and still remains the drug of 
choice that has enhanced life span in mammals (Harrison et al., 2009). It has been interesting 
to note that mice that are genetically altered to have low levels of mTORC1but have normal 
mTORC2 levels show an increase in longevity and a genetic knockout of S6K1, which is an 
mTORC1substrate results in mice having increased life span (Selman et al., 2009; Lamming 
et al., 2012). These findings further validate that a decrease in expression of mTORC1 or 
S6K1 can signal a progression towards longevity in mammals in relation to mTOR (Yang et 
al., 2012). This suggests that mTORC1and associated pathways are promoters of aging 
process and inhibition of TOR activity can have beneficial effects on aging, although certain 
undesirable effects have been observed in mice as a result of this mTOR inhibition that 
include insulin resistance, testicular degeneration, development of cataract and abnormal 
wound healing (Wilkinson et al., 2012; López-Otín et al., 2013).  
The remaining two nutrient sensing networks including sirtuins and AMPK mainly respond 
to nutrient deprivation and works through catabolism as opposed to the anabolic approach 
used by IIS and mTOR signalling pathways and therefore, up regulation of the sirtuins and 
AMPK promotes health span (Alers et al., 2012). AMPK activation has multiple 
consequences and most importantly it leads to deactivation of mTORC1signalling and has 
also shown to improve life span in worms and mice following metformin treatment (Onken 
and Driscoll, 2010; Anisimov et al., 2011; Mair et al., 2011). SIRT1 is involved in 
deacetylation of PGC-1 alpha leading to its activation which in turn encompasses a wide 
range of metabolic responses, including mitochondrial biogenesis, increased fatty acid 
metabolism and improved antioxidant mechanisms (Rodgers et al., 2005; Fernandez-Marcos 
and Auwerx, 2011). Both AMPK and SIRT1 are activated by nutrient scarcity and when there 
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is high energy demand, so they are sometimes unified in their response creating a positive 
feedback loop and activating PGC-1 alpha through phosphorylation and deacetylation 
respectively (Price et al., 2012).  
 
1.13.5 Inflammatory response involving altered intercellular communications 
Age progression is linked with several other changes that take place simultaneously and can 
be attributed towards signs of aging and include intercellular communications disruptions at 
endocrine, neuroendocrine and neuronal level (López-Otín, 2013). It has been shown that 
neurohormonal signalling declines as aging occurs and secretion of proinflammatory 
cytokines from senescent cells leads to inflammatory response causing attenuation of the 
immune response and decreased defence mechanisms against pathogens creating an overall 
change in extracellular environment (Russell and Kahn, 2007; Zhong et al., 2010; Rando and 
Chang, 2012). Inflammaging is the term that has been used recently to describe age related 
alterations in the intercellular communication which manifests itself as having a 
proinflammatory phenotype  (Salminen et al., 2012; López-Otín et al., 2013). This 
inflammation can result from previously accumulated damaged tissue that has been affected 
by proinflammatory cytokines or a failure of immune system to eliminate senescent cells and 
pathogens allowing senescent cells to keep on secreting proinflammatory secretome or due to 
reduced autophagy response and finally inflammaging can also occur due to activation of  NF 
κB transcription factor (Green et al., 2011; Salminen et al., 2012). These changes result in the 
activation of several important proinflammatory pathways that result in the production of 
inflammatory interferons TNFα and IL-1β (Green et al., 2011). Human aging is closely 
linked and correlated with two inflammation associated pathologies  namely obesity and 
diabetes mellitus in which inflammation plays  a major role in acceleration of aging (Barzilai 
et al., 2012). Impaired inflammatory response is the hallmark of atherosclerosis and 
Inflammaging has recently been shown to disrupt epidermal stem cell function and has led to 
gradual decline in adaptive immune system (Tabas, 2010; Deeks, 2011; Doles et al., 2012). 
This associated immunosenescence further aggravates aging process due to the failure of 
elimination of dead and infected cells promoting their malignant transformation (Davoli and 
De Lange, 2011; Senovilla et al., 2012). Several large scale studies have confirmed the 
importance of inflammatory processes in the progression of aging and overexpression of 
NFκB signalling mechanism is a vital sign of aging (de Magalhães et al., 2009; Lee et al., 
2012). Transgenic mice have shown reversal of aging symptoms to varying degree of extent 
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when NFκB inhibition has been achieved through conditional expression in aged skin tissue  
(Adler et al., 2007). Similar results have been obtained recently by inhibition of NFκB 
signalling activity in mouse models through genetic and pharmacologic interventions (Osorio 
et al., 2012; Tilstra et al., 2012). More recently, it has been suggested that hypothalamus is 
involved in mediating aging, as inflammation activates NFκB in hypothalamus which 
responds by decreasing the production of gonadotropin releasing hormone (GnRH) by 
neurons which results in muscle weakness, skin atrophy, reduced neurogenesis and other age-
related symptoms (Zhang et al., 2013). Recent studies on mRNA decay factor AUF1 has 
further revealed links between inflammatory response and aging, as a deficient mice shows 
signs of premature aging coupled with cell senescence (Pont et al., 2012). AUF1 has been 
shown to promote cytokine mRNA degradation thereby promoting inflammatory response 
and has been involved in maintaining telomere length by the activation of TERT so a 
deficiency of this factor can accelerate aging through different pathways (Pont et al., 2012) 
Sirtuins have long been shown to have an impact on inflammation associated aging. SIRT 
1has shown to down regulate inflammation related genes by deacetylation of histones and 
inhibition of NFκB signalling (Xie et al., 2013). Similarly, a decrease in expression of SIRT1 
results in progression of several inflammatory pathologies and mice studies have confirmed 
the anti-inflammatory response to pharmacologic activation of SIRT1 (Zhang et al., 2010; 
Gillum et al., 2011; Yao et al., 2012). SIRT2 and SIRT6 are the other two sirtuins that have 
shown to reduce inflammatory response by deacetylation of NFκB (Kawahara et al., 2009; 
Rothgiesser et al., 2010). It has been reported recently that age-associated changes can be 
transferred from one tissue to another referred to as inter organ communication in which 
senescent cells are able to induce senescence to adjacent cells via gap junction mediated 
signalling that also involves reactive oxygen species   (Nelson et al., 2012). Conversely, it 
has been shown that life span enhancing alterations attempted in one tissue can have an 
adverse and retarding effect in the other  (Tomás-Loba et al., 2008; Durieux et al., 2011; 
Lavasani et al., 2012).  
 
1.13.6 Summary and perspectives  
Studying pathways involved in aging in different cell types can help in building a structured 
format to investigate molecular mechanisms underlying aging and can help in interventional 
research aimed at improving human health (Martin, 2012). Next-generation sequencing 
technologies have recently established a special impact in aging research by making it 
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possible to evaluate genetic and epigenetic changes in individual cells of an aged subject (de 
Magalhães et al., 2010; Gundry and Vijg, 2012; Miller, 2012). More recently, there has been 
great advancement in aging research and whole genome sequencing analysis has been carried 
out in individuals having exceptional longevity and comparative genome studies along with 
in depth study of age-related epigenetic alterations have been underway (Kim et al., 2011; 
Heyn et al., 2012; Sebastiani et al., 2012). This is essential to have more in vivo studies and 
analysis with gain or loss of function experimental models to validate the importance of these 
hallmarks of aging and understand the mechanics involved in progression of aging and age-
related diseases (Kirkwood, 2008; Gems and Partridge, 2013).  
 
1.14 Role of PGC-1 alpha coactivators in biological systems  
Coactivators are considered as proteins that are involved in regulation of gene expression but 
they do not directly interact with the DNA, instead they regulate this by interacting with 
transcription factors. Peroxisome proliferator activated receptor gamma coactivator 1- alpha 
(PGC-1α) belongs to a family of transcriptional coactivators that has been shown to bind with 
numerous transcription factors and includes most nuclear receptors (Handschin and 
Spiegelman, 2006; Rowe et al., 2010; Patten and Arany, 2012). These transcriptional 
coactivators have recently been shown to be involved in regulation of mitochondrial biology 
in different tissues including heart, liver and brain (Handschin and Spiegelman, 2006). PGC-
1 alpha has shown reduced expression in various models of failing heart and considered to be 
important contributors towards abnormal oxidative metabolism and as oxidative 
phosphorylation mainly occurs in mitochondria, heart and all these tissues maintain high 
mitochondrial content (Rowe et al., 2010). Apart from being a master regulator of 
mitochondrial activity, PGC-1 alpha is also involved in the regulation of several biological 
functions in different tissues that includes angiogenesis in skeletal muscle, gluconeogenesis 
and fatty acid metabolism (Patten and Arany, 2012). Reduced PGC-1 alpha expression has 
recently been implicated in neurodegenerative disorders like Parkinson‟s disease and in 
transgenic mouse model of Huntington‟s disease (Chaturvedi et al., 2010; Zheng et al., 2010; 
Shin et al., 2011).  
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1.14.1 PGC-1 alpha regulation and its role in cardiovascular system 
Mitochondrial biogenesis and mitophagy which refers to the elimination of damaged 
mitochondrial content by means of a strict immunosurveillance mechanisms are two 
processes that work in tandem and maintain a balance so that the mitochondrial content 
remains in check. It has been shown that peroxisome proliferator-activated receptor-γ 
coactivator (PGC-1α) plays a central role in coordinating this mitochondrial biogenesis which 
is an extremely complex process and several aspects of which are still not completely 
understood (Nisoli et al., 2003; Patten and Arany, 2012). This formation of new mitochondria 
involves replication of mitochondrial DNA (mtDNA) along with expression and activation of 
several mitochondrial and nuclear genes. PGC-1 alpha being a transcriptional coactivator 
activates mitochondrial factors A and B commonly known as transcription factor A 
mitochondrial (TFAM) and transcription factor B mitochondrial (TFBM) which in turn 
activate the mitochondrial genes encoded by mitochondrial DNA (mtDNA) and include 
genes involved in regulation of electron transport chain (Handschin et al., 2003; Rowe et al., 
2010). 
PGC-1 alpha is known to be activated by several stimuli which have high energy demands 
and in order to achieve that they require mitochondrial synthesis. These stimuli include 
exercise, cold exposure, caloric restriction and hypoxia (Nisoli et al., 2003; Patten and Arany, 
2012). On the other hand, the expression of PGC-1 alpha is regulated by several factors that 
include nitric oxide (NO), activation of sympathetic nervous system, cyclic adenosine 
monophosphate (cAMP), AMP-activated protein kinase (AMPK), calcineurin, 
calcium/calmodulin -dependent protein kinase and tumour suppressor p53 (Li et al., 2007; 
Trausch-Azar et al., 2010).  In addition to that, PGC-1 alpha is also regulated through 
posttranslational modifications. Most important of these modification include deacetylation 
by sirtuins (SIRT1) which increases PGC-1 alpha activity and acetyltransferase GCN5 which 
leads to a decrease in PGC-1 alpha expression (Olson et al., 2008; Dominy Jr et al., 2010). 
Phosphorylation of PGC-1 alpha by AMPK, p38 mitogen-activated protein kinase, Akt and 
glycogen synthase kinase-3 causes an increase in expression of PGC-1 alpha (Li et al., 2007; 
Miura et al., 2007; Pogozelski et al., 2009). More recently identified modifications include 
O-GlcNAc and phosphorylation by S6 and Clk2 kinases which mainly modify PGC-1 alpha 
activity in liver (Housley et al., 2009; Rodgers et al., 2010; Lustig et al., 2011). 
PGC-1 alpha is considered to be a master regulator and in addition to mitochondrial 
biogenesis, it controls the expression of several genes that are involved in regulation of 
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glucose and fatty acid metabolism in cardiac myocytes as well as many other cell types.    
(Leone and Kelly, 2011; Riehle et al., 2011). Mitochondrial content is much lower in 
endothelium as compared to cardiac myocytes, the latter being highly oxidative and has high 
energy demands. It has been shown that in rats mitochondria covers nearly 5% of the 
cytoplasmic volume in endothelial cells, whereas more than 30% is occupied by 
mitochondria in cardiac myocytes (Oldendorf et al., 1977; Barth et al., 1992). This further 
explains that PGC-1 alpha is mainly activated in conditions that require more energy in the 
form of ATP production. PGC-1 alpha is known to play an important role in angiogenesis by 
regulating the expression of vascular endothelial growth factor-1(Valle et al., 2005; Arany et 
al., 2008). It also plays a role in regulating metabolism in cardiac myocytes and genetic 
deletion of PGC-1 alpha can contribute towards heart failure. Diabetes patients show an 
increase in cardiac PGC-1 alpha expression which again promotes heart failure (Leone and 
Kelly, 2011; Riehle et al., 2011).  
 
1.14.2 PGC-1 alpha and its role in endothelial cells  
Mitochondrial content is much lower in endothelial cells as compared other cell types with 
high energy demands including oxidative tissues of heart, lung, brain and liver. 
Mitochondrial distribution within a cell has also been very interesting to note, as active 
endothelial cells at blood-brain barrier show much higher mitochondrial content as compared 
to endothelial cells in other capillary beds (Oldendorf et al., 1977; Park et al., 2011). In 
normal conditions, energy requirements are much lower in endothelial cells therefore, PGC-1 
alpha is suggested to play a different role in endothelial cells although it is well known that it 
is expressed in endothelial cells and regulates mitochondrial synthesis (Nisoli et al., 2003). 
PGC-1 alpha regulates reactive oxygen species and provides defence against oxidative stress. 
It has been shown that induction of PGC-1 alpha by viral transfection leads to an increase in 
expression of antioxidants including catalase, MnSOD and thiroredoxin-2 along with 
uncoupling protein-2 (UCP-2) all of which are involved in combating oxidative stress 
mechanism. PGC-1 over expression has been shown to decrease inflammatory activity, 
increase NO bioavailability and prevent endothelial cell apoptosis (Valle et al., 2005; Schulz 
et al., 2008). It has recently been reported that PGC-1 alpha promotes antioxidative 
mechanisms by inducing mitochondrial synthesis and providing fresh and undamaged 
mitochondria that are prone to produce much less reactive oxygen species (Twig et al., 2008). 
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1.14.3 PGC-1 alpha and its clinical significance     
Recent studies have focused on using PGC-1 alpha as a therapuertic strategy to overcome 
atherosclerosis, as it imparts positive effects on endothelial phenotype, but how effective this 
endothelial specific PGC-1 alpha overexpression can prove still remains to be seen. 
Interestingly, it has been shown recently that PGC-1 alpha null mice with an apolipoprotein 
E
-/-
 background showed decreased lesion formation, but this could be due to the fact that 
PGC-1 alpha null mice are thin and show signs of hyperactivity that could naturally limit 
athersosclerosis progression (Stein et al., 2010). Similarly, PGC-1β has shown a 
compensatory increase in expression due to loss of PGC-1α (Mitra et al., 2012). It has been 
suggested to have mouse models having  double knockouts of PGC-1α and β so that issues 
can be sorted (Patten and Arany, 2012). Endothelial –specific overexpression of PGC-1 alpha 
has recently been shown to have protective effect against hypertension.  
In a clinical setting, it is well known that PGC-1 alpha expression and associated 
mitochondrial content are lower in patients suffering from diabetes mellitus manifested by 
insulin resistance and disrupted energy metabolism (Kelley et al., 2002; Mootha et al., 2003; 
Petersen et al., 2004). In patients diagnosed with pulmonary hypertension lower 
mitochondrial mass in endothelial cells has beeen reported (Xu et al., 2007). A biopsy taken 
from subcutaneous tissue of a diabetic patient has revealed lower than normal mitochondrial 
content in the arterioles (Kizhakekuttu et al., 2012). Epidemiological data suggests that PGC-
1 alpha is closely asssociated with vascular pathologies and linkage analysis confirm that 
PGC-1 alpha polymorphisms are linked with coronary artery disease, carotid atherosclerosis 
and hypertensive disorders (Oberkofler et al., 2003; Iglseder et al., 2006; Zhang et al., 2008). 
As a result of this convincing data, more research is now directed towards developing drugs 
that can activate PGC-1 alpha which in turn would improve mitochondrial biogenesis and 
provide defence against cardiovascular diseases (Kitami et al., 2012).  
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Chapter 2. Aims and objectives 
 
Aim 1: To characterise the phenotype of endothelial colony forming cells (ECFCs) 
isolated from cord blood compared to human umbilical vein endothelial cells (HUVECs) 
isolated from the same donor. 
In order to achieve these goals human umbilical cord mononuclear cells (day 0 MNCs) were 
isolated from cord blood using ficoll based lymphoprep. They were differentiated towards 
endothelial lineage by growing in endothelial specific EBM- 2 media. This resulted in 
isolation of early EPCs from these cord blood mononuclear cells (day 7). The same 
mononuclear cells were grown in macrophage specific media (RPM1 + Human monocyte 
colony stimulating factor) and were differentiated towards macrophage lineage (day 7). This 
was done to distinguish between early and late EPCs as the former are known to be related to 
monocyte-macrophage lineage. Cells were frozen down and RNA was extracted. The 
remaining mononuclear cells were further cultured under normoxic conditions (20% O2) for 
2-3 weeks resulting in isolation of late EPCs also known as endothelial colony forming cells 
(ECFCs) or out growth endothelial cells (OECs).  Once an endothelial colony was observed, 
it was picked and grown under normal conditions for 4-6 weeks in order to get late EPCs or 
ECFCs. In order to have a better comparison all these early and late EPCs and macrophages 
were isolated from same mononuclear cells (day 0 MNCs) derived from the cord blood of the 
same donor. Once isolated, morphological analysis of the isolated cell types was carried out 
which was followed by molecular profiling of these cells. RNA extraction was carried out 
from all these cell types at different point times followed by qPCR analysis. The mRNA 
expression level of cell surface markers including CD34, CD31, CD14, CD45, CD105, 
CD144, CD146 and vWF was carried out. In order to validate these results and to 
differentiate them from mature endothelial cells (HUVEC) at protein level, FACS analysis 
with cell surface markers including CD34, CD14, CD146, and CD144 and direct 
immunofluorescence analysis with vWF antibody was performed comparing early and late 
ECFCs and HUVEC.  
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Aim 2: To elucidate the effects of hyperoxia as a model of oxidative stress on ECFCs vs 
HUVECs, focusing on telomere length, telomerase activity and PGC-1 alpha expression. 
One of the aims of this project was to study the effect of mild oxidative stress on the 
expression of PGC-1α and its downstream targets in human endothelial progenitor cells 
(ECFCs) and mature endothelial cells (HUVEC). Hyperoxia has already been established as a 
model of mild oxidative stress, as it leads to increased intracellular generation of hydrogen 
peroxide and reactive oxygen species (ROS) accelerating the accumulation of DNA single 
strand breaks causing cellular senescence. In addition to that, hyperoxia increases MCP-1, a 
crucial molecule which is involved in the initiation and development of atherosclerosis 
(Harrington, 2000).  
Recently, it has been shown that telomere dysfunction in the nucleus leads to deactivation of 
PGC-1 proteins in the mitochondria via activation of p53 (Sahin et al., 2011). They showed 
that a mice null in either Tert or Terc genes leads to p53- mediated apoptosis and growth 
arrest in several tissues and repression of PGC genes and their downstream networks leading 
to impaired mitochondrial biogenesis, oxidative phosphorylation and gluconeogenesis (Sahin 
et al., 2011). We, therefore, hypothesized that mild oxidative stress would lead to telomere 
dysfunction in human endothelial cells, and as a consequence of that a decrease in the 
expression of PGC-1α in endothelial progenitor cells (ECFCs) and mature endothelial cells 
(HUVEC). As PGC-1α is a key regulator of mitochondrial biogenesis and oxidative 
metabolism, a decrease in its expression would lead to an impairment of mitochondrial 
activity in these cells. This could in turn lead to a decrease in the angiogenic potential of 
these cells as mitochondrial deregulation has already been linked with several vascular 
dysfunctions.  
In order to achieve this goal, we isolated late endothelial progenitor cells (ECFCs) and 
mature endothelial cells (HUVEC) from human cord blood and human umbilical vein, 
respectively. Following subculture of cells for 2 passages, we exposed them to conditions of  
mild oxidative stress (40% O2). This was be followed by extraction of RNA at different time 
points from these cells followed by cDNA synthesis. Real time quantitative PCR was used to 
assess the mRNA expression level of PGC-1α and its downstream targets including ERR-
alpha and G6- Phosphatase. Our initial results indicated that ECFCs grow much better than 
HUVEC under conditions of mild oxidative stress (40% O2). HUVEC grew at a slower rate 
and did not grow well after few passages in hyperoxic conditions, and we therefore 
hypothesized that ECFCs are much more resistant to stress than HUVEC. In order to test this, 
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we isolated ECFCs from human umbilical cord blood and HUVEC from the umbilical cord. 
Cells were grown for 2 passages in normoxia (20% O2) and then split and cultured 
simultaneously in both normoxic and hyperoxic conditions (40% O2). This was followed by 
comparing the growth kinetics of both these cell types and measurement of telomerase 
activity and telomere length under normal and hyperoxic conditions. 
 
Aim 3: To determine the effect of oxidative stress on the expression of PGC-1 alpha and 
its downstream targets involved in regulating reactive oxygen species (ROS), oxidative 
metabolism and angiogenesis in ECFCs and HUVEC 
Cellular stress has been shown to be one factor leading to increased ROS production resulting 
in activation and up regulation of PGC-1 alpha (Wareski et al., 2009). The cellular response 
to this oxidative stress is an increased ATP production and availability by transcription of 
oxidative phosphorylation (OXPHOS) regulated genes (Pascual et al., 2005; Stravodimou et 
al., 2012). We therefore, proposed that exposing these endothelial progenitor cells to mild 
oxidative stress (40% O2) would lead to an increase in ROS production and an increase in 
PGC-1 alpha expression. This in turn would lead to ROS regulation by PGC-1 alpha and 
increased expression of genes involved in oxidative phosphorylation.  
Similarly, PGC-1 alpha coactivators have been shown to be involved in regulation of wide 
range of metabolic programs including gluconeogenesis and responses to fasting in liver, 
fatty acid oxidation and import mechanisms and angiogenesis in skeletal muscle (Yoon et al., 
2001; Chinsomboon et al., 2009). We therefore investigated the role that oxidative stress 
could play in ECFCs and HUVEC when grown in hyperoxic conditions. It has been shown 
before that PGC-1 alpha is activated by lack of nutrients and oxygen and regulates VEGF 
expression and angiogenesis by co activating nuclear receptor ERR alpha (Arany et al., 
2008). Hypoxia has been known to induce VEGF expression and angiogenesis, but role of 
hyperoxia in angiogenesis has not been well understood and is an emerging area of research.  
Our earlier results showed that ECFCs were much more resistant than HUVEC when exposed 
to oxidative stress (40% O2). We proposed that ECFCs would behave differently in terms of 
gene expression analysis and both these cell types might be using different pathways to 
counteract stress environment. In order to test this hypothesis, we carried out gene expression 
analysis using low density array in ECFCs and HUVEC grown in normoxia and hyperoxia 
and checked for genes involved in oxidative phosphorylation, genes involved in antioxidative 
mechanisms, genes involved in DNA damage and inflammatory response, oxidative 
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metabolism and angiogenesis. This was followed by qPCR validation for genes that showed 
significant change in expression when ECFCs or HUVEC were grown in hyperoxia. 
Hypothesis: 
We, therefore hypothesized that endothelial colony forming cells (ECFCs) that have been 
derived from an endothelial colony would behave differently in conditions of oxidative stress 
as compared to mature endothelial cells (HUVEC). As they have shown to be more resistant 
to oxidative stress they would up regulate genes involved in different pathways as compared 
to HUVEC. The difference would be evident both in terms of gene expression analysis and 
functional assays.  
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Chapter 3. Materials and Methods 
 
3.1 Isolation of human endothelial progenitor cells (early EPCs) from cord 
blood mononuclear cells 
Before starting the isolation, 6 well plates were coated with fibronectin in order to provide an 
attachment surface for the cells. 1 ml of fibronectin which was diluted in phosphate buffer 
solution (PBS) 1:100 was used per well of a 6 well plate. Fibronectin was removed after 30 
min, and the plates were allowed to dry under the hood. 
Once collected, the cord blood was mixed with PBS (1:1) and the mix was layered on to 
equal volume of ficoll solution in a way that the blood was not mixed with the ficoll but it 
continued to swim on it. This was allowed to centrifuge for 20 min without brakes at 800 × g. 
After the centrifugation was complete, three different phases could be seen as shown in the 
figure 3.1. The white blood cells were carefully removed using a pipette along with some 
plasma which could not be avoided. It was important that no ficoll was taken along with the 
WBCs as this could damage the cells. This mix of WBC and serum was transferred to a new 
50 ml falcon and PBS was added to make it to 50 ml. This was subjected to centrifugation at 
800 x g for 10 min with brakes. The supernatant was aspirated and the pellet was resuspended 
in 50 ml of PBS. At this point cells were counted with a dilution of 1:20 and then cells were 
resuspended in EBM- 2 media containing single Quots, 10% FBS and Pen/Strep at a 
concentration of around 8 million cells/ml. 2 ml of this cell suspension was added to each 
well of the 6 well plate. Some cells were frozen down the same day as human cord blood 
mononuclear cells (HUCBC) also known as day 0 MNCs at -80˚C.                                  
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Figure 3.1. Showing lymphoprep preparation using ficoll. Adapted from (current protocols.com). 
 
3.2 Isolation and differentiation of human cord blood mononuclear cells 
(HUCBC) in to macrophages 
Macrophages are the resident phagocytic cells found in lymphoid and nonlymphoid tissues 
and are derived from hematopoietic stem cells. Cord blood was received from donors from 
Queen Elizabeth Hospital Gateshead and was subjected to lymphoprep separation 
using ficoll. WBC layer was obtained and PBS was added to that, followed by centrifugation 
at 800 x g for 20 min without brakes. Supernatant was removed and the cells were again 
resuspended in 50 ml of PBS. Cells were counted at this stage and around 15 million cells 
were plated per well of a 6 well plate. The plates did not require coating with fibronectin. The 
cells were grown in RPMI media and human monocyte colony stimulating factor was added 
in the media so that the mononuclear cells could be differentiated towards macrophage 
lineage. After 3 days cells started to change their morphological appearance and resembled 
macrophages. RNA was extracted from cells at day 7 and kept frozen at -80°C. 
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3.3 Isolation and culture of Human endothelial colony forming cells (ECFCs) 
derived from cord blood 
 
Human endothelial colony forming cells (ECFCs) were derived from human cord blood. 
Before starting the isolation, well plates were coated with Type 1 rat tail collagen (BD 
Biosciences), which was diluted in 0.02N acetic acid, as collagen is insoluble at neutral PH. 
0.02 N acetic acid was prepared by adding distilled water to glacial acetic acid. Plates were 
coated with collagen for an hour at room temperature and then the solution was aspirated, and 
the plates were washed once with PBS, so that the acid was completely removed which could 
damage the cells. Plates were allowed to air dry for 30 min. 
Fresh cord blood (50-120ml) once received from the hospital, was diluted with PBS 1:1, and 
then a lymphoprep separation of blood: PBS was performed as explained earlier. The 
mononuclear cells collected as a result were transferred to a new 50 ml falcon and PBS was 
added to make it a 50 ml suspension. This mix was subjected to centrifugation at 800 × g for 
5 min without brakes to gently pellet the cells. Supernatant was removed and dilution with 
PBS and centrifugation was repeated. Again the supernatant was aspirated and cells were 
resuspended in 50 ml PBS. At that point, cells were counted using a haemocytometer with 
1:20 dilution and also using Vi-Cell XR 2.03 (Beckman Coulter) using 1:10 dilution. In all, 
400-700 million cells were obtained depending upon the volume of cord blood received. The 
supernatant was removed and the cells were then resuspended in 12 ml of complete EBM- 2 
media (with single Quotes) that additionally contained 20% FBS and 2% Pen/Strep. 2 ml of 
this suspension was added to each well of the collagen-coated 6 well plate. Around 60 million 
cells were seeded per well. After 48-72 hr non adherent cells were removed by changing the 
culture media. The media was changed on alternate days and at around 3 days of culture big 
round cells started to appear, which were proposed to be early EPCs or circulating angiogenic 
cells (CACs). An endothelial colony was observed after 3-4 weeks of culture, and this was 
picked up using a pipette tip and grown in T25 flask. Once confluent enough, the cells were 
split and the cells were grown for several passages till P5 and kept frozen down and stored at 
-80˚C.  
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3.4 Isolation and culture of human umbilical vein endothelial cells (HUVEC)  
Human umbilical vein endothelial cells (HUVEC) were isolated from the umbilical cord of 
the new born. Once received, the umbilical cord was washed with 1× PBS using a 50 ml 
syringe several times so that the cord was clean and there was no blood or clot visible. The 
two ends of the cord were tidily cut with a sterile scalpel and a cannula was introduced at one 
end of the vein, which was the widest vessel having a thick lumen as shown in figure 3.2 B. 
Once inside the vein, the cannula was tightly maintained by stitching around the cord using 
surgical needle. Cord was then washed from inside with PBS using a 50 ml syringe. This was 
followed by injection of collagenase (0.2% in PBS) at the end of the vein that contained the 
cannula, and leakage at the other end was stopped by using a clamp with a surgical clip. The 
cord was then incubated for 30 min at 37°C. After incubation, the cord was gently squeezed 
and the cells were collected in a sterile falcon tube by washing with 40 ml of PBS. This was 
followed by a centrifugation at 500 × g for 5 min. The supernatant was carefully discarded 
and the pellet was resuspended in 12 ml of culture media containing M199 Earle 1×, 0.2M 
Glutamine, 1M HEPES, 7.5% NAHCO3, Penicillin/Streptomycin (10000/10000) and 20 % 
foetal bovine serum (FBS). The cells were dissociated by aspiration and repulsion using a 
pipette. 2ml of the cell suspension was added to each well. Cells were incubated at 37°C in 
humidified air (95%) with 5% CO2. After 48 hr non-adherent cells were removed by changing 
the culture medium. The culture medium was changed on alternate days and attached 
endothelial cells were visible after 48 hrs. These cells reached confluence at around 3-5 days 
of culture and showed “cobblestone” appearance on observation under microscope. They 
were split when around 70-80% confluent, using Trypsin-EDTA and then regularly passaged 
till P5.  
             A                                                   B 
 
Figure 3.2. Showing human umbilical cord and human umbilical vein. Adapted from 
www.mothersofchange.com.  
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3.5 Passaging of endothelial cells 
The cells were examined routinely under the microscope for sub confluence. Once the cells 
reached a confluence of around 70-80%, normally after 3-5 days, they were split. Cells were 
split using Trypsin-EDTA in a ratio of 1:4. Medium was aspirated, and the cells were washed 
with PBS. Trypsin was added to the flask and incubated for 5 minutes and the flask was 
tapped with both hands in order to detach the cells. A scraper was used to detach the cells that 
were firmly attached. An equal volume of medium containing FBS was added to neutralize 
the Trypsin and the resulting mixture was transferred to a 15 ml falcon tube. Centrifugation 
was carried out at 500 × g for 5 min. The supernatant was sucked and the cell pellet thus 
obtained was resuspended in fresh medium and transferred to each of the four T25 flasks. The 
flasks were put in an incubator at 37˚C, with 5% CO2 in humidified conditions (>95%). 
 
3.6 Culture of ECFCs and HUVEC in conditions of normoxia and hyperoxia 
 
Normoxia (20%O2): 
ECFCs were isolated from cord blood and for the purpose of having a better comparison 
mature endothelial cells were isolated from the umbilical vein of the same donor. ECFCs 
were derived from cord blood by differentiation of Human cord blood mononuclear cells 
(HUCBC) by growing them in endothelial specific media (EBM-2). Cells were grown on 
collagen coated plates. These mononuclear cells were allowed to differentiate in endothelial 
media and cells were washed with PBS regularly followed by change of media every 
alternate day. It took 3-4 weeks before an endothelial colony appeared and in some cases 
there was no colony formation observed even after 1 month of cell culture and for some 
isolations more than one colony was obtained from the same isolation. Once a colony was 
observed, it was picked using a pipette tip and allowed to grow in smaller volumes either in a 
T25 flask or in 1-2 wells of a 6 well plate. The cells obtained from these colonies were grown 
again in EBM-2 media and were named as endothelial colony forming cells (ECFCs) as 
shown before. These ECFCs were sub cultured and split regularly using Trypsin-EDTA or 
some times by using cell scraper when cells became too adherent. Cells were split in a ratio 
of 1:3. ECFCs were grown till late passages (P16-P18) in normoxia (20% O2). Cells were 
frozen down at -80°C in freezing media containing DMSO. Cells were used for downstream 
applications for experiments including RNA extraction followed by qPCR, Telomerase 
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activity measurement using TRAP assay, measurement of telomere length across passages 
using flow-FISH, direct immunofluorescence analysis, multicolour flow cytometry and gene 
expression analysis using low density array (LDA) followed by qPCR validation (same donor 
analysis). 1million cells were replated and two million cells were frozen down with each 
passage. Cells were split every 3-7 days and passage 10 corresponds to around 8 weeks of 
culture.  
Mature endothelial cells (HUVEC) were derived from the umbilical cord of the same donor 
in some cases (n=6). Apart from that, most HUVEC were isolated and grown but for several 
samples no endothelial colony was obtained from the same cord blood sample. HUVEC were 
grown in 6 well plates coated with human fibronectin. 1ml of fibronectin diluted in PBS 
(1:100) was used to coat the plates. Plates were allowed to dry down after coating for 30 min. 
HUVEC were grown till late passages (P16-P18) and cells were regularly passaged using 
Trypsin-EDTA in a ratio of 1:3. HUVEC were initially used as a positive control for the 
study to differentiate endothelial progenitor cells from mature endothelial cells. HUVEC 
were isolated from umbilical vein of the cord using collagenase. Cells were grown in 
normoxia (20% O2) and cells were regularly washed with PBS and media was changed on 
alternate days. HUVEC were grown in endothelial specific media (EBM-2) and showed no 
further change in morphology. 1 million cells were plated each time, both for ECFCs and 
HUVEC. Once they were around 70% confluent they were split using trypsin in a ratio of 1:3. 
1 million cells were replated and 2 million cells were frozen down with each passage. This 
was carried out till passage 16-18. Cells were passaged after every 3-5 days and passage 10 
corresponds to around 8-10 weeks of culture.  
Hyperoxia (40%O2): 
Hyperoxia can lead to oxidative stress and this has been shown before. We therefore exposed 
the cells to hyperoxia in order to study their behaviour under stress conditions and to test if it 
was different for ECFCs and HUVEC. Both ECFCs and HUVEC were grown in normoxia 
till P2 and then were split and incubated in hyperoxic conditions (37°C with 5% CO2 and 
40%O2). ECFCs were grown in either T25 flasks or 6 well plates coated with rat tail collagen 
in hyperoxia and as shown in growth curves grew well. HUVEC were grown in either T25 
flasks or 6 well plates and showed much less resistance to stress conditions. Cells were split 
using Trypsin-EDTA in a ratio of 1:3. 2 million cells were frozen down with each passage 
and stored at -80°C in freezing media containing 20 % DMSO. 
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3.7 RNA extraction from EPCs, macrophages, ECFCs and HUVEC 
RNA isolation was carried out using Trizol method in 1 ml volume. Cells were trypsinized 
using 0.1% Trypsin-EDTA. An equal volume of EBM-2 media containing 20 % FBS was 
added to neutralize the trypsin. This was followed by centrifugation at 1000 rpm for 5 min. 
Cells were washed twice with Phosphate Buffer Solution (PBS without Ca
++
 and Mg
++
). 
After washing, the supernatant was removed and the cell pellet was resuspended in 1 ml of 
Trizol, and left for incubation at room temperature for 5 min. This suspension was then 
transferred to an eppendorf   tube and 1/5 Volume (200 µL) of chloroform was added and the 
suspension was shaken vigorously for 15s. After incubation at room temperature for 2-3 min, 
cells were centrifuged at 12000 × g for 15 min, and the upper aqueous layer was then 
transferred to another eppendorf tube. A half volume (500 µL) of isopropanol was added and 
the cell sample was incubated at room temperature for 10 min. This was followed by another 
centrifugation at 12000 × g for 15 min, and a small pellet was obtained as a result. The 
supernatant was removed and 1 volume of 70% ethanol was added. A vortex for 30s was 
followed by centrifugation at 7500 × g for 5 min. Ethanol was removed and the pellet was 
allowed to air dry for about 15 min. Around 30 µL RNase free water was added and then 
incubated for 10 min at 60˚C. Eluted RNA was quantified using Nanodrop and then kept at -
80˚C. 
RNA extraction was also carried out using the RNeasy Mini kit (Qiagen). Frozen cell pellet 
was taken from -80˚C and then subjected to homogenization in 600 µL of Buffer RLT. The 
lysate was centrifuged for 3 min at high speed and the supernatant was carefully removed by 
means of a pipette and transferred into a new eppendorf   tube. An equal volume of 70% 
ethanol was added to the cleared lysate, and mixed well by gentle pipetting. The mixture thus 
produced along with any precipitate formed was transferred into an RNeasy spin column 
which was placed in a 2 ml collection tube. This was subjected to Centrifugation at 13000 
rpm for 15s. This was followed by DNase digestion to eliminate any genomic DNA 
contamination. 350 µL of Buffer RW1 was added to the spin column. After centrifugation 80 
µL DNase (10 µL DNase mixed with 70 µL Buffer RDD) was directly added to the column 
membrane, and incubated for 15min at room temperature. 350 µL of Buffer RW1 was added 
to wash the spin column. After the DNase digestion the spin column was twice washed by 
500 µL of Buffer RPE. Finally the RNA was eluted in around 20-25 µL of RNase-free water. 
The eluted RNA was quantified using the Nanodrop and kept frozen at -80°C. 
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Table 3.1 Primer sequences and annealing temperatures designed for qPCR 
Gene Name 
 
Primer Sequence Product 
Size 
 
Annealing Temp 
 
1 CD31 
NM_000442.4 
F 
R 
AACAGTGTTGACATGAAGAGCC 
TGTAAAACAGCACGTCATCCTT 
148 bp 
 
55˚C 
2 CD34 
NM_001773.2 
F 
R 
GCGCTTTGCTTGCTGAGTTT 
GCCATGTTGAGACACAGGGT 
183 bp 55˚C 
3 CD144 
NM_001795.3 
F 
R 
GATCAAGTCAAGCGTGAGTCG 
AGCCTCTCAATGGCGAACAC 
114 bp 55˚C 
4 vWF 
NM_000552.3 
F 
R 
AGCCTTGTGAAACTGAAGCAT 
GGCCATCCCAGTCCATCTG 
154 bp 55˚C 
5 CD 133 
NM_001145852.1 
F 
R 
TGGCTGGGTGGCCTGGTCAT 
GACACAGCCTCGGGTGGTCG 
123 bp 60˚C 
6 CD146 
NM_006500.2 
F 
R 
TCCCGCAGCCCCTGAGAGAC 
CAGCGATAGCCGCCTCCTGC 
174 bp 60˚C 
7 CD105 
NM_000118.2 
F 
R 
GCCGTGCTGGGCATCACCTT 
CACTGTGGGGGCCTGGGGTA 
107 bp 60˚C 
8 CD309 
NM_002253.2 
F 
R 
GCGGGCCAATGGAGGGGAAC 
AAGGCACCACGGCCAAGAGG 
165 bp 60˚C 
9 CD14 
NM_001174105.1 
F 
R 
CGGCGGTGTCAACCTAGAG 
GCCTACCAGTAGCTGAGCAG 
142 bp 60˚C 
10 CD115 
NM_005211.3 
F 
R 
TCCAAAACACGGGGACCTATC 
TCCTCGAACACGACCACCT 
133 bp 
 
60˚C 
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11 CD45 
NM_002838.3 
F 
R 
CTCCGCCGCCAATGCAAAACT 
GAGCTGTGGTGTGCAAGGCTGAG 
144 bp 61˚C 
12 ACTA 2 
NM_001613.2 
F 
R 
TGCTGAGCGTGAGATTGTCCGG 
AGGGTCTCTCTGGGCAGCGGAA 
176 bp 
 
60˚C 
13 BMP4 
NM_130851.2 
F 
R 
GCGGGACTTCGAGGCGACAC 
GCCGGGCGCTCAGGATACTC 
171bp 63˚C 
14 TBP 
NM_001172085.1 
F 
R 
TCAGTGCCGTGGTTCGTGGC 
GCCACGCCAGCTTCGGAGAG 
184 bp 
 
60˚C 
15 PGC-1 α 
NM_013261.3 
F 
R 
TGTTTTTGACGACGAAGCAG 
AATGAATAGGATTGCGTGCC 
183 bp 60˚C 
16 CAT 
NM_001752.3 
F 
R 
GCTTCAGGGCCGCCTTTTTGC 
ATCGGGCCGTCACGCTGGTA 
126 bp 60˚C 
17 SOD3 
NM_003102.2 
F 
R 
GCCTCCTGCACTCGCGCTAA 
GAGTCGGGCACCTTTCCAGCTC 
123 bp 60˚C 
18 GPX1 
NM_000581.2 
F 
R 
TGGGCATCAGGAGAACGCCA 
CGCACCGTTCACCTCGCACT 
118 bp 60˚C 
19 G6PC 
NM_000151.3 
F 
R 
TGTGAGACTGGACCAGGGAGCC 
AGCTGCACAGCCCAGAATCCC 
167 bp 60˚C 
20 ERRα 
NM_004451.3 
F 
R 
AGGACCATCCAGGGGAGCATCG 
TTGAGCATGCCCACCCGCAG 
125 bp 60˚C 
21 SIRT1 
NM_012238.4 
F 
R 
CTCCAAGGCCACGGATAGGTCCA 
TCAGGTGGAGGTATTGTTTCCGG
CA 
112 bp 60˚C 
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22 PGC-1β 
NM_001172699.1 
F 
R 
CTCACTGGCGGACAGCACCC 
GGGAGAGGCTGGAGCTGGCT 
217 bp 60˚C 
23 GLUT4 
NM_001042.2 
F 
R 
GGGGCCTGCCAGAAAGAGTCTG 
AGCTGCAGCACGACCGCAAT 
177bp 60˚C 
24 CD105 
NM_001278138.1 
 
F 
R 
GGTGACCCGCGCTTCAGCTT 
 
CTTGCTGGGGACGCGTGTG 
 
291 bp 60˚C 
25 CD241 
NM_000324.2 
F 
R 
TGGGCGCCTCCAACACGTCTAT 
GGTTCCAGCTGGCTGTGGTCA 
226 bp 60˚C 
26 CD235 
NM_002099.6 
F 
R 
CGGGACACATATGCAGCCACTCC 
GGCAAGTTGTACCCTTTCTCCGGT 
105 bp 60˚C 
27 TEK/TIE2 
NM_000459.3 
F 
R 
TCACTTCGCTGCCGACGTGG 
CGCACTGGGAGCCTTCCCATT 
183 bp 60˚C 
28 SYK 
NM_001174167.1 
F 
R 
TGTGCCTGCTGCACGAAGGG 
GGGGAGGACGCAGGATGGGA 
241 bp 60˚C 
29 CD146 
NM_006500.2 
F 
R 
AACGTCAACGGCACGGCAAGT 
CCGGCTCCGGCAGCTTTCTC 
274 bp 60˚C 
30 SIRT3 
NM_001017524.2 
F 
R 
GCTTGGCGGCAGGGACGATTA 
CCCCGGCGATCTGAAGTCTGG 
221 bp 60˚C 
31 PGC-1 α 
NM_013261.3 
NM_013261.3 
F 
R 
F 
R 
ACTGCAGGCCTAACTCCACCCAC 
AACTCGGATTGCTCCGGCCC 
AGACGTCCCTGCTCGGAGCTT 
TGGGTGGAGTTAGGCCTGCAGT 
191 bp 
 
283 bp 
60˚C 
 
60˚C 
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3.8 Primer optimization  
 
Figure 3.3. Showing RT-PCR results for primer testing. N stands for negative control where H20 was used 
instead of cDNA. P stands for the positive control used which for macrophage markers (CD14, CD115) was day 
7 macrophage cDNA, and for all other markers was HUVECS. TBP was used as a house keeping gene. 100 bp 
DNA ladder was used. 
 
3.9 Reverse Transcription PCR 
RT-PCR allows the formation of cDNA fragments from RNA. These fragments are then 
amplified using specific set of primers. Up to 500 ng of RNA was mixed with 1 µL oligo dt 
primer and 10mM of dNTP, and dH2O was added to adjust the total volume to 13 µL. This 
mixture was incubated at 65˚C for 5 min, and then immediately put on ice for 1 min. This 
chilling was followed by addition of 4 µL of 5 x FSB (first strand buffer) along with 2 µL of 
DTT, and the mixture was allowed to incubate at 42˚C for 2 min. 1 µL reverse transcriptase 
(Superscript III) was added. Incubation was carried out at 42ºC for 1 hr to synthesize the 
cDNA, followed by incubation at 70˚C for 15 min in order to inactivate the enzyme. PCR 
was then carried out using a reaction setup with a final volume of 50 µL, and the annealing 
temperature was set specifically for each primer. The duration of extension was set according 
to the expected size of the product. 
 
3.10 Quantitative polymerase chain reaction (qPCR) 
Quantitative PCR refers to a laboratory technique based on PCR, which is used to amplify 
and at the same time quantify a targeted DNA molecule. This leads to both the detection and 
quantification of one or more sequences in a DNA sample. There are two main methods used 
for detection of PCR products in real-time PCR. These include, use of non-specific 
fluorescent dyes that intercalate with any double-stranded DNA and use of sequence-specific 
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DNA probes that have a fluorescent reporter tagged to them that allows detection only when 
the probe hybridizes with its complementary DNA target. 
The gene expression analysis for the comparison between early and late EPCs and mature 
endothelial cells (HUVEC) was done using fast SYBR Green fluorescent chemistry. The 
method followed was real-time reverse-transcription PCR which is often referred to as qRT-
PCR. RNA was extracted from the cells at different point times and was reverse transcribed 
to synthesize cDNA. For all the cDNA preparations, 100- 500 ng of RNA was used. Expected 
product size was around 100-200 bp. SYBR Green master mix was used and once the 
samples were prepared they were put in the light cycler (7500 Fast Real–time PCR system 
Applied Biosystems). Each sample contained 33 µL of fast SYBR Green master mix, 24.75 
µL of dH2O, .875 µL of each of the primer and 3.3 µL of cDNA prepared from total RNA. 
All the samples were run in triplicates. An increase in DNA product during the PCR lead to 
an increase in fluorescence intensity and was measured at each cycle allowing DNA 
concentrations to be quantified. As shown in the figure 3.4, the results are shown like this 
plot, where cycles are shown against ∆Rn. Rn value or the normalized reporter value 
represents the fluorescence signal from SYBR Green normalized to the signal of the passive 
reference dye for a given reaction. ∆Rn represents the difference between Rn values of an 
experimental reaction and Rn values of the baseline signals generated by the machine. As 
shown in the figure 3.5, a higher gene expression shows signals at earlier PCR cycles, 
whereas the negative control used for the reaction showing no expression of the gene is 
shown at higher cycles having high CT value. Quantitative PCR was carried out in triplicates 
for each sample and n represents the number of donors. 
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Figure 3.4. An amplification plot for a qPCR showing gene expression in terms of number of cycles 
and corresponding CT values. 
 
In order to confirm the specificity of the primers that were designed for the PCR and to make 
sure that the SYBR Green is not detecting any nonspecific double-stranded DNA including 
primer dimers and contaminating DNA and PCR product from misannealed primer, a melt 
curve was analysed for all the primers. Melt curve analysis is a tool to assess the dissociation-
characteristics of double-stranded DNA during heating. As more than one peak on a melt 
curve would indicate that the primers are producing nonspecific products. As shown in the 
figure there was only one peek seen in the melt curve, confirming that the primers were 
specific for the DNA target. 
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                              Figure 3.5.  Showing melt curve stage during qPCR reaction. 
 
3.11 Agarose gel electrophoresis 
The concentration of agarose and applied electrical field depends upon the size of DNA 
sequences. Usually 3gm of agarose was added in 150 ml of 1 × TBE Buffer, and allowed to 
mix thoroughly by heating in microwave for around 2-3 min. The mixture was then allowed 
to cool down at around 60˚C, and then 150 µL of Gel Red (10 mg/ml) was added. This 
agarose mixture was poured into the gel chamber and allowed to solidify. 1× TBE was used 
as the electrophoresis buffer. 6× loading buffer was added to the samples and these were then 
loaded in to the gel. Electrophoresis was carried out at a voltage of around 80-110v, current 
of 400 mA for about 60-120 min. Sizes of the DNA fragments were determined by 
comparison with a 100 bp DNA ladder. The gel was observed under UV light. 
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Figure 3.6. Schematic representation of the methods used for low density array (LDA). 
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3.12 Taqman array micro fluidic cards background 
Taqman array micro fluidic cards are 384-well cards which are loaded with dried down gene 
expression assays. These cards allow gene expression measurement using comparative ∆∆CT 
method and using relative quantification for gene expression analysis. These cards are 
provided in different formats and the format used included using one sample per card and 192 
genes to be analysed together including endogenous controls. Taqman array custom 
microfluidic cards were used that allowed selecting target genes (Taqman assays) and 
appropriate endogenous controls.  
                          A 
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                                                           B 
 
                                                          
 
Figure 3.7. A), B) Showing Taqman array micro fluidic card design and channels containing Taqman 
assays in dried down form. (Adapted from applied Biosystems). 
 
3.12.1 Assay selection strategy 
The assays were selected based on three different criteria. We proposed that ECFCs are the 
endothelial progenitor cells that must be at an earlier stage of differentiation as compared to 
mature endothelial and as there is still no marker that can distinguish between these cells and 
mature endothelial cells (HUVEC). Therefore, several genes were picked that were expected 
to show expression in progenitor cells and absence in mature endothelial cells and vice versa. 
We needed to test whether we can find genes that show high and low level of expression in 
ECFCs and HUVEC and could differentiate these cells on the basis of gene expression 
analysis.  
Secondly, as our earlier results indicated that there was an up regulation of antioxidative 
genes in ECFCs and HUVEC when grown in hyperoxia (40% O2) and also there was an up 
regulation of PGC-1 alpha and its downstream targets. As PGC-1 alpha is a transcriptional co 
activator we needed to investigate its downstream targets to establish if growing these cells in 
hyperoxia can have an effect on its downstream transcriptional factors that are known to be 
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involved in angiogenesis, electron transport chain assembly and mtDNA transcription as 
shown in figure below.  
 
Figure 3.8. Showing schematic representation of PGC-1α and its downstream targets. Adapted from 
(Arany et al. 2010). 
 
Thirdly, as we proposed that oxidative stress (40% O2) could be used as a model to study 
atherosclerosis in ECFCs so we checked for genes that were involved in DNA damage, 
telomere dysfunctioning and inflammatory response and angiogenesis and if this leads to 
change in expression as a result of exposure to oxidative stress and if this response was 
different in mature endothelial cells grown in hyperoxia. 
 
3.12.2 Endogenous controls used for the array 
All the data were analysed using relative quantification method (∆∆CT) and the data were 
normalized to three housekeeping genes that were used an endogenous control. These 
included: 
18s rRNA  
Hypoxanthine phosphoribosyl transferase (HPRT1)   
TATA box binding protein (TBP)  
 
  
 
 60 
 
3.12.3 Low density array (LDA) gene map 
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Schematic representation of the low density array (LDA). In all, 192 assays were used. 3 assays were used as 
endogenous controls. The assays were run in duplicates. 
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3.12.4 Isolation of total RNA from ECFC and HUVEC samples and DNase treatment 
RNA was extracted from ECFC and HUVEC samples using Qiagen RNeasy mini kit. Cells 
were kept frozen down at -80°C in freezing media containing DMSO. Cells were taken out 
from the freezer and quickly thawed and then transferred to a new eppendorf tube. This was 
followed by centrifugation at 800 x g for 5 min. Supernatant was removed and the cell pellet 
was disrupted by adding buffer RLT. The volume of lysis buffer used depended upon the no 
of cells: 
 
Table 3.2. Showing volume of lysis buffer to be used for extraction of total RNA 
Number of cells Volume of RLT Buffer 
1-5 x 10
6 
350 µL 
5 x 10
6
-1 x 10
7 
600 µL 
  
Cells were mixed well by gentle vortex or pipetting and the resulting cell lysate was directly 
transferred into a QIA shredder spin column which was placed in a collection tube. The 
column was subjected to centrifugation at 13000 x g for 2 min. This step was performed in 
order to homogenize the lysate as improper homogenization can lead to reduced RNA yield. 
Equal volume (350 µL) of  70% ethanol was added to the homogenized lysate and mixed 
well by pipetting. The resultant 700 µL of the sample along with some precipitates that were 
formed were transferred to the RNeasy spin column which was placed in a collection tube. 
This was allowed to centrifuge for 15s at 13000 x g. The flow-through was discarded. The 
next step was to treat the samples with DNase in order to avoid genomic DNA contamination. 
350 µL of wash buffer RW1 was added to the RNeasy spin column and lid was gently closed. 
This was followed by centrifugation for 15s at 13000 x g. Flow-through was discarded. 
DNase mix was prepared separately by adding 10 µL of DNase 1 from the stock to 70 µL of 
RDD buffer followed by gentle mixing. This DNase mix was added to the RNeasy column 
and incubated at room temperature for 15 min. After this incubation, 350 µL of buffer RW1 
was added to the column and centrifuged at 13000 x g for 15s. Flow-through was discarded. 
This was followed by addition of 500 µL of buffer RPE to the RNeasy spin column and 
centrifugation at 13000 x g for 15s. This step was repeated with an additional centrifugation 
for 2 min at 13000 x g so that no residual ethanol is carried over that can affect downstream 
reactions. An optional step was performed by placing the RNeasy spin column in a separate 
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and new 2ml collecting tube and centrifugation for 1 min at full speed. This was done to 
avoid any carryover of buffer RPE. The spin column was finally placed in a 1.5 ml eppendorf 
tube and 10-20 µL of RNase free water was added to the column membrane directly. This 
was followed by a final centrifugation for 1 min at 13000 x g. RNA was eluted and quantified 
using Nanodrop.  The quality of RNA was assessed by measuring A260/A280 ratio which 
was found to be around 1.7 - 2.1. 
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3.13.5 Samples used for Taqman low density array (LDA)  
                        
Same donor analysis 
Batch 1:   ECFC 1, ECFC H1, HUVEC 1 and HUVEC H1  
Batch 2:   ECFC 2, ECFC H2, HUVEC 2 and HUVEC H2    
Batch 3:   ECFC 3, ECFC H3, HUVEC 3 and HUVEC H3  
ECFC 1, 2, 3 = ECFCs grown in normoxia (20%O2) till P5. 
ECFC H1, H2, H3 = ECFCs grown in normoxia till P2 and then grown in 
hyperoxia (40%O2) till P5.  
HUVEC 1, 2, 3 = HUVEC grown in normoxia till P5.  
HUVEC H1, H2, H3 = HUVEC grown in normoxia till P2 and then grown 
in hyperoxia (40%O2) till P5. 
LDA samples were run in duplicates and n represents the number of donors. Three donors 
each (n=3) for ECFC normoxia, ECFC hyperoxia, HUVEC normoxia and HUVEC 
hyperoxia. One day 0 MNC sample was used that was a calibrator or reference sample and all 
the gene expression analysis was plotted relative to that. In all, thirteen array cards were used. 
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                                     Table 3.3. Showing RNA purity analysis 
LDA Sample A260/280 Ratio 
ECFC  1 2.07 
ECFC H1 2.04 
HUVEC 1 2.08 
HUVEC H1 2.07 
ECFC 2 2.06 
ECFCH 2 1.71 
HUVEC 2 2.08 
HUVEC H2 2.07 
ECFC 3 2.11 
ECFC H3 2.07 
HUVEC 3 2.06 
HUVEC H3 1.96 
                                    
 3.12.6 RNA integrity analysis using bioanalyzer 
After RNA extraction and quantification it was important to evaluate the integrity of RNA 
samples that would be used for the low density array (LDA). 
RNA evaluation is the first and most important step involved in gene expression analysis. 
This RNA evaluation was carried out using Agilent RNA 6000 Pico kit.  By using 
electrophoretic separation, the RNA samples were separated on micro fabricated chips and 
detected through laser via fluorescence detection. The bioanalyzer provides an 
electropherogram for the RNA sample along with a gel image and gives the RNA 
concentration and the ribosomal ratio (28s/18s). RNA integrity number (RIN) was developed 
to assess the RNA quality and grades from 1 -10 in increasing order of integrity. 
 
Figure 3.9. Showing an electropherogram with the regions indicative of RNA quality. (Adapted from Agilent 
technologies).  
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3.12.7 Preparation of RNA ladder 
RNA ladder was spun down and allowed to heat denature for 2 min at 70°C. It was 
immediately put on ice to get cooled down. 90 µL of RNase-free water was added to the 
ladder and thoroughly mixed. Once prepared, the ladder was aliquoted into several RNase 
free vials and kept at -80°C.  
 
Figure 3.10. Showing RNA 6000 Pico ladder. Seven well resolved peaks are illustrated including the first 
marker peak and the six RNA peaks.            
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
Table 3.4. Showing gene names and assay ID information used for LDA 
Gene Symbol Assay ID Location on Array 
Card 
PPARGC1A Hs01016719_m1 A01 
PRKAA1 Hs01562315_m1 A02 
PPARGC1B Hs00991677_m1 A03 
UCP1 Hs00222453_m1 A04 
UCP2 Hs01075227_m1 A05 
FOXO1 Hs01054576_m1 A06 
RPS6KB1 Hs00177357_m1 A07 
PCK2 Hs00388934_m1 A08 
G6PD Hs00166169_m1 A09 
AKT1 Hs00178289_m1 A10 
AKT3 Hs00987350_m1 A12 
CLK2 Hs00241874_m1 A13 
STK11 Hs00176092_m1 A14 
CAB39 Hs00212451_m1 A15 
MTOR Hs00234508_m1 A16 
PPARGC1A Hs00173304_m1 A17 
MT-ATP6 Hs02596862_m1 A18 
HNF4A Hs00230853_m1 A19 
MT-ATP8 Hs02596863_m1 A20 
MT-CO3 Hs02596866_g1 A21 
MT-CO2 Hs02596865_g1 A22 
MT-CO1 Hs02596864_g1 A23 
NOS3 Hs00167166_m1 A24 
THPO Hs00171249_m1 C01 
TEK Hs00176096_m1 C02 
TERF1 Hs00744634_s1 C03 
TERF2 Hs00194619_m1 C04 
RAD50 Hs00990023_m1 C05 
HNRNPF Hs00359014_m1 C06 
TNKS Hs00186671_m1 C07 
TINF2 Hs00173291_m1 C08 
FIGF PIR-FIGF Hs00189521_m1 C09 
TGFB1 Hs00171257_m1 C10 
TGFB2 Hs00234244_m1 C11 
CCL2 Hs00234244_m1 C12 
VCAM1 Hs00174239_m1 C13 
CD68 Hs00154355_m1 C14 
ICAM1 Hs00164932_m1 C15 
MPO Hs00924296_m1 C16 
SIRT1 Hs00202021_m1 C17 
SIRT2 Hs00247263_m1 C18 
SIRT3 Hs00202030_m1 C19 
SIRT4 Hs00202033_m1 C20 
HIF1A Hs00936376_m1 C21 
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BRCA1 Hs01556193_m1 C22 
ATR Hs00354807_m1 C23 
SOD2 Hs00167309_m1 C24 
CAT Hs00156308_m1 E01 
AIFM1 Hs00269879_m1 E02 
GPX1 Hs00829989_gH E03 
ABCG2 Hs00184979_m1 E04 
KDR Hs00176676_m1 E05 
CDH5 Hs00174344_m1 E06 
ENG Hs00923996_m1 E07 
GYPA Hs00266777_m1 E08 
ITGA2B Hs01116228_m1 E09 
SRXN1 Hs00607800_m1 E10 
CD34 Hs00990732_m1 E11 
PECAM1 Hs00169777_m1 E12 
PROM1 Hs01009250_m1 E13 
PTPRC Hs04189704_m1 E14 
CD36 Hs01567185_m1 E15 
MCAM Hs00174838_m1 E16 
BMPR2 Hs00176148_m1 E17 
KIT Hs00174029_m1 E18 
CASP3 Hs00234387_m1 E19 
TERT Hs00972656_m1 E20 
TERC Hs03454202_s1 E21 
TEP1 Hs00200091_m1 E22 
PINX1 Hs00363223_m1 E23 
MEN1 Hs00365720_m1 E24 
PPARG Hs01115513_m1 G01 
RFC1 Hs01099126_m1 G02 
POLE2 Hs00160277_m1 G03 
SMC6 Hs00226378_m1 G04 
SLC2A4 Hs00168966_m1 G05 
ESRRA Hs01067166_g1 G06 
PPRC1 Hs00209379_m1 G07 
GSK3A Hs00997938_m1 G08 
GSK3B Hs01047719_m1 G09 
PPARGC1A Hs00173304_m1 G10 
PPARGC1A Hs01016722_m1 G11 
PPARGC1A Hs01016721_m1 G12 
PPRC1 Hs00209379_m1 G13 
TFAM Hs01082775_m1 G14 
TFB1M Hs00274971_m1 G15 
TFB2M Hs00915025_m1 G16 
MEF2A Hs01050409_m1 G17 
MEF2B Hs01021286_m1 G18 
MEF2C Hs00231149_m1 G19 
MEF2D Hs00954735_m1 G20 
CAMKK2 Hs00198032_m1 G21 
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CREBBP Hs00231733_m1 G22 
CPT1A Hs00912671_m1 G23 
DGAT1 Hs00201385_m1 G24 
FGF21 Hs00173927_m1 I01 
DNM1L Hs00247147_m1 I02 
FOXO3 Hs00818121_m1 I03 
GPAM Hs01573680_m1 I04 
LDHB Hs00929956_m1 I05 
MFN2 Hs00208382_m1 I06 
NRF1 Hs00192316_m1 I07 
PDGFA Hs00964426_m1 I08 
PDK4 Hs01037712_m1 I09 
PPARA Hs00947539_m1 I10 
TNF Hs99999043_m1 I11 
ZFYVE9 Hs00245109_m1 I12 
AIFM1 Hs00377585_m1 I13 
CCL2 Hs00234140_m1 I14 
PROX1 Hs00896294_m1 I15 
ANGPT2 Hs01048043_m1 I16 
ANGPT4 Hs00907078_m1 I17 
ANGPT1 Hs00375822_m1 I18 
VEGFB Hs00173634_m1 I19 
VEGFC Hs00153458_m1 I20 
TGFA Hs00608187_m1 I21 
FGF1 Hs00265254_m1 I22 
FGF2 Hs00266645_m1 I23 
FGF4 Hs00999691_m1 I24 
CXCL12 Hs00171022_m1 K01 
PTN Hs00383235_m1 K02 
CXCL2 Hs00601975_m1 K03 
LECT1 Hs00993254_m1 K04 
HEY1 Hs01114113_m1 K05 
AMOT Hs00611096_m1 K06 
NRP1 Hs00826128_m1 K07 
NRP2 Hs00187290_m1 K08 
PDGFRA Hs00998018_m1 K09 
PDGFRB Hs01019589_m1 K10 
CCL3 Hs00234142_m1 K11 
PLA2G4A Hs00233352_m1 K12 
SMPD1 Hs01086851_m1 K13 
POT1 Hs00209984_m1 K14 
MRE11A Hs00967443_m1 K15 
XRCC5 Hs00221707_m1 K16 
NBN Hs01039836_m1 K17 
ACTA2 Hs00909449_m1 K18 
MAPK3 Hs00946872_m1 K19 
ITPKB Hs00176666_m1 K20 
MAPK14 Hs00176247_m1 K21 
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PIK3R5 Hs01046353_m1 K22 
RAF1 Hs00234119_m1 K23 
CASP9 Hs00154261_m1 K24 
BAD Hs00188930_m1 M01 
PXN Hs01104424_m1 M02 
SOS1 Hs00362308_m1 M03 
MTMR12 Hs00539666_m1 M04 
PTK2 Hs01056457_m1 M05 
STAT3 Hs00374280_m1 M06 
TNFSF10 Hs00921974_m1 M07 
INS Hs02741908_m1 M08 
BCL2 Hs00608023_m1 M09 
TAF6 Hs00425763_m1 M10 
VEGFA Hs00900055_m1 M11 
FLT1 Hs01052961_m1 M12 
SIRT5 Hs00978335_m1 M13 
SIRT6 Hs00213036_m1 M14 
SIRT7 Hs01034735_m1 M15 
TP53 Hs01034249_m1 M16 
TERT Hs00972651_m1 M17 
GPX4 Hs00157812_m1 M18 
VWF Hs01109446_m1 M19 
BMP4 Hs00370078_m1 M20 
IGF1 Hs01547656_m1 M21 
FLT4 Hs01047677_m1 M22 
TNFRSF10B Hs00366278_m1 M23 
KLF4 Hs00358836_m1 M24 
CXCR4 Hs00237052_m1 O01 
HMOX1 Hs01110250_m1 O02 
PTGS2 Hs00153133_m1 O03 
EDN1 Hs00174961_m1 O04 
HPRT1 Hs02800695_m1 O05 
HDAC5 Hs00608366_m1 O06 
TBP Hs00427620_m1 O07 
MT-ND3 Hs02596875_s1 O08 
MT-CYB Hs02596867_m1 O09 
OGT Hs00269228_m1 O10 
PRMT1 Hs01587651_m1 O11 
NAT10 Hs01120371_m1 O12 
NFATC1 Hs00542678_m1 O13 
KITLG Hs00241497_m1 O14 
NFKB1 Hs00765730_m1 O15 
PON1 Hs00166557_m1 O16 
TXN2 Hs00912509_g1 O17 
PRDX5 Hs00201536_m1 O18 
ROCK1 Hs01127699_m1 O19 
ROCK2 Hs00178154_m1 O20 
ESSRG Hs00155006_m1 O21 
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1L10 Hs00961622_m1 O22 
1L1A Hs00174092_m1 O23 
CSF1R Hs00911250_m1 O24 
 
 
3.12.8 Electropherogram showing RNA integrity analysis of samples used for LDA 
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3.12.9 cDNA synthesis using high capacity RNA-to-cDNA Kit 
After extraction of total RNA from ECFC and HUVEC samples next step was to reverse 
transcribe it to produce complementary cDNA. High capacity kit was used to do this 
synthesis. The kit contained RT buffer mix (2X) that was stored at 4°C and RT enzyme mix 
(20X) that was kept at -20°C.  
 
Preparation of RT reaction: 
All the kit components were thawed on ice. RNA samples were taken out from -80°C and 
kept on ice. The following table was used to calculate the exact volume of the components to 
be used for the desired number of reactions. In all, 13 samples and array cards were used for a 
total of 8 reactions per card making it a total of 104 reactions for this LDA experiment. 
Table 3.5. Showing reverse transcription preparation 
Components Volume/Reaction 
2 X RT Buffer 10 x 8 = 80 µL 
20 X RT Enzyme mix 1x8 =8 µL 
Nuclease-free H2O To make it to 400 µL 
RNA Sample Up to 9 µL 
Total per reaction  400 µL 
 
The reaction was mixed well by pipetting and kept on ice. 
 
Reverse transcription of the samples: 
RT reaction mix was aliquot in to Eppendorf tubes and the tubes were sealed with appropriate 
caps. In order to remove the air bubbles, the tubes were briefly centrifuged. Reverse 
transcription was started by incubating the tubes at 37°C for 60 min. The reaction was 
stopped by heating at 95°C for 5 min and immediately put on ice. The cDNA samples were 
kept at -20°C until they were used to perform the PCR. 
 
Preparation of PCR mix: 
Taqman fast advanced master mix was used for this purpose. cDNA samples that were kept at 
-20°C were taken out and thawed by at room temperature. Sample tubes were briefly 
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vortexed followed by centrifugation. The following table represents the calculations that were 
used for this array. 
 
Table 3.6. Showing final calculations for the PCR to be loaded in fill reservoir  
Component Volume per fill reservoir 
cDNA Sample (50 ng) + nuclease-free H2O 50 µL 
Taqman Fast advanced master mix 50 µL 
Total volume 100 µL 
  
 
3.12.10 Loading the PCR reaction mixes in to array card reservoirs 
For each card one cDNA sample was used. Taqman array card was removed from 4°C and 
kept at room temperature for about 30 min. Sample was removed from -20°C and thawed at 
room temperature. Each sample contained 400 µL of cDNA and nuclease free water. Equal 
volume of Taqman fast advanced master mix was added to the sample and mixed well by 
pipetting. 100 µL of sample specific master mix was loaded in to each reservoir.  
3.12.11 Centrifugation of array cards 
After loading the PCR master mix to all 8 fill reservoirs, the next step was to centrifuge the 
cards so that the cDNA sample could be distributed evenly across the wells. Centrifugation 
was carried out using Heraeus centrifuge machine and bucket type was set to 15679. The card 
was centrifuged using settings shown below in the table. 
 
Table 3.7. Showing centrifugation settings used for LDA  
Parameter QUIKSet (Knob-operated) 
Up Ramp rate  3 
Down Ramp rate  N/A 
Rotational speed 1200 rpm 
Centrifugation time 2 x 1 min 
                                                             
Once the centrifugation was completed, the card was removed and checked properly if filling 
was complete. It was confirmed that the amount of cDNA sample left in each fill reservoir 
was uniform and consistent. If it was not found to be like that, an additional 1 min 
centrifugation was performed.  
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3.12.12 Sealing of array cards 
After centrifugation was complete, the next step was to seal the array cards. This was a very 
important step because sealing of the card allows the isolation of wells after cDNA samples 
were evenly distributed following centrifugation. The sealer works by using a carriage to seal 
the fluidic channels of the array. It was important to check that the sealer‟s carriage was in 
starting position which could otherwise damage the card if allowed to seal in that position. 
Taqman array card was inserted in to the sealer in such a way that the end with fill reservoir 
was closest to the arrows at the base of the sealer. Array card was gently pushed until it was 
fixed securely in the insert plate. The carriage was pushed across the sealer‟s base in the 
direction of the arrows indicated on the sealer. It was important to perform this step slowly 
and steadily to finish the sealing smoothly. 
Once the card was sealed the last step was to trim the filling reservoirs from the array card 
using scissors. The card was run on ABI prism 7900 sequence detection system.  
 
3.12.13 Real time data analysis 
Data analysis was carried out using SDS 2.3 software and RQ manager version 1.2. 
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3.13 qPCR Validation for low density array 
                                    
Batch 4: ECFC4, ECFC H4, RNA extracted from samples from Batch 2 
but at different passages. P4 for normoxia and P2 for hyperoxia samples. 
HUVEC4, HUVEC H4 RNA extracted from samples from an additional 
batch at P5 and P3.   
Batch 5: ECFC5, ECFC H5, HUVEC5 and HUVEC H5. RNA extracted 
from different samples from Batch 1 but at same passages. P5 for normoxia 
and P3 for hyperoxia. 
Batch 6: ECFC 6, ECFC H6, HUVEC 6, HUVEC H6. RNA extraction from 
an additional batch. All from same donor.  P5 for normoxia and P3 for 
hyperoxia.    
 
3.13.1 Rationale for qPCR validation 
After finishing the LDA experiments, the next step was to validate the results. There were 
several genes that showed up regulation in ECFCs when grown in hyperoxia (40% O2) and 
several genes that showed down regulation in HUVEC when gown in hyperoxia (40% O2). 
So it was important to see if this difference persists with different samples and if this changes 
across passages. In order to do that we picked the genes that showed statistically significant 
difference amongst samples and used Taqman gene expression assays to validate these results 
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across different samples. Samples were run in triplicates and n represents the number of 
donors.  
Taqman gene expression assays are pre-optimized primer and probe based assays designed 
for qPCR analysis. The primers are formulated at a concentration of 20 µm. Each assay 
contains three target-specific oligonucleotides. They include: 
Unlabelled PCR Primer pair 
Taqman probe with FAM dye label and minor groove binder (MGB) moiety on the 5ʹ end 
non fluorescent quencher (NFQ) on the 3ʹ end. Taqman gene expression assays are used to 
amplify cDNA in the qPCR step in RT–PCR. We used two step RT-PCR approach using 
total RNA isolated from samples. RNA was quantified using Nanodrop. 
 
                                  Table 3.8. Showing RNA purity analysis  
qPCR Sample A260/280 Ratio 
ECFC 4 2.03 
ECFCH4 2.18 
HUVEC 4 2.12 
HUVEC H4 2.03 
ECFC 5 2.03 
ECFC H5 1.93 
HUVEC 5 1.91 
HUVEC H5 1.95 
ECFC 6 2.07 
ECFC H6 1.96 
HUVEC 6 2.12 
HUVEC H6 2.10 
 
3.13.2 qPCR using Taqman gene expression assays 
These assays are based on 5ʹ nuclease activity of Taq DNA polymerase. Taqman probes 
hybridize to the target DNA between two unlabelled primers. Signal from the fluorescent dye 
on the 5ʹ end of the probe is quenched by NFQ on its 3ʹ end. This occurs through 
fluorescence resonance energy transfer (FRET). During PCR, Taq polymerase extends the 
unlabelled primer using template as a guide. When the polymerase reaches the Taqman 
probe, it cleaves the molecule, separating the dye from the quencher and allowing it to 
fluoresce. This fluorescence is detected by the PCR machine using nonquenched FAM dye. 
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With each PCR cycle, there is a release of dye molecules which results in an increase in 
fluorescence intensity that is proportional to the amount of amplicon synthesized.                  
 
Table 3.9.  Showing Taqman gene expression assay IDs and transcript accession information 
Gene 
Symbol 
Gene 
ID 
Assay ID Transcript 
Accession 
Location 
on NCBI 
Genome 
Assembly 
Location 
on 
Transcript 
or Gene 
Size 
of 
Amp 
(bp) 
ITPKB 3707 Hs00176666_m1 NM_002221.3 226819391 2583 71 
PRDX5 25824 Hs00201536_m1 NM_181651.2 64085560 299 128 
PPARGC1A 10891 Hs01016721_m1 NM_013261.3 23793644 2413 80 
MT-ATP8 4509 Hs02596863_g1 NC_012920.ATP8.0 NA 38 120 
MT-CYB 4519 Hs02596867_s1 NC_012920.CYB.0 NA 692 151 
MT-ND3 4537 Hs02596875_s1 NC_012920.ND3.0 NA 118 150 
VEGFC 7424 Hs00153458_m1 NM_005429.2 177604691 1140 126 
GPX4 2879 Hs00157812_m1 NM_001039847.1 1103936 197 123 
PON1 5444 Hs00166557_m1 NM_000446.5 94927669 1010 122 
PECAM1 5175 Hs00169777_m1 NM_000442.4 NA 2376 65 
CXCL12 6387 Hs00171022_m1 NM_199168.3 44872506 273 77 
KIT 3815 Hs00174029_m1 NM_001093772.1 55524095 154 64 
IL1A 3552 Hs00174092_m1 NM_000575.3 113531488 1578 69 
KDR 3791 Hs00176676_m1 NM_002253.2 55944426 2567 84 
ABCG2 9429 Hs00184979_m1 NM_004827.2 89011416 1027 92 
NRP2 8828 Hs00187290_m1 NM_018534.3 206547224 863 81 
SIRT4 23409 Hs00202033_m1 NM_012240.2 120740124 559 106 
FGF2 2247 Hs00266645_m1 NM_002006.4 123747863 649 82 
ANGPT1 284 Hs00375822_m1 NM_001199859.1 108261710 925 74 
PCK2 5106 Hs00388934_m1 NM_001018073.1 24563483 405 73 
TBP 6908 Hs00427620_m1 NM_001172085.1 170863421 578 91 
TGFA 7039 Hs00608187_m1 NM_001099691.2 70674410 614 70 
PROX1 5629 Hs00896294_m1 NM_002763.3 214161860 2301 74 
VEGFA 7422 Hs00900055_m1 NM_001025366.2 43737946 1352 59 
CDH5 1003 Hs00901463_m1 NM_001795.3 66400525 1994 63 
ACTA2 59 Hs00909449_m1 NM_001141945.1 90694831 455 64 
TEK 7010 Hs00945146_m1 NM_000459.3 27109147 3742 123 
PDGFRA 5156 Hs00998018_m1 NM_006206.4 55095264 2481 84 
PROM1 8842 Hs01009250_m1 NM_002609.3 15969849 2864 75 
PDGFRB 5159 Hs01019589_m1 NM_002609.3 149493400 3374 62 
TP53 7157 Hs01034249_m1 NM_001126112.2 7571720 1301 108 
PDK4 5166 Hs01037712_m1 NM_002612.3 95212807 1098   74 
FLT1 2321 Hs01052961_m1 NM_001159920.1 28959688 1387 72 
PPARG 5468 Hs01115513_m1 NM_138711.3 12330436 812 90 
NOS3 4846 Hs01574659_m1 NM_001160109.1 150690892 266 107 
HPRT1 3251 Hs02800695_m1 NM_000194.2 133594175 297 82 
18S HSRN Hs99999901_s1 X03205.1 109078 604 187 
ANGPT2 285 Hs01048043_m1 NM_001118888.1 6357172 973 113 
MT-C01 4512 Hs02596864_g1 NC_012920.CO1.0 NA 613 94 
VWF 7450 Hs01109446_m1 NM_000552.3 6058040 308 56 
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Table 3.10. Showing statistical analysis for the samples used for LDA and qPCR 
validation using two way ANOVA 
Gene Name 
 
ECFC 
20%Vs40% 
HUVEC  
20%Vs40% 
ABCG2 *P ˂ 0.05 ns P ˃ 0.05 
ACTA 2 ***P ˂ 0.001 ns P ˃ 0.05 
ANGPT1 ***P ˂ 0.001 ns P ˃ 0.05 
ANGPT2 ***P ˂ 0.001 * P ˂ 0.01 
CDH5 *P ˂ 0.05 ns P ˃ 0.05 
CXCL12 ***P ˂ 0.001 ns P ˃ 0.05 
FGF2 *P ˂ 0.05 ns P ˃ 0.05 
FLT1 **P ˂ 0.01 ns P ˃ 0.05 
GPX4 *P ˂ 0.05 ns P ˃ 0.05 
IL1A *P ˂ 0.05 **P ˂ 0.01 
ITPKB *P ˂ 0.05 ns P ˃ 0.05 
KDR ***P<0.001 ns P > 0.05 
KIT *P < 0.05 ns P > 0.05 
MT-ATP8 ***P<0.001 ns P < 0.05 
MT-C01 *P < 0.05 ns P > 0.05 
MT-CYB *P < 0.05 ns P > 0.05 
MT-ND3 *P < 0.05 ns P > 0.05 
NOS3 *P < 0.05 ns P > 0.05 
NRP2 ns P > 0.05 ns P > 0.05 
PCK2 ns P > 0.05 * P < 0.05 
PDGFRA *P < 0.05 ns P > 0.05 
PDGFRB *P < 0.05 ns P > 0.05 
PDK4 ns P > 0.05 *P < 0.05 
PECAM1 *P < 0.05 ns P > 0.05 
PPARG **P<0.01 ns P > 0.05 
PPARGC1A *P < 0.05 ns P > 0.05 
PRDX5 ns P > 0.05 ns P > 0.05 
PROM1 ***P<0.001 ns P > 0.05 
PROX1 *P < 0.05 ns P > 0.05 
SIRT4 ns P > 0.05 ***P<0.001 
TEK ns P > 0.05 ns P > 0.05 
TGFA ns P > 0.05 ***P<0.001 
TP53 ns P > 0.05 *P < 0.05 
VEGF A ***P<0.001 ns P > 0.05 
VEGF C ***P<0.001 *P < 0.05 
VWF ns P > 0.05 ***P<0.001 
  
 
 
 82 
 
3.14 Telomerase activity measurement using telomeric repeat 
amplification protocol (TRAP) assay 
 
 
Figure 3.11. Showing TRAP assay used for the measurement of telomerase activity. (Adapted from De Cian 
et al., 2007).  
 
TRAP assay also known as telomeric repetition amplification protocol is used to measure 
telomerase activity in desired cell types. Telomerase is an enzyme, belonging to ribonucleo 
protein family. It acts as a reverse transcriptase and has its own RNA molecule which is used 
as a template for telomere elongation, which is shortened with each replicative cycle. The 
main function of telomerase is to add DNA sequence repeats (TTAGGG) at 3’ end of the 
telomeric DNA strands located in regions at the extreme ends of eukaryotic chromosomes 
called telomeres.  
Human telomerase consists of two main catalytic subunits, a protein component that has 
reverse transcriptase activity called human telomerase reverse transcriptase (TERT or 
hTERT), being encoded by the same gene and the telomerase RNA (TERC), that acts as a 
template for this telomere repeats. Telomerase therefore elongates telomeres in DNA strands 
allowing senescent cells to exceed the Hay flick limit (number of times a cell population can 
divide before the cell division stops) and potentially becomes immortal, as seen in cancer 
cells. 
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ACX (HPLC purified) 100ng/ µL    5‟- GCGCGGCTTACCCTTACCCTTACCCTAACC-3‟ 
TS (HPLC purified) 100ng/ µL       5‟- AATCCGTCGAGCAGAGTT-3‟ 
 
TRAP assay was carried out on two cell types endothelial progenitor cells ECFCs and mature 
endothelial cells HUVEC while cord blood mononuclear cells (HUCBC) were used as 
reference samples to which relative telomerase activity was measured.  
Endothelial colony forming cells (ECFCs) were obtained from umbilical cord blood and 
allowed to differentiate in endothelial specific media (EBM-2). The cells were grown in 
normoxia (20% oxygen) and hyperoxia (40% oxygen). In normoxia cells were grown till 
passage 10 (P10) and were passaged regularly once they became around 70-80% confluent. 
Trypsin–EDTA was used to split the cells. Once the cells were grown for passage 2 (P2) in 
normoxia they were incubated in hyperoxia for an additional passage (P1). Cells were frozen 
down with each passage in freezing media containing DMSO. Mature endothelial cells 
HUVEC were isolated from human umbilical vein and were grown in normoxia (20% 
oxygen) till passage 10 (P10). The cells were split regularly once they grew to 70-80% 
confluence.  
Frozen cells were thawed quickly and spun down at 800 x g for 5 min. Supernatant was 
aspirated and the cell pellet was resuspended in NP40 cell lysis buffer to produce 50,000 
cells/ µL suspensions. The resultant cell suspension was incubated for 30 min on ice. This 
was followed by a centrifugation at 16000 x g at 4°C for 20 min. The supernatant as 
transferred to a pre-cooled eppendorf and the sample was ready to use for the assay. 
No of cells used for telomerase activity measurement (TRAP assay) 
100,000 cells/triplicate 
300,000 cells/sample 
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Table 3.11. Showing calculations used for telomerase activity measurement 
Material Volume per tube in µL Volume per triplicate in µL 
Sybr Green PCR Master mix 12.5 37.5 
ACX primer 1 3 
TS primer 1 3 
dH2O 8.25 24.75 
EGTA .25 .75 
 
Final volume used per tube was 75 µL, so 69 µL of this master mix was used and 6 µL of 
sample was added. The resultant mixture was divided in to three triplicates of 25 µL each and 
samples were placed in the PCR machine rack and the TRAP assay programme was run.  
There were five controls used for the TRAP assay, to make sure that it has worked well. 
These controls included the following as shown in the table below: 
Table 3.12. Showing controls used for TRAP   
1 Distilled water (dH2O) 
2 No primers (ACX and TS) 
3 NP40  
4 R8 1: 100 
5 R8 1: 1000 
 
The PCR programme used for the TRAP assay was as follows: 
Table 3.13. Showing PCR programme used for the assay 
Elongation 25°C for 30 min 
Denaturation 95° C for 10 min 
Denaturation 95° C for 10 sec 
Annealing 60 ° C for 1 min 
PCR cycles 40 
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3.15 Direct immunofluorescence analysis 
Immunofluorescence refers to the labelling of antigens by using fluorescent dyes. This 
technique is widely used to detect subcellular distribution of specific biomolecule targets with 
in a cell. Immunofluorescence-stained cells or tissue sections can be studied in detail using 
light microscopy, confocal microscopy and flow cytometry analysis. The first step is to 
prepare cells and making them attached to a solid support. The next step is to fix and 
permeabilize the cells in order to ensure proper access of the antibody to its specific antigen. 
The third step involves incubation with the antibody. Antibody which is not bound is 
removed by washing and unbound antibody is detected either directly (if primary antibody is 
fluorochrome-labelled) or indirectly using a secondary antibody, labelled with a 
fluorochrome. Finally, the staining is evaluated by using fluorescent microscopy. 
3.15.1 Experimental design 
We needed to test whether endothelial colony forming cells (ECFCs) were at an earlier stage 
of differentiation than mature endothelial cells (HUVEC). As it was shown in our earlier data 
that mRNA expression analysis confirmed that the ECFCs showed much lower expression of 
vWF transcripts than mature endothelial cells which had much higher expression of vWF. In 
order to test this, ECFCs and HUVEC were grown in special chamber slides (Lab-TEK II Cat 
# 154526). Around 10,000 cells were plated in each well. For a better comparison early (P5) 
and late passage (P15) cells were used both for ECFCs and HUVEC. IgG matched isotype 
control (Human IgG (Normal) Life technologies (Molecular Probes) Cat # 12000C) was used 
as a negative control.  
 
Figure 3.12. Showing cells stained with human IgG antibody used as an isotype control for the direct 
Immunofluorescence analysis. Images taken at 10 X magnification. Scale on the bar represents 100 µm. DAPI 
was used to stain the nuclei. 
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3.15.2 Staining procedure  
Cells were grown in chambered slides and incubated at 37°C at 5% CO2 in normoxia. Cells 
were checked for attachment the next day. Cells were attached well and washed briefly with 
PBS. Fixation of cells was carried out using methanol (Sigma Aldrich Cat # 179337). 500 µL 
methanol was added and cells were kept at -20°C for 10 min. Methanol was removed using a 
sucking pump. Permeabilization was carried out by adding 500 µL cooled acetone (Sigma 
Aldrich Cat # W332607) and cells were kept at -20°C for 1 min. Cells were rinsed twice in 
wash buffer (0.05% Tween 20 in PBS) for 2 min. This was followed by incubation in 
blocking buffer (2% BSA diluted in PBS) for 30 min in order to avoid nonspecific binding of 
the immunoglobulin. Primary antibody (Sheep PAb to vWF, Applied Biosciences Cat #8820) 
was diluted in antibody buffer (2% BSA in PBS). The final concentration used was 1:2000. 
Cells were incubated with primary antibody diluted in buffer for 60 min at room temperature 
in a humidified chamber. After this incubation cells were washed 5-6 times with the wash 
buffer. Excess buffer was removed and cells were counterstained with mounting media 
containing DAPI (Vectashield Cat # H-1200). Chambers were removed and slides were 
mounted using glass cover slips. 
Axio imager fluorescent microscope B162 was used to inspect the slides. Images were taken 
at 10 X magnification and Image J software (Fiji) was used for analysing and counting the 
FITC positive cells required for statistical analysis that was done using unpaired t tests. 
3.15.3 Limitation of the Experiment 
Human IgG (Normal) was used as a negative control for the experiments. A better control 
would have been Human IgG (FITC).  
 
3.16 Flow FISH (Fluorescent in situ hybridization)  
Flow FISH is rapidly emerging as a powerful tool to measure length of telomere repeats in 
cells. This technique allows using fluorescent in situ hybridization (FISH) in conjunction 
with a labelled peptic nucleic acid (PNA) probe which is specific for those telomere repeats 
along with measurement of fluorescence using flow cytometry. This method to measure the 
lengths is working on the fact that, at decreased ionic strength, PNA can anneal to 
complementary single stranded DNA sequences. Hybridized PNA probe used (C3TA2)3 
(FITC-conjugated) for these experiments was based on the principal that low levels of 
fluorescent signals could be detected  by a  laser flow cytometer (FACS Canto II in this case) 
and  Propidium Iodide was used a counter stain. So, only those cells were gated which took 
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up propidium iodide as shown in figure 3.13. Only those samples were included in which at 
least 1000 events were obtained with the desired gate. Figure 3.1 shows the gating strategy 
and the control used for the experiment for measuring telomere lengths ECFCs and HUVEC 
across passages. Thymocytes were used as a control and a reference telomere length.    
 
 
 
 
Figure 3.13. Showing histogram of the analysis of thymocytes which were used a control for flow FISH 
experiments used to measure the telomere length of ECFC and HUVEC samples across passages. Thymocytes 
were used as reference telomere length which was nearly 1.5 times longer than found in human endothelial 
cells.  
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3.16.1 Telomere length measurement using flow FISH 
After measuring the telomerase activity of ECFC and HUVEC samples in both normoxia and 
hyperoxia it was needed to measure telomere lengths of ECFC and HUVEC samples across 
passages. This was to test whether telomere length is decreasing with each replicative cycle 
in both these cells. Secondly, to check if these progenitor cells (ECFCs) are different from 
mature endothelial cells in terms of preserving their telomere lengths and if there was a 
difference in hyperoxia conditions. ECFCs were derived from cord blood and cells were 
passaged regularly using Trypsin-EDTA. Cells were split in a ratio of 1:3. ECFC samples 
used were grown in normoxia (20% O2) and early to late passage samples were used (P2-
P16). HUVEC were isolated from umbilical vein of the cord and cells were grown in 
normoxia. Cells were split regularly in a ratio of 1:3. Measurement of telomere lengths was 
done across passages in HUVEC samples (P2-P16). Bovine thymocytes were used as an 
internal control for the study, and used as a reference being a sample with known telomere 
length. 
 
3.16.2 Flow FISH Assay 
Bovine thymocytes were frozen down at -80°C. They were thawed at room temperature. 500 
µL of FBS was added to the cells and freezing media. This suspension was mixed well by 
pipetting and transferred to an eppendorf tube. This was subjected to centrifugation at 300 x g 
for 5 min. Supernatant was sucked down and the pellet was resuspended in 1 ml of PBS 
containing 5% FBS and mixed well by pipetting. This cell mix was transferred to a 15 ml 
falcon tube and 2 ml of this PBS was added. This was kept on ice till other samples were 
ready for cell count. 
HUVEC samples were frozen down at -80°C. Cells were taken out and thawed at room 
temperature. 2 ml of PBS containing 5 % FBS was added to the cell mix containing freezing 
media. Cells were counted using Vi-Cell XR 2.03 (Beckman Coulter). 300,000 cells were 
used per triplicate for PNA
+ 
samples. 300,000 cells were used for 1 PNA
-
 sample. 
ECFC samples were kept at -80°C. Cells were thawed by rolling fingers and 2 ml of PBS 
with 5% FBS was added. Cells were counted and 300,000 cells were used per duplicate. 
Viable cell count was used for calculations for all cell types. Cell mix was centrifuged for 10 
min at 2000 x g. Supernatant was aspirated and cells were resuspended in 300 µL of 
hybridization mix in separate tubes. 
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3.16.3 Preparation of hybridization mix 
Ultra-pure formamide was taken out from -20°C and thawed at room temperature. Water bath 
was set at 87°C. Hybridization mix was prepared using following calculations. 
 
Table 3.14. Showing hybridization mix preparation for flow FISH 
Material End Concentration Volume for 6 
PNA
- 
Tubes 
Volume for 12
 
PNA
+
  Tubes 
1M Tris PH 7.1 20mM 50 µL 90 µL 
1M NaCl 20mM 50 µL 90 µL 
BSA 10% 1% 250 µL 450  µL 
Ultra pure Formamide 75% 1876 µL 3376 µL  
dH2O  249 µL 449  µL 
PNA Probe 30µg/ml 0.3µg/ml  45 µL 
Negative Control (TE 
Buffer) 
 45 µL   
 
Cells were incubated in dark for 10 min after resuspension in hybridization mix. This was 
followed by 15 min of placement in water bath at 87°C. Cells were removed from water bath 
and kept at room temperature in dark for approximately 2 hrs. 
After this incubation, cells were washed using two different washing solutions. Cells were 
vortexed and centrifuged for 5 min at 2000 x g. Supernatant was sucked till around 100 µL 
still remained. This wash was repeated for two additional times. Table below shows the 
content and concentration of wash solution I. 
 
Table 3.15. Showing wash buffer I preparation 
Materials End Concentration Volume for 12 Tubes 
Formamide  75% 45 ml 
1M Tris PH 7.1 10 mM 600 µL 
BSA 10% 1% 6 ml 
Tween20 10% 1% 6 ml 
dH2O  2.4 ml 
 
This wash was followed by a second wash and table below shows the content and 
concentrations of the materials used. 
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Table 3.16. Showing wash buffer II preparation 
Materials End Concentration Volume for 12 Tubes 
BSA 10% 1% 1.5 ml 
Tween20 10% 1% 1.5 ml 
1M HEPES 10mM 150 µL 
Glucose  11.9 ml 
 
1 ml of wash solution 2 was added to each tube and cells were centrifuged for 10 min at 2000 
x g. Supernatant was sucked till 50 µL remained. 
 
Table 3.17. Showing DNA counterstain mix preparation 
Material End Concentration 12 Tubes 
Propidium Iodide 0.06 µg/ml 45 µL 
RNase A 10 µg/ml 4.5 µL 
BSA 10% 0.1 % 45 µL 
PBS  4405.5 µL 
 
Telomere length measurement calculation: 
Relative telomere length was measured using following method. 
Mean fluorescence measurements were obtained for both PNA
+
 and PNA
–
 samples. An 
average was taken for the positively stained samples used in duplicates (ECFC) and 
triplicates (HUVEC). This value was subtracted from the PNA
–
 mean fluorescence values 
obtained. Thymocytes were used as a reference telomere length and telomere length 
measurements were calculated relative to the mean fluorescence values obtained for 
thymocytes. 
 
3.17 Multicolour flow cytometry 
Multicolour flow cytometry involves using several antibodies together each having a 
different fluorochrome to stain them followed by analysis using a flow cytometer. In order to 
confirm the expression of cell surface markers at protein level, several important markers 
were checked. This included FACS analysis with antibodies for markers that showed 
expression at mRNA level in earlier experiments in human cord blood mononuclear cells, 
ECFCs and HUVEC samples. Unstained cells were used for gating and used as a negative 
control. The analysis was carried out using antibodies as shown in the table below. 
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                 Table 3.18. Showing set up used for Multicolour flow cytometry  
Antibodies Fluorochrome Volume Used 
Mouse Anti Human 
CD34 
APC Conjugate 5 µL 
Mouse Anti Human 
CD144 
FITC 10 µL 
Mouse Anti Human 
CD14 
Pacific Blue 
Conjugate 
5 µL 
Mouse Anti Human 
CD146 
PE 10 µL 
 
One million cells were used per sample. Cells were resuspended in 500 µL of PBS and 
transferred to a labelled FACS tube. Antibodies were added and cells were incubated at room 
temp for 20-30 min. This was followed by a wash and then cells were analysed for FACS 
using FACS Canto II. Gating strategy for this experiment was devised using unstained 
samples. All the gates were set using that as shown in figure below. For all the samples 
including cord blood mononuclear cells (MNCs), ECFCs and HUVEC a negative (unstained) 
sample was used to set up the gates. 
 
 
 
Figure 3.14. Gating strategy of unstained cells used for the detection of ECFCs and HUVEC. These 
unstained cells were used for setting gates for the positive and stained samples. 
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Table 3.19. Showing list of materials and associated information used for the study  
Product  Manufacturer Catalogue no  
 
Rat Tail Collagen BD Biosciences #354236 
 
Human  Plasma Fibronectin  Chemicon (Millipore) #FC010 
 
EBM-2 media Clonetics #CC 3156 
 
Single Quotes Clonetics #CC4176 
 
Foetal Bovine Serum Clonetics #CC 4101A 
 
Hydrocortisone Clonetics #CC 4112A 
 
h FGF Clonetics #CC 4113 A 
 
VEGF Clonetics #CC 4114 A 
 
R3- IGF Clonetics # CC 4115 A 
 
Ascorbic  Acid Clonetics # CC 4116 A 
 
GA -1000 Clonetics # CC 4381 A 
 
Heparin Clonetics #CC 4396 A 
 
RPMI 1640 Gibco (Invitrogen) #21875 
 
Medium M-199 Sigma- Aldrich #M 4530 
 
HEPES 1M Gibco (Invitrogen) #15630 
 
L- Glutamine Gibco (Invitrogen) #25030 
 
Trypsin-EDTA PAA #L11-004 
 
Penicillin/Streptomycin Gibco (Invitrogen) #15070 
 
TRizol Invitrogen #15596-026 
 
Taq DNA Polymerase Fermentas # EP0402 
 
Random Hexamer Primer Fermentas #S0142 
 
Fast SYBR Green 
 
Applied Biosciences # 4385618 
6 X Loading Dye Promega #G1881 
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RNase H Fermentas              #EN0201 
 
dNTP - mix Invitrogen #10297-117 
 
First Strand Buffer 5 X Invitrogen              #10812-014 
 
0.1M DTT Invitrogen             #18080-044 
RNase Inhibitor Fermentas #EO0381 
 
Superscript Reverse 
Transcriptase 
Invitrogen #18064-022 
 
100 bp DNA Ladder Invitrogen #10488-058 
 
Agarose Lonza SeaKem #50004 
 
Hematocytometer ROTH #T728.1 
Phosphate Buffer Solution PAA #H15-002 
 
DMSO  Sigma-Aldrich #D2650 
 
25 mM MgCl2 Fermentas #R0971 
 
Collagenase Gibco (Invitrogen) # 17101-015 
 
Ficoll-Hypaque Biochrom #L6115 
Pipette Tips  0.1-10µl Star Lab #S1111-3700 
Pipette Tips  1-200µl Star Lab #S1111-1700 
Pipette Tips  101-1000µl Star Lab #S1111-2721 
Pipette Tips  101-1000µl Star Lab #S1122-1830 
RNeasy Mini Kit Qiagen #74104 
Glucose Sigma-Aldrich #G5400 
Formamide ultra-pure Invitrogen #15515-026 
Hydrochloric acid (HCl) Sigma-Aldrich #H1758 
Sodium chloride Sigma-Aldrich #S6191 
TE buffer Qiagen #11910 
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Tris (Trizma base) Sigma-Aldrich #T-1503 
Tween 20 Sigma-Aldrich #P-1379 
Propidium iodide (PI) Molecular Probes #P-1304MP 
PNA probe (C3TA2)3 (FITC-
conjugated) 
Panagene Custom order 
Mouse anti human CD 34 APC 
conjugate 
BD Pharmingen #560940 
Human CD 14 Pacific Blue 
Conjugate 
Invitrogen #MHCD 1428 
PE Mouse Anti-Human CD146 
Monoclonal 
BD Pharmingen #561013 
Sheep pAb  vWF  Applied Biosciences #8822 
Human IgG  Molecular Probes #12000C 
Methanol  Sigma- Aldrich # 179337 
Chamber slides  Lab-TEK II # 154526 
Acetone  Sigma- Aldrich # W332607 
Mounting media containing 
DAPI 
Vectashield # H-1200 
RNase A (100 mg/ml) Qiagen #19101 
FITC Mouse Anti-Human 
CD144 
BD Pharmingen #560874 
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Chapter 4. Isolation and characterization of human endothelial 
progenitor cells (ECFCs) and comparison with mature endothelial 
cells (HUVEC) 
4.1 Introduction 
The human vasculature provides a dynamic network in the body for gaseous exchange and 
delivery of nutrients and circulation of cells. Blood vessel formation is considered as a 
fundamental aspect of development and any abnormality or irregularity in that can lead to 
fatal disease and therefore making it a therapeutic target.  It has been proposed for long that 
endothelial progenitor cells (EPCs) hold great promise in the field of vascular biology, as 
their ability to differentiate in to endothelial cells can be used as a tool to re-endothelialize 
damaged blood vessels and facilitate the process of maintaining an intact endothelium. 
Similarly, low EPC count has been associated with coronary heart diseases (CHD). But till 
now, the identification of an endothelial progenitor cell has been a matter of debate, as there 
is no unique marker that can distinguish these cells from mature endothelial cells. They are 
therefore, identified on the basis of the expression of several cell surface markers. The first 
aim of our study was to isolate endothelial progenitor cells (ECFCs) from cord blood and 
differentiate them from early EPCs and macrophages derived from the same cord blood and 
compare them with mature endothelial cells which were derived from human umbilical vein 
of the same donor. This was followed by characterization of all these cell types isolated from 
the same donor, at mRNA and protein level and comparison with mature endothelial cells. In 
order to carry out this study our first goal was to isolate the correct endothelial progenitor 
cells as there has been so many discrepancies associated with their identification. To provide 
a better comparison we decided to isolate the cells from the same donor. This meant that the 
umbilical cord blood used to isolate the endothelial progenitor cells was from the same donor 
whose umbilical cord was used for the isolation of human umbilical vein endothelial cells 
(HUVEC). The study was designed in such a way that human umbilical cord mononuclear 
cells (HUCBC) also known as day 0 mononuclear cells (MNCs) were used as a starting 
population for the comparison and they were isolated from cord blood using ficoll based 
lymphoprep separation. Macrophages were used as a control for the study for two reasons. 
Firstly, it has been shown that the early EPCs are related to monocyte-macrophage lineage 
and the endothelial progenitor cells (ECFCs) should be distinguished from them on the basis 
of expression of monocyte-macrophage markers (Yoder et al. 2007).  Secondly, macrophages 
are known to be resistant to oxidative stress (Dernbach et al. 2004) and therefore it was 
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important to make sure that the endothelial progenitor cells isolated for testing further 
hypothesis were not composed of a mix of cell populations like monocyte and macrophages. 
 
4.2 Results 
4.2.1 Isolation and morphological analysis of cell types isolated from cord blood and 
human umbilical vein of the same donor 
The human cord blood mononuclear cells (HUCBC) also known as MNCs were isolated from 
cord blood using lymphoprep. A cell pellet was obtained after centrifugation and around 5-10 
million cells were frozen down for carrying out RNA extractions. These were designated as 
day 0 MNCs or the starting population from which all the cell types were derived apart from 
mature endothelial cells (HUVEC), which were derived from the umbilical vein of the same 
donor. Morphologically, the MNCs appeared as small rounded cells as shown in figure 4.1A. 
After freezing down cells, the remaining MNCs were divided into three cultures to isolate 
early EPCs, macrophages and ECFCs from the same donor. Around 10-15 million cells per 
well were plated in order to isolate early EPCs also known as circulating angiogenic cells 
(CACs) and the cells were allowed to differentiate in endothelial specific media in normoxia. 
Cells were washed and the media was changed regularly. After 3-5 days of culture early 
EPCs were seen visible and were found to be the adherent cells. They appeared as rounded 
cells as shown in figure 4.1B.  All cells that were not attached were washed away and the 
supernatant was removed. After 7 days of culture early EPCs were frozen down and RNA 
extraction was performed. Around 10-15 million MNCs were allowed to differentiate in 
macrophage specific media and grown under the same culture conditions. After 3-5 days of 
culture in macrophage specific media these MNCs started to differentiate towards 
macrophage lineage and became elongated fibroblast shaped cells as shown in figure 4.1C. 
These cells were adherent and were washed regularly and the media was changed on alternate 
days till day 7. Cells were then frozen down at this stage and RNA extraction was carried out.  
In order to derive ECFCs, around 60-70 million MNCs were plated per well and cells were 
allowed to differentiate in endothelial specific media. Cells were washed regularly and after 
14-21 days, adherent cells forming clusters and resembling an endothelial colony were 
observed under the microscope. Figure 4.1D, shows the edge of the colony that distinguishes 
it from confluent cells that cover the entire well plate. The colony was picked and the cells 
were grown separately for a period of around 6-8 weeks, and were classified as endothelial 
colony forming cells or ECFCs as shown in figure 4.1E. Mature endothelial cells were 
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derived from human umbilical vein and were morphologically similar to ECFCs as shown in 
figure 4.1F. HUVEC demonstrated typical cobble stone appearance. The isolation of all these 
cell types from the same donor was difficult because not all isolations lead to colony 
formation and ECFCs have been shown to be a rare population of cells. 
 
A) Day 0 MNCs (HUCBC)                        B) Early EPCs (CACs)                               C) Macrophages  
            
D) Endothelial Colony                         E) ECFCs in culture                                  F) HUVEC in culture 
         
Figure 4.1. Morphological analysis of different cell types isolated from human umbilical cord blood and 
human umbilical vein. A) MNCs were isolated from cord blood after ficoll based separation. Scale = 50µm. B) 
Early EPCs were isolated from cord blood by differentiating MNCs in endothelial specific media. Scale = 50µm. 
C) Macrophages were derived from cord blood by differentiating MNCs in macrophage specific media.  D) 
Showing the edge of an endothelial colony derived from cord blood. Scale = 200µm E) ECFCs derived from an 
endothelial colony after 6 weeks of culture. Scale =100µm. F) Mature endothelial cells derived from human 
umbilical vein. Scale = 50µm. Images taken at 10 x magnification. 
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4.2.2 Gene expression analysis of hematopoietic stem cell and macrophage specific 
markers in early EPCs, macrophages, late EPCs (ECFCs) and mature endothelial cells 
(HUVEC) derived from the same donor 
 
After successful isolation and culture of early EPCs or circulating angiogenic cells (CACs), 
macrophages and late EPCs or ECFCs from cord blood and mature endothelial cells 
(HUVEC) from the same donor, the next step was to carry out the characterization of these 
cells at mRNA level. RNA extraction was carried out from frozen samples including day 0 
MNCs, day 7 EPCs, day 7 macrophages and early passage ECFCs (P4) and HUVEC (P4). 
Specific primers were designed for cell surface markers for qPCR analysis. There were 
several important markers that were chosen to be tested for expression in these cell types. 
These included the CD34 gene that encodes CD34 protein and has been used as a common 
marker for EPC identification, and has shown to be expressed in hematopoietic stems cells, 
hematopoietic progenitor cells and circulating endothelial cells. The results as depicted in 
figure 4.2A, showed high expression of CD34 in early EPCs which is consistent with the 
earlier findings, but there was no CD34 expression seen in macrophages. As EPCs 
differentiate there is a gradual decline in the levels of CD34 but it still showed some level of 
expression in ECFCs which are known to retain low expression of this cell surface marker. 
HUVEC did not show any expression of the marker at mRNA level. CACs showed more than 
2 fold higher mRNA abundance of CD34 in comparison to ECFCs and HUVEC and the 
difference was found to be statistically significant. Gene expression was plotted relative to 
day 0 MNCs that were taken as 0 or no expression. 
The next gene  to test was PECAM-1 that encodes CD31 protein also known as platelet 
endothelial cell adhesion molecule-1 (PECAM-1) and  is a type 1 trans membrane 
glycoprotein, belonging to immunoglobulin gene super family (Stockinger et al., 1990). 
CD31 shows a wide range of cellular distribution with the highest level of expression shown 
in endothelial cells (Woodfin et al., 2007). The results showed that there was much higher 
expression of CD31 in the endothelial colony forming cells (ECFCs)  obtained from the 
umbilical cord blood as shown in figure 4.2B, and there was also expression seen in mature 
endothelial cells (HUVEC).  Early EPCs and macrophages showed much lower levels of 
CD31 as compared to ECFCs and HUVEC. ECFCs showed a 2 fold increase in expression as 
compared to HUVEC, but the difference was not found to be statistically significant.  
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In order to differentiate early EPCs from ECFCs and mature endothelial cells it was 
important to confirm the expression of certain monocyte-macrophage markers which are 
known to be expressed in early EPCs and macrophages and are not expressed in ECFCs and 
HUVEC. Human CD14 gene encodes a protein that is a well-known marker to identify the 
cells of monocyte-macrophage lineage, and was first identified as a receptor for the endotoxin 
lipopolysaccharide (LPS) (Wright et al., 1990). ECFCs showed no expression of CD14, as 
shown in figure 4.2C, and there was much higher expression of the gene seen in 
macrophages. There was some expression seen in early EPCs which is consistent with what 
has been known before and EPCs are known to gain the expression of CD14 as they 
differentiate (Estes et al., 2010). As shown in figure 4.2, early EPCs showed more than 3 fold 
increase in mRNA level of expression in comparison to ECFCs and HUVEC and the 
difference was found to be statistically significant.  
Protein tyrosine phosphatase receptor type C also known as CD45 is differentially expressed 
in subsets of leucocytes, and on all differentiated hematopoietic stem cells. It is a human 
enzyme encoded by PTPRC gene. mRNA level of expression of CD45 was tested as it is not 
expressed by endothelial cells or erythrocytes (Baldwin et al., 2000). It is a leukocyte marker 
and as the MNCs differentiate, they lose the expression of CD45 as shown in figure 4.2D. 
There was no expression of PTPRC seen in ECFC or HUVEC, as shown in figure 4.2D, 
which is consistent with the previous findings and further confirmed that these colony 
derived cells are the cells of interest, as the ECFCs are known to be negative for this 
leukocyte marker (Zhang et al. 2009). 
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Figure 4.2. Gene expression analysis of hematopoietic stem cell and monocyte-macrophage specific markers 
in early and late endothelial progenitor cells and macrophages derived from cord blood and mature 
endothelial cells derived from the umbilical cord of the same donor. A) Gene expression analysis of cell 
surface marker CD34 in early and late EPCs and HUVEC showing higher expression in early EPCs (day7) and 
ECFCs still retaining CD34 expression. B) Gene expression profile of endothelial cell surface marker PECAM-1 
and comparison between early and late EPCs showing that both cell types express this marker with higher level 
of expression in ECFCs and HUVEC. C) Gene expression analysis of macrophage specific marker CD14 in cell 
types isolated from cord blood and umbilical vein confirming the expression of CD14 in macrophages and in 
early EPCs suggesting that these cells belong to monocytic-macrophage lineages. ECFCs and HUVEC did not 
show CD14 expression. D) Gene expression analysis of cell surface marker CD45 showing expression in early 
EPCs and macrophages and absence in ECFCs and HUVEC. All data are normalized to TBP (TATA box binding 
protein) which was used as a housekeeping gene. Gene expression is plotted relative to cord blood 
mononuclear cells. All values are calculated as ± SEM, n=3-5. * P < .05, **P< .01, *** P < 0.001, ns stands for 
not statistically significant. 
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4.2.3 Gene expression analysis of endothelial markers in early EPCs, macrophages, ECFCs 
and HUVEC derived from cord blood and umbilical cord of the same donor 
After the confirmation of expression of monocyte-macrophage markers in early EPCs and 
macrophages and absence of these markers in endothelial progenitor cells (ECFCs) and 
mature endothelial cells (HUVEC), it was important to check the mRNA level of certain 
endothelial markers in these isolated cell types. Endothelial progenitor cells (ECFCs) and 
mature endothelial cells were expected to show the expression of endothelial markers; 
whereas early EPCs and macrophages should not be showing these markers. In order to test 
this, we carried out gene expression analysis for certain markers that included CD105, 
CD144, CD146 and vWF. Early EPCs, macrophages and ECFCs were derived from cord 
blood samples (n=3 for EPC and macrophages, n=5 for ECFCs) and mature endothelial cells 
(HUVEC n=5) were derived from umbilical veins of the same donors. RNA was extracted 
from frozen down cells at day 7 for early EPCs (CACs) and macrophages and early passage 
ECFCs (P4) and HUVEC (P4).  
The human endoglin gene encodes endoglin protein also known as CD105, which is a type I 
membrane glycoprotein located on the surface of endothelial and haematopoietic cells, 
forming part of the TGF-β complex. It is required for extra embryonic angiogenesis and plays 
a role in cardiovascular development in mammals (Arthur et al., 2000; Conley et al., 2000).  
As shown in the figure 4.3A, there was no expression of CD105 gene in early EPCs and 
macrophages, but there was high level of expression seen in ECFCs and mature endothelial 
cell also showed expression of endoglin. There was more than 2000 fold increase in 
expression of CD105 in ECFCs in comparison to early EPCs and the difference was found to 
be statistically significant. There was significant difference between expression level of 
CD105 in ECFCs and HUVEC. 
CDH5 is a human gene that encodes a member of cadherin family of proteins namely CD144 
also known as VE-cadherin that plays an important role in maintaining newly formed blood 
vessels (Corada et al., 2001). It mainly shows expression in endothelial cells. As shown in the 
figure 4.3B, there was no expression of CDH5 seen in early EPCs and in macrophages as 
expected, but there was higher expression seen in early EPCs and ECFCs as compared to 
HUVEC.  
MCAM is a human gene that encodes the protein CD146 also known as the melanoma cell 
adhesion molecule (MCAM). CD146 is a member of Ig super family and mainly shows the 
expression in endothelial cells including ECFCs and CECs. The results were consistent with 
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the previous findings and showed high expression of CD146 in ECFCs as compared to early 
EPCs (Yoder et al. 2007). There was more than 50 fold increase in mRNA level of 
expression of CD146 in ECFCs as compared to early EPCs and the difference was found to 
be statistically significant. As expected, macrophages showed no expression of CD146 as 
shown in figure 4.3C.  
Von Willibrand factor (vWF) is a blood glycoprotein encoded by vWF gene that is 
exclusively found in endothelial cells and megakaryocytes and is produced and stored in 
weibel-palade bodies in endothelial cells and platelet granules (Mannucci, 1995).  As shown 
in figure 4.3D, there was no expression of vWF gene in early EPCs and macrophages. ECFCs 
showed low level of gene expression of vWF and mature endothelial cells HUVEC strongly 
expressed this endothelial marker. Statistical analysis was carried out that suggested that 
vWF could be used as a marker that could distinguish between endothelial progenitor cells 
(ECFCs) and mature endothelial cells (HUVEC). ECFCs showed low level of gene 
expression and as these cells differentiate towards endothelial lineage they would start 
strongly expressing this specific endothelial marker. There was several thousand fold increase 
in expression of vWF in ECFCs as compared to HUVEC. The difference between mRNA 
expression level of ECFCs and HUVEC was found to be statistically significant. 
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Figure 4.3. Gene expression analysis of endothelial markers in early and late endothelial progenitor cells and 
macrophages derived from umbilical cord blood and mature endothelial cells derived from the umbilical 
cord of the same donor. A) Gene expression analysis of cell surface marker endoglin (CD105) in early EPCs 
(day7) and macrophages showing no expression, and ECFCs showing high expression levels of CD 105. B) Gene 
expression profiling of endothelial specific marker vWF, showing a high level of expression in mature 
endothelial cells and a very low level of expression in ECFCs. There was no vWF expression seen in early EPCs 
and macrophages. C) Gene expression analysis for CD144 (VE-cadherin), showing high expression in ECFCs and 
low expression in mature endothelial cells. There was no expression seen in macrophages. D) Gene expression 
analysis of cell surface marker CD146 (MCAM), showing high expression in endothelial cells and no expression 
in early EPCs. All data are normalized to TBP (TATA box binding protein) which was used as a housekeeping 
gene. Gene expression is plotted relative to human cord blood mononuclear cells (HUCBC). All values are 
calculated as ± SEM, n=3 (CACs and macrophages) and n=5 (ECFCs and HUVEC).  * P < .05, ** P< .01, *** P < 
0.001 
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4.2.4 Multicolor flow cytometry analysis for the expression of cell surface markers CD14, 
CD34, CD144 and CD146 in endothelial colony forming cells (ECFCs) 
As shown in figures 4.2 and 4.3 there was confirmation of the expression of endothelial 
markers in ECFCs and HUVEC and no expression in early EPCs. There was expression of 
markers like CD14 and CD45 which are known to be monocyte-macrophage specific and 
leukocyte markers in early EPCs and absence in ECFCs and HUVEC. The next step was to 
validate these results and confirm the expression and absence of these markers at protein 
level. Antibodies against cell surface marker CD14, CD34, CD144 and CD146 (Mouse-anti 
human) were used to stain the cells each linked to a different fluorochrome. ECFCs were 
isolated from cord blood and were derived from an endothelial colony which was observed at 
around 3 weeks of culture and differentiation of cord blood mononuclear cells in endothelial 
specific media.  Cells were passaged and split regularly and fresh cells were used for staining. 
All four antibodies having different fluorochrome were used together to stain the cells and 
analysis was carried out using FACS. As shown in figure 4.4, ECFCs showed low level of 
expression of hematopoietic stem cell marker CD34, and very low level of expression of 
monocyte-macrophage marker CD14. ECFCs have been known to retain the expression of 
CD34 and are distinguished from early EPCs on the basis of absence of expression of 
monocyte-macrophage markers like CD14. Early EPCs retained high expression of CD14. As 
shown in figure 4.4, ECFCs showed high level of expression of CD146 also known as 
MCAM, which is known to be expressed in endothelial progenitors and endothelial cells. 
ECFCs also expressed CD144 also known as VE-cadherin which is mainly present in 
endothelial cells and known to play an important role in maintaining newly formed vessels. 
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Figure 4.4. Multicolour flow cytometry analysis showing cell surface markers in ECFCs. The analysis was 
carried out using antibodies against cell surface markers, each having a different fluorochrome. The ECFCs 
were isolated from cord blood and the cells were passaged once they reached confluence. Fresh cells were 
used for flow cytometry analysis. The figure shows the confirmation of the expression of endothelial markers 
CD146 and CD144 and absence of monocyte-macrophage marker CD14 in endothelial colony forming cells 
(ECFCs). The ECFCs as shown above retained low level of CD34 expression. n=3 n represents number of donors. 
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4.2.5 Multicolor flow cytometry analysis for the protein expression of cell surface 
markers CD14, CD34, CD144 and CD146 in mature endothelial cells HUVEC. 
Mature endothelial cells (HUVEC) were derived from the umbilical vein. Cells were grown 
in endothelial specific med and regularly passaged. After the confirmation of expression of 
endothelial markers at mRNA level, as shown in figures 4.2 and 4.3, it was important to 
validate the expression at protein level. Cells were stained with antibodies for cell surface 
markers including CD14, CD34, CD144 and CD146. Cells were stained with four antibodies 
together each having a different fluorochrome. Analysis was carried out using FACS canto II. 
As shown in figure 4.5, HUVEC strongly expressed endothelial markers CD144 and CD146. 
They showed absence of CD14 expression which is known to be a monocyte-macrophage 
marker. HUVEC also retained high level of expression of CD34. 
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Figure 4.5. Multicolour flow cytometry analysis in HUVEC. The analysis was carried out using antibodies 
against cell surface markers, each having a different fluorochrome. HUVEC are mature endothelial cells which 
were isolated from human umbilical vein. Fresh cells at early passages were used for this analysis. The figure 
shows the confirmation of the expression of endothelial cell surface markers CD146 and CD144 and absence of 
macrophage marker CD14 in mature endothelial cells (HUVEC). HUVEC have shown to retain CD34 expression. 
n=3, where n represents number of donors. 
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4.2.6 Protein expression analysis for cell surface markers CD14, CD34, CD144 and CD146 
in cord blood mononuclear cells (day 0 MNCs), endothelial colony forming cells (ECFCs) 
and HUVEC. 
After confirmation of expression of endothelial markers in ECFCs and HUVEC and absence 
of monocyte-macrophage markers CD14 and CD45, the next step was to confirm the 
expression at protein level. As shown in figure 6, FACS analysis was carried out using 
antibodies for CD14, CD34, CD144 and CD146. Cells were stained with all these antibodies 
together and a comparison was made between MNCs, ECFCs and HUVEC based on the 
percentages of cells positive for these cell surface markers. As shown in figure 6, cord blood 
mononuclear cells showed the greatest percentage of CD14
+
 cells, whereas ECFCs and 
HUVEC showed almost no expression of this monocyte-macrophage marker. Mature 
endothelial cells HUVEC showed highest percentage of CD34
+
 cells, and ECFCs still 
maintained CD34 expression. MNCs did not show any expression of CD144
+
 and CD146
+
 
cells as was expected, as these markers are expressed in endothelial progenitors and mature 
endothelial cells. ECFCs showed low expression of CD144 protein as compared to HUVEC, 
which has been shown before. CD146 which is known to be expressed in mature endothelial 
cells showed the highest percentage of positive cells in both ECFCs and HUVEC. 
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       A                                                                     B 
 
       C                                                                       D        
 
Figure 4.6. Protein expression analysis of the haematopoietic stem cell and endothelial markers in cell types 
derived from cord blood and umbilical cord. A) The figure shows the expression of monocyte-macrophage 
marker CD14 in cord blood mononuclear cells, whereas there was no protein expression of CD14 seen in ECFCs 
and HUVEC. ECFCs were derived from a colony that was observed at day 14 to day 21 of culture B) Protein 
expression analysis of haematopoietic stem cell marker CD34 showing high expression in mature endothelial 
cells HUVEC. C) Protein expression analysis of CD144 (VE-cadherin) in day 0 MNC and ECFCs and HUVEC 
confirming expression of CD144 in endothelial progenitors and mature endothelial cells and no expression in 
MNCs. D) Protein expression analysis of cell surface marker CD146 confirming the expression in ECFCs and 
HUVEC and absence in MNCs. Statistical analysis was carried out using one way ANOVA, followed by Tukeys 
multiple comparison tests. All values are calculated as ± SEM, n=3.  * P < .05, ** P< .01, *** P < 0.001. 
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4.2.7 Cell surface marker expression analysis of CD34+/CD14- cell population in mature 
endothelial cells HUVEC 
CD34 is considered to be a marker of hematopoietic cell lineage, but has been known to show 
expression in endothelial cells and endothelial progenitor cells. Our earlier FACS analysis 
showed high percentage of CD34 population in HUVEC. Therefore, we further analysed this 
cell population and as shown in figure 4.7, HUVEC were stained with antibodies for CD14, 
CD34, CD144 and CD146 and all of all them were tagged with a different fluorochrome. 
Cells were analysed using FACS and CD34
+
/CD14
-
 cell population was isolated. This 
population was further analysed and as shown in figure 4.7 E, double positives and double 
negative (CD144
+
/CD146
+
 and CD144
-
/CD146
-
) cell populations were obtained and 
statistical analysis was carried out. 
                A                                                              B 
 
 
        C                                                                    D 
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                                    F 
 
Figure 4.7. Protein expression analysis of CD34
+
/CD14
-
 cell population sorted by FACS analysis. The analysis 
was carried out on mature endothelial cells (HUVEC) isolated from human umbilical vein. FACS analysis was 
done using antibodies for cell surface markers including heamtopoietic stem cell marker CD34, macrophage 
specific marker CD14, and endothelial markers CD144 and CD146. Fresh cells were used for the analysis. More 
than 70% of this sorted poulation was found to be double positive for CD144 and CD146 which are both 
endothelial markers. Less than 10% was double negative for CD146 and CD144. The difference between 
double positives and double negatives was found to be statistically significant. Statistical analysis was carried 
out using one way ANOVA, followed by Tukeys multiple comparison tests. All values are calculated as ± SEM, 
n=3.  * P < .05, ** P< .01, *** P < 0.001. 
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4.2.8 Immunofluorescence analysis for vWF expression in ECFCs and HUVEC comparing 
early and late passages for the protein expression of vWF 
Von willibrand factor (vWF) is a blood glycoprotein involved in platelet adhesion. Our 
earlier results indicated that at mRNA level vWF showed higher expression in mature 
endothelial cells than in endothelial progenitors (ECFCs) and the difference was found to be 
statistically significant. In order to confirm and validate this at protein level we performed 
direct immunofluorescence analysis. ECFCs were isolated from cord blood and derived from 
an endothelial colony. Cells were passaged regularly and early passage (P5) and late passage 
(P15) ECFCs were used for comparison so that the level of expression of vWF in early and 
late ECFCs could be observed. The next comparison was between HUVEC grown at same 
passages. HUVEC were isolated from umbilical vein and early (P5) and late passage (P15) 
cells were used. Cells were grown in special chamber slides and stained with vWF antibody 
and observed under microscope. As shown in figure 4.8, early and late ECFCS showed much 
lower level of expression as compared to HUVEC at same passages which was determined by 
counting FITC positive cells for both ECFCs and HUVEC. Statistical analysis was carried 
out and the difference was found to be significant. This further confirmed that ECFCs which 
are endothelial progenitors showed low level of expression of vWF as compared to mature 
endothelial cells HUVEC and could be used as a marker to distinguish between these two cell 
types. 
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 A                     HUVEC P5                               B                   HUVEC P15 
 
C                             ECFC P5                                  D                    ECFC P15 
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Figure 4.8. Immunofluorescence analysis for the protein expression of vWF (von Willibrand factor) in 
endothelial progenitor cells (ECFCs) and mature endothelial cells (HUVEC).  vWF antibody was used for 
staining ECFCs and HUVEC having FITC tagged as a fluorescent marker. Human IgG isotype control was used as 
a negative control for the experiments. Figure A and B showing mature endothelial cells which were obtained 
from the human umbilical vein. Cells were passaged regularly and grown till late passage P15. 
Immunofluorescence was done using vWF antibody on early (P5) and late passage (P15) HUVEC. Figure C and 
D showing ECFCs which were derived from an endothelial colony obtained by differentiation of mononuclear 
cells from cord blood. Cells were passaged regularly and immunofluorescence was carried out on early (P5) 
and late passage (P15) ECFCs. Figure E shows lower expression of vWF in early passage ECFCs as compared to 
early passage HUVEC and late passage ECFCs as compared to late passage HUVEC. vWF positive cells were 
counted in these cells and statistical analysis was done using unpaired t test. n=3, where n represents number 
of donors. The difference was found to be statistically significant and the results as shown in the figure indicate 
that the ECFCs are at an earlier stage of differentiation as compared to HUVEC.  
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4.3 Discussion 
There has been a lot of debate regarding the identification of human EPCs as there has not 
been a single marker that can be used for their prospective isolation from peripheral or cord 
blood. The term human EPC has been used for different population subsets and cell types 
depending upon the expression of several cell surface antigens. It has now been shown that 
most of these EPCs actually belonged to hematopoietic subsets that support blood vessel 
formation but were not directly involved in the process of blood vessel formation. These 
EPCs are broadly divided in two main categories, proangiogenic haemopoietic cells for 
which the term EPC has been used, since Asahara et al. for the first time reported prospective 
isolation of these cells from peripheral blood (Asahara et al., 1997). These cells showed the 
expression of cell surface markers including CD31, CD34, CD202b (Tie2), CD309 (VEGFR-
2/KDR), CD62E, CD45, UEA-1, and the uptake of acetylated LDL. These cells lacked the 
expression of monocyte lineage marker CD14. These findings were further validated by 
several groups (Shi et al., 1998) and  it has been shown  that  these EPCs can be isolated from 
bone marrow and other sources (Takahashi et al., 1999; Kalka et al., 2000b). Similarly, 
CD34
+
, CD133
+
, CD309
+
  cell populations have been isolated from peripheral blood and 
named as circulating endothelial precursors (Peichev et al., 2000; Gill et al., 2001). CD31
+
 
CD202b
+ 
CD309
+
 cells have been isolated that form myeloid colonies in an in vitro system 
also termed as CFU-Hill and have been named as EPCs (Hill et al., 2003; Smadja et al., 
2008). It has been shown that CD45
+ 
CD133
+
 CD34
+ 
CD144
+
 and CD309
+ 
cell populations 
have been isolated and termed as EPCs (Fox et al., 2008b; Smythe et al., 2008). It has 
recently been shown that the early EPCs belong to the monocytic-macrophage lineage and 
are termed as proangiogenic cells and express several cell surface antigens including CD31, 
CD45 and in some cases CD309 and CD202b. They are further differentiated on the basis of  
additional expression of CD133, CD34 and absence of CD14 expression and are classified as 
immature progenitors (Estes et al., 2010). Circulating angiogenic cells (CACs) with further 
differentiating potential start expressing CD14 and loose the expression of  CD133 and are 
termed as cells of mature monocytic lineage (Estes et al., 2010).  
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Table 4.1. Showing analysis of the phenotypic properties of CACs and ECFC 
 
Early EPCs/CACs ECFCs 
CD45
+ 
CD45
- 
CD14
+ 
CD14
- 
CD115
+ 
CD115
- 
CD31
+ 
CD31
+ 
CD146
low 
CD146
high 
CD144
+/- 
CD144
++ 
CD105
+ 
CD105
+ 
VWF
+/- 
VWF
+ 
CD34
+/- 
CD34
+/- 
CD133
+ 
CD133
- 
CD117 (KIT)
+ 
CD117 (KIT)
+/- 
VEGFR1
+ 
VEGFR1
+ 
VEGFR2
+ 
VEGFR2
++ 
AcLDL uptake
+ 
AcLDL uptake
+ 
ALDH
+ 
ALDH
+ 
 
They are identified as supportive cells that promote but are not directly involved in vascular 
repair whereas late EPCs which are derived  from an endothelial colony and also known as 
endothelial colony forming cells (ECFCs) are true endothelial progenitors that can be 
transplanted in immunodeficient mice and have the ability to  form vascular structures in vivo  
(Yoder et al., 2007). These cells have shown to have the capacity to form chimeric blood 
vessels in a xenograft model of vessel formation (Yoder et al., 2007). Yoder et al. (2007) 
were the first group to analyse the proliferative potential of human EPCs in clonogenic assays 
in vitro. This assay included plating of single EPCs in collagen-coated plates and the number 
of colonies developed over 14 days were enumerated. The developing cells displayed a 
typical cobblestone morphology and showed differing proliferative potential, with high 
proliferative potential colony-forming cells (HPP-ECFCs) giving rise to low proliferative 
potential colony-forming cells (LPP-ECFCs) and finally to mature non-dividing endothelial 
cells. The LPP-ECFCs formed colonies of less than 2000 cells, and failed to form colonies on 
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replating, whereas HPP-ECFCs formed colonies containing greater than 2000 cells and 
formed at least secondary colonies. Those forming tertiary colonies were proposed to have 
much higher proliferative potential (Reinisch et al., 2009).  
It was therefore important to isolate the true EPCs. The first step was to isolate both early and 
late EPCs and distinguish them on the basis of expression of cell surface markers as these 
EPCs have been characterized on the basis of the expression or lack of expression of certain 
biomarkers used for their isolation. The second step was to distinguish between endothelial 
progenitor cells (ECFCs) and mature endothelial cells (HUVEC). The study was designed in 
such a way that human umbilical cord mononuclear cells (HUCBC) also known as day 0 
MNCs were used as a starting population. They were differentiated to produce early EPCs 
also known as circulating angiogenic cells (CACs) when grown in endothelial specific media 
and to macrophages when grown in macrophage specific growth media. Human umbilical 
cord mononuclear cells (HUCBC) were obtained from the umbilical cord of normal newborn 
deliveries. They are known to be a mixed population of cells including cells of hematopoietic, 
endothelial stem cell and mesenchymal origin (Henning et al., 2012). These cells have 
recently been used to overcome cell depletion in the bone marrow caused by treatment of 
several hematological malignancies and disorders including acute lymphoid and myeloid 
leukemia and aplastic anemia (Broxmeyer et al., 2011). These HUCBC lack the expression of 
the major histocompatibility complex antigen MHC ІІ which minimizes the risk of transplant 
rejection from the recipient.  Morphologically, they appeared as rounded cells as shown in 
figure 4.1A. Early EPCs also known as circulating angiogenic cells (CACs) were derived 
from these HUCBC (day 0 MNCs). They were allowed to differentiate in endothelial specific 
media and were found to be non-proliferative cells that did not form endothelial colony after 
14 days of culture. They appeared as rounded cells as shown in figure 4.1B.  
Macrophages were also derived from the same day 0 mononuclear cells which were allowed 
to differentiate in macrophage specific media. The macrophages were seen after around 5-7 
days of culture and resembled elongated fibroblast like structures as shown in figure 4.1C. 
Macrophages were used as a control for two reasons. Firstly, it has been shown that the early 
EPCs are related to monocyte-macrophage lineage and the endothelial progenitor cells should 
be distinguished from them on the basis of expression of macrophage markers (Yoder et al. 
2007) Secondly, macrophages are known to be resistant to oxidative stress (Dernbach et al., 
2004) and therefore it was important to make sure that the endothelial progenitor cells 
isolated for testing further hypothesis are not composed of a mix of cell populations like 
monocyte and macrophages.   
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We characterized them first on the basis of gene expression analysis for cell surface markers 
including PECAM-1, CD34, CD14, PTPRC, MCAM, CDH5, END and vWF.  
PECAM-1 has  shown varied level of expression in several hematopoietic cells and human 
early EPCs (Rehman et al., 2003). Our results showed that there was a decreased expression 
of this gene in early EPCs in comparison to HUVEC which is consistent with the previous 
findings (Furuhata et al., 2007). 
Strong expression of PECAM-1 in ECFCs suggests that these might be the endothelial 
progenitors that are involved in post-natal vasculogenesis, as shown before CD31 forms part 
of a mechanosensory complex that mediates endothelial cell response to shear stress (Tzima 
et al. 2005), and a recent study indicates that CD31 has a role in arteriogenesis and collateral 
remodelling (Chen et al. 2010). 
The results showed that early EPCs (CACs) derived from umbilical cord blood showed the 
expression of hematopoietic markers like CD34 and CD31and also expressed macrophage 
specific markers like CD14 and CD45 as shown in figure 4.2, and could be clearly 
distinguished from late EPCs or ECFCS and mature endothelial cells and fulfilled the criteria 
of being proangiogenic cells as has been shown before (Estes et al., 2010).   
The expression of CD34 and CD31decreases gradually as the EPC differentiation occurs, but 
ECFCs still maintain the expression of both CD34 and CD31 (Richardson and Yoder 2010). 
The results indicated that both ECFCs and HUVEC did not express macrophage specific 
markers CD14 and CD45, as shown in figure 4.2. The difference again was found to be 
statistically significant. Figure 4.3 shows the differential gene expression analysis of 
endothelial markers in these cell types. The results indicated that early EPCs and 
macrophages did not show the expression of endothelial markers as expected. There were 
several markers that showed statistically significant difference in the gene expression analysis 
of ECFCs and HUVEC. Endoglin and CDH5 can be used as markers to distinguish between 
endothelial progenitor cells and mature endothelial cells but vWF showed much higher 
expression in HUVEC as compared to ECFCs.  
The expression of cell surface markers was confirmed at protein level by using FACS 
analysis, as shown in figure 4.4 and 4.5. This was based on using multicolor flow cytometry. 
The cell surface markers CD34, CD14, CD144 and CD146 were all tagged with different 
fluorochrome, so that the expression level of each could be quantified at the same time. The 
results further confirmed that colony derived endothelial cells (ECFCs) showed the 
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expression of cell surface markers CD144 and CD146 and lacked the expression of 
monocyte-macrophage marker CD14 and could be used to function as true EPCs. We found 
that mRNA expression of CD34 and CD144 was different as compared to protein expression 
mainly in HUVEC. This could be due to the fact that different donors were used for the 
FACS analysis using multicolour flow cytometry and RNA and protein expression does not 
always match. FACS analysis was carried out on fresh cells. 
The results confirmed that we had successfully isolated the true EPCs also known as 
endothelial colony forming cells (ECFCs). These cells can be defined as proliferative cells 
that were first isolated from peripheral blood but this is no more considered a rich source of 
ECFCs. They have since then been isolated from cord blood, human aorta and umbilical vein 
and also pulmonary aorta of the rat (Ingram et al., 2004; Ingram et al., 2005; Alvarez et al., 
2008). They were identified in search of a true endothelial progenitor but till now there has 
been no specific marker that can distinguish them from other endothelial cells. ECFCs have 
shown to express cell-surface markers including CD34, CD31, CD146 and CD105 but still it 
remains unclear if these cells belong to uni or multipotent stem cell lineage or are endothelial 
cells with high level of proliferative potential as they have been shown to achieve over 100 
population doublings in vitro (Ingram et al., 2004; Ingram et al., 2005). Our results indicate 
that ECFCs can be further distinguished from mature endothelial cells by the expression level 
of vWF. It has been shown before that vWF stains for both ECFCs and mature endothelial 
cells (Doung et al., 2011). But as shown in figure 4.8 we compared early and late passage 
ECFCs with early and late passage mature endothelial cells (HUVEC) and we found that 
there was statistically significant difference between ECFCs and HUVEC compared at same 
passages (P5 and P15) in terms of number of vWF positive cells demonstrated by direct 
immunofluorescence analysis that stains for vWF intracelluarly. 
The results as shown in this section clearly indicate that we have successfully isolated the 
true EPCs from cord blood. These cells are derived from an endothelial colony and fulfil the 
criteria of being ECFCs as recently proposed by Yoder et al,. 2010. As shown in figure 4.1 
these cells are morphologically different from early EPCs also known as CACs. The 
molecular characterization of these cells showed that they are distinguished from CACs and 
also from mature endothelial cells on the basis of expression of several cell surface markers. 
There have been several studies before that have characterized these ECFCs using different 
strategies and our results further validate them. Cord blood and peripheral blood derived 
CD34
+
 cells have been used to generate ECFCs and it has been shown that its CD34
+
/CD45
-
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cell population that produces ECFCs whereas CD34
+
/CD45
-
  and CD133
+
 cells failed to 
generate ECFCs (Timmermans et al., 2007). Our results also showed that the ECFCs were 
CD34
+
/CD45
-
. Protein expression analysis was carried out using FACS and showed the 
expression of these cell surface markers in ECFCs and HUVEC. There was higher protein 
expression of CD34 seen in HUVEC and also CD144 had higher expression in HUVEC as 
compared to mRNA expression and this could be due to the fact that the FACS analysis was 
carried out in different donors and also mRNA level of expression does not always match 
with protein expression. Also, FACS analysis was carried out on fresh cells, whereas qPCR 
was performed on samples that were frozen down. Immunofluorescence analysis was 
performed with vWF and it was shown that ECFCs can be distinguished from mature 
endothelial cells (HUVEC) both at mRNA and protein level by the expression of vWF.  
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Chapter 5. Investigating the effect of oxidative stress on PGC-1 alpha 
expression and growth kinetics and telomere dynamics of ECFCs and 
HUVEC 
 
5.1 Introduction 
In eukaryotes, mitochondrial activity is responsible for controlling the cellular and systemic 
metabolism. Similarly, the energy homeostasis is maintained through regulation of tissue-
specific metabolic pathways, and at molecular level main hormonal and nutrient pathways 
depend upon the genes encoding for metabolic enzymes. One of the major players involved 
in this are the PGC transcriptional complexes. PGC-1α is one of the members of this small 
family of transcriptional coactivators, that also includes PGC-1β and PGC-related 
coactivators (PRC), all of which are promoters of mitochondrial biogenesis and oxidative 
metabolism (Wu et al., 1999). Although, apart from PRC which shows ubiquitous expression, 
both PGC1- α and PGC1-β are mainly expressed in oxidative tissues including heart, brain, 
liver, muscle, kidney, pancreas and brown adipose tissue (Uldry et al., 2006). PGC-1α also 
regulates reactive oxygen species (ROS) and apoptosis in mature endothelial cells (St-Pierre 
et al., 2006). Dysregulation of the gene encoding PGC-1α leads to a wide variety of 
pathological conditions and therefore pharmacological regulation of its expression and 
activity can be used as a novel approach to treat several diseases. 
It has been shown that PGC-1α can be induced by lack of nutrients and oxygen; leading to 
VEGF expression and promoting angiogenesis in cultured muscle cells and also skeletal 
muscle in vivo (Arany et al., 2008). Similarly, it has been shown that PGC-1α knockout mice 
fails to show neovascularisation after an ischemic insult, which in normal circumstances is 
carried out by the stimulation of VEGF and other angiogenic factors in response to hypoxia, 
leading to vascularisation as a protection against ischemic injury .  
Telomeres are DNA repeats at the ends of chromosomes, helping to maintain their integrity. 
They are widely regarded as the internal biological clock of a living organism, and shorten by 
a few base pairs with every cell division (Blasco, 2005). Telomere shortening can be 
compensated or slowed down by concomitant activation of telomerase, a DNA polymerase 
and specialized ribonucleoprotein. The catalytic core of telomerase is composed of an RNA 
subunit (TERC) serving as a template for sequence addition and a reverse transcriptase 
(TERT) subunit that facilitates the replication of telomeres. Oxidative stress is an important 
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factor that contributes to telomere attrition (Von Zglinicki, 2002). Correlative evidence from 
human population studies suggests an association of short telomeres with conditions of 
increased oxidative stress, including smoking, obesity and coronary heart disease (CHD).  
It has been shown recently, that telomerase is essential in maintaining a healthy human 
lifespan. Accumulating evidence from premature ageing (progeroid) syndromes, such as 
Werner syndrome or dyskeratosis congenita, both of which show mutations in either TERT or 
TERC, paralleled by short telomeres are a proof of this (Sahin et al., 2011). Similarly, a third-
generation telomerase knockout mouse displays an age-related phenotype with shortened 
lifespan. The reactivation of telomerase in aged telomerase-deficient mice even leads to a 
reversal of tissue degeneration, suggesting that telomere rejuvenation strategies for age-
associated diseases might prove a therapeutic alternative, especially those driven by 
accumulating genotoxic stress. Recently it has been shown that telomere abnormality in the 
nucleus leads to deactivation of PGC1 proteins in the mitochondria via activation of p53. 
Sahin et al 2011 showed that a mice null in either Tert or Terc genes leads to p53 mediated 
apoptosis and growth arrest in several tissues and repression of PGC genes and their 
downstream targets leading to impaired mitochondrial biogenesis. 
We, therefore, hypothesized that  mild oxidative stress would lead to telomere dysfunction in 
endothelial cells, and as a consequence of that a decrease in the expression of PGC-1α in 
endothelial progenitor cells (ECFCs) and mature endothelial cells (ECs). As PGC-1α is a key 
regulator of mitochondrial biogenesis and oxidative metabolism, a decrease in its expression 
would lead to an impairment of mitochondrial activity in these cells. This would in turn lead 
to a decrease in the angiogenic potential of these cells.   
Telomeres are complex DNA-protein structures located at each end of the chromosomes. 
Telomeres are shortened with each cycle of cell replication, and can be a predictor of 
organismal age (Blackburn, 2001). Telomere preservation requires intact telomerase enzyme 
activity and maintenance of telomere length itself (Edo and Andrés, 2005). Recently, it has 
been shown that critically shortened telomeres are linked to age-related cardiovascular 
diseases and promote apoptosis and cellular senescence (Samani et al., 2001; Brouilette et al., 
2003; Brouilette et al., 2008; De Meyer et al., 2008; Samani and Van Der Harst, 2008; Butt et 
al., 2010; Aviv, 2012). Similarly, it has been proposed that endothelial cells within an 
atherosclerotic plaque show signs of cell senescence, whether this is linked to shortening of 
telomere length and does this differ between endothelial progenitor cells and mature 
endothelial cells remains to be seen. Our initial results indicated that endothelial progenitor 
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cells (ECFCs) could be grown for a longer period of time and grow at a faster rate in 
comparison to mature endothelial cells (HUVEC) in conditions of oxidative stress. It has 
already been shown that chronic oxidative stress leads to telomere dysfunctioning and 
promotes cell senescence in human endothelial cells (Kurz et al., 2004). We therefore 
proposed that ECFCs are better equipped to counteract this ROS mechanism and could be the 
cells that take part in repairing damaged endothelium. 
It has been shown that oxidative stress is one of the factors associated with telomere 
dysfunction, and as a result of that cells grown in hyperoxia show telomere shortening (Von 
Zglinicki, 2002).Telomere shortening can be compensated or slowed down by concomitant 
activation of telomerase, a DNA polymerase and specialized ribonucleoprotein. The catalytic 
core of telomerase is composed of an RNA subunit (TERC) serving as a template for 
sequence addition and a reverse transcriptase (TERT) subunit that facilitates the replication of 
telomeres (Von Zglinicki, 2002).  
We had hypothesized that oxidative stress would lead to telomere dysfunction and a decrease 
in the level of PGC-1α as shown in mice recently (Sahin et al. 2011), but again instead of a 
decrease in the levels of PGC-1α, its  mRNA transcripts were increased, as shown in figure 
5.5C. Also, several downstream targets of PGC-1α showed an increase in gene expression as 
shown in figure 5.5 D. 
 
5.2 Results 
5.2.1 Growth kinetics of ECFCs and HUVEC grown in normoxia and hyperoxia 
Endothelial colony forming cells (ECFCs) were isolated from human cord blood. Cord blood 
mononuclear cells were plated at a density of 60-70 million cells per well of a 6 well plate. 
They were allowed to differentiate in endothelial media so that they could differentiate 
towards endothelial lineage. Once an endothelial colony was observed usually after 14-21 
days of culture, it was picked and grown in the same endothelial media. ECFCs were derived 
from these endothelial colonies which were observed in the culture dishes. Cells were grown 
and split once they became 70-80% confluent. 1 million cells were plated to start the ECFC 
culture and that was taken as P0 and day 0. Cells were split regularly in a ratio of 1:3 and 1 
million cells were replated and the rest were frozen down each time cells were passaged. 
ECFCs were grown till late passages in normoxia (20% O2) as shown in figure 5.1A, 
indicated by red circles. ECFCs were grown in normoxia till P2 and then cells were split and 
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1 million cells were plated and cells were placed in hyperoxic incubator (40% O2). All the 
conditions and cell culture media was same for the cells grown in hyperoxia and the only 
difference was oxygen concentration. This was counted as starting day for ECFC hyperoxia 
cell culture and cells were passaged regularly once they became confluent.1 million cells 
were plated each time and cells were split in a ratio of 1:3. One million cells were plated 
again and the rest were frozen down. As shown in the growth kinetics of ECFCs in figure 
5.1A, ECFCs grew in hyperoxia at a rate that was slightly slower than that of cells grown in 
normoxia but the difference was not found to be statistically significant.  
Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical vein. Cells 
were plated and allowed to grow and observed under microscope regularly for a cobble stone 
appearance known for these mature endothelial cells. Once these cells became around 70-
80% confluent they were split and counted using a haemocytometer. 1 million cells were 
replated and this started HUVEC cell culture and this was taken as P0 as shown in figure 
5.1B, and indicated by red circles. Cells were allowed to grow in normoxia (20% O2) and 
split again once they became confluent, in a ratio of 1:3. 1 million cells were plated again and 
the rest were frozen down. Cells were passaged regularly and cells were grown over a period 
of 8 weeks as shown in figure 5.1B.  
Cells were split after P2 and 1 million cells were plated and placed in hyperoxia (40% O2). 
This was counted as P0 and then cells were allowed to grow in hyperoxic conditions. 
HUVEC grew at a much slower rate in hyperoxia as compared to cells grown in normoxia 
and were found to be much less resistant than ECFCs to oxidative stress (40% O2). The 
difference as shown in growth kinetics was found to be statistically significant. As shown in 
the figure ECFCs were found to be growing at a faster rate after 7 days than HUVEC grown 
in hyperoxia and the cells grown in normoxia almost showed similar growth pattern till day 
40 as shown in the figure.  
For both ECFCs and HUVEC, 1 million cells were plated to start the culture that was taken as 
P0. Cells were grown till they were around 70% confluent. At this stage the cells were split 
using trypsin in a ratio of 1:3. 1 million cells were replated and the rest were frozen down at -
80°C in freezing media containing DMSO to be used in later experiments. The cells were 
regularly passaged in around 3-7 days as shown in figure 5.1. Early passage cells grew faster 
and were split at around 3days in culture. Late passage cells took nearly 7 days to be 70% 
confluent. Cells at P10 correspond to around 8 weeks of culture as shown in figure 5.1. 
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                               A 
    
                                 B 
         
Figure 5.1. Illustrating the growth kinetics of endothelial colony forming cells (ECFCs) and mature 
endothelial cells (HUVEC) derived from cord blood and human umbilical vein of the same donor. Figure A 
and B showing the comparison between growth behaviour of ECFCs and HUVEC grown in normoxia (20% O2) 
and hyperoxia (40% O2). Statistical analysis was carried out using two sample t tests between the slopes of the 
normoxia and hyperoxia curves for both ECFCs and HUVEC. The difference was found to be statistically 
significant with a p value of .001 for the comparison between HUVEC grown in normoxia and hyperoxia, and a 
p value of .02 for the comparison between ECFCs and HUVEC grown in hyperoxia. The difference between 
ECFCs grown in normoxia and hyperoxia and ECFCs and HUVEC grown in normoxia was not found to be 
statistically significant with a p value of ≥ .05 in both cases.   
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5.2.2 Telomerase activity measurement using TRAP assay in ECFCs and HUVEC grown in 
normoxia and hyperoxia 
As shown in growth kinetics of ECFCs and HUVEC in figure 5.1, we proposed that as 
endothelial progenitor cells (ECFCs) grow much better in hyperoxia as compared to mature 
endothelial cells (HUVEC), they might show a higher level of telomerase activity when 
grown in hyperoxia that could be compensating for a shortening of telomere length due to 
oxidative stress. In order to test this, ECFCs were isolated from umbilical cord blood and 
derived from an endothelial colony. ECFCs were grown in normoxia till late passage (P9) so 
that a change in telomerase activity could be measured and to test whether these cells would 
show a change in telomerase activity across passages. Telomerase activity was measured 
using TRAP assay and as shown in figure 5.2, there was no statistically significant difference 
found between early and late passage ECFCs and also there was no change in telomerase 
activity in ECFCs grown in hyperoxia. We expected to have higher telomerase activity in 
ECFCs grown in hyperoxia, but the difference found was not statistically significant.   
Similarly, mature endothelial cells HUVEC were isolated from human umbilical vein and 
grown over a period of 2-3 weeks. The cells were then split and grown in normoxic and 
hyperoxic conditions, and cells were frozen down at different passages, early and late passage 
till P11 and telomerase activity was measured using a sensitive TRAP assay as shown in 
figure 5.2. There was no change in telomerase activity in mature endothelial cells (HUVEC) 
grown in normoxia across passages and also there was no significant change in telomerase 
activity of cells grown in hyperoxic conditions, and again the difference shown did not 
achieve statistical significance.  
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Figure 5.2. Longitudinal comparison of the measurement of telomerase activity in endothelial colony 
forming cells (ECFCs) and mature endothelial cells using a TRAP assay. Figure A showing the changes in 
telomerase activity in HUVEC grown across passages in normoxia and compared to HUVEC grown in hyperoxia. 
Figure B showing the changes in telomerase activity across early and late passages in endothelial colony 
forming cells (ECFCs) derived from cord blood and compared to ECFCs grown in hyperoxic conditions (40%O2). 
The cells were cultured over a period of 6- 8 weeks.  Statistical analysis was carried out using one way ANOVA, 
followed by Tukeys multiple comparison tests. The telomerase activity seems to go up across passages and in 
hyperoxia but the difference was not statistically significant with a p value of >.05 in all cases. ns stand for not 
statistically significant. n=6. 
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5.2.3 Telomere length measurement analysis of HUVEC grown in normoxia and 
comparison between early and late passage cells 
After measuring the telomerase activity of HUVEC samples across passages, as shown in the 
figure 5.3, we measured telomere length of HUVEC from early to late passages (young and 
old cells). Mature endothelial cells HUVEC were isolated from umbilical vein. Cells were 
grown in normoxia (20% O2) and once around 70-80% confluent they were split and 1 
million cells were plated to start the culture taken as P0. Cells were passaged regularly and 
split in a ratio of 1:3. 1 million cells were replated and the rest were frozen down.  Cells were 
grown till late passage P16 (10-12 weeks of culture) so that any change in telomere length as 
the cells grow older could be detected. As shown in figure 5.3, the results showed that the 
telomere length goes down from early passage to late passage and the difference was found to 
be statistically significant. This could be as a result of cellular senescence as telomere length 
is shortened with each replicative cycle. In order to compensate for this attrition of telomere 
length, we proposed that the telomerase activity would increase and compensate for this loss, 
but as shown in figure 5.3, the telomerase activity did not increase across passages and also 
showed no significant increase in the activity under oxidative stress conditions (40% O2). 
 
A                                                         B                                                                C 
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Figure 5.3. Flow FISH data analysis for the measurement of telomere lengths in early and late passage 
mature endothelial cells (HUVEC). Flow FISH is a PNA probe based assay in which mean fluorescence based on 
FITC signal is used to measure the telomere lengths. Thymocytes were used as an internal control and as a 
reference telomere length for telomere length measurements in HUVEC. Mature endothelial cells HUVEC were 
isolated from human umbilical vein and were grown in normoxia. Cells were passaged till P16 over a period of 
5-6 weeks to compare telomere lengths of early and late passage endothelial cells. Propidium Iodide was used 
as a counter stain and cells were gated based on PI uptake. Telomere length seems to go down across 
passages, and the difference was found to be statistically significant. Statistical analysis was carried out using 
one way ANOVA followed by Dunn’s multiple comparison tests. n=3.  
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5.2.4 Telomere length measurement analysis of ECFC grown in normoxia and comparison 
between early and late passage cells 
After successful measurement of telomerase activity in ECFCs grown in both normoxia and 
hyperoxia, the next step was to measure the telomere length of ECFCs grown over a period of 
8-10 weeks till passage 16. ECFCs were obtained from umbilical cord blood by 
differentiation of cord blood mononuclear cells in endothelial specific media. Cells were 
grown till an endothelial colony was seen which was observable at around 3-4 weeks of 
culture. Once a colony was seen it was picked up and grown in culture. The cells were grown 
in normoxia and were regularly passaged. Cells were frozen down at each passage and 1 
million cells were plated each time  the cells were split using trypsin-EDTA. As shown in 
figure 5.5, there was a decrease in telomere length of ECFCs when grown from early to late 
passages. This further confirms that these ECFCs were not stem cells and have committed to 
endothelial progeny. This was shown in less than 3 samples so the statistical analysis was not 
carried out. 
 
         A                                           B                                              C 
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Figure 5.4. Flow FISH data analysis for the measurement of telomere lengths in early and late passage 
endothelial progenitor cells (ECFCs). Flow FISH is a PNA probe based assay in which mean fluorescence based 
on FITC signal is used to measure the telomere lengths. Thymocytes were used as an internal control. ECFCs 
were isolated from cord blood derived endothelial colony. Cells were grown in normoxia and passaged till P16. 
As shown in the figure the telomere length decreases from early to late passage. n=1. 
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5.2.5 Gene expression analysis of PGC-1 alpha and its downstream targets in ECFC and 
HUVEC grown in normoxia and hyperoxia 
Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) belongs 
to a family of transcriptional coactivators that orchestrate a wide range of genetic programs. 
PGC-1 alpha induction occurs as a result of coactivation of certain transcription factors 
including estrogen- related receptor alpha (ERR alpha), nuclear respiratory factor-1 and 2 
(NRF-1, 2) and many others (Patten and Arany, 2012). PGC-1 alpha promotes angiogenesis 
by inducing the expression of vascular endothelial growth factor (VEGF) along with other 
angiogenic factors (Arany et al., 2008). This induction of VEGF occurs through co activation 
of ERR alpha and is independent of the well-studied hypoxia- inducible factor (HIF-1 alpha) 
pathway (Arany et al., 2008). As shown in figure 5.5, we investigated the effect of oxidative 
stress (40% O2) on the gene expression analysis of PGC-1 alpha and its downstream targets 
including ERR alpha and Glucose 6 phosphate dehydrogenase (G6PD). We first compared 
the expression of PGC-1 alpha in early EPCs derived from cord blood and late EPCs or 
ECFCs derived from the cord blood to mature endothelial cells (HUVEC) derived from the 
umbilical vein of the same donor. RNA extraction was carried out followed by quantitative 
PCR analysis. As shown in figure 5.5A, there was a decrease in the expression level of PGC-
1 alpha in ECFCs as compared to early EPCs and the difference was found to be statistically 
significant. The difference between the gene expression level of PGC-1 alpha in ECFCs and 
HUVEC was not statistically significant. As shown in fig 5.5B, we compared the expression 
level of PGC-1 alpha in ECFCs and HUVEC grown in normoxia (20% O2) and in conditions 
of oxidative stress (40% O2). The cells were grown in normoxia till passage 2 (P2) and then 
exposed to oxidative stress by incubating in hyperoxia. We found that there was an up 
regulation of PGC-1alpha gene expression level in both ECFCs and HUVEC, although the 
difference was not found to be statistically significant. We then investigated, if this increase 
in gene expression level caused any change in the expression level of any of the downstream 
targets of PGC-1 alpha. As shown in figures 5.5C and D, we compared the gene expression 
level of glucose 6 phosphatase and ERR alpha in both ECFC and HUVEC. The cells were 
grown in normoxia till P2 and then exposed to oxidative stress, by growing in 40% O2. It was 
found that there was an up regulation of both these genes in ECFCs and HUVEC suggesting 
that this oxidative stress has led to an activation of PGC-1 alpha, which showed a slight but 
insignificant increase in expression which in turn co activated other transcription factors 
involved in other biological functions.   
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Figure 5. Gene expression analysis of PGC-1 alpha and its downstream targets in normal and hyperoxic 
conditions. The figure shows that PGC-1 alpha expression level goes down as the EPC differentiation occurs. 
The cells were exposed to hyperoxia till passage 1 (P1) that corresponds to 3-5 days of culture. Statistical 
analysis was carried out using one way ANOVA followed by Tukeys multiple comparison tests. The figure 
further shows the gene expression analysis of PGC-1 alpha and its downstream targets in ECFCs and HUVEC 
grown in normal (20% O2) and hyperoxic conditions (40% O2). The expression increases for both targets in 
hyperoxia but the difference was not statistically significant. n=3 (HUVEC 20% and 40% O2) and n=5 (ECFC 20% 
and 40% O2). All values are calculated as ± SEM. * P < .05, ** P< .01, *** P < 0.001. 
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5.2.6 Gene expression analysis of antioxidative genes in HUVEC grown in hyperoxia 
Cardiovascular risk factors are responsible for increased ROS production in the vascular wall 
which eventually leads to oxidative stress. This occurs when ROS production exceeds anti 
oxidative defence mechanism which in the vessel wall is composed of a set of antioxidative 
enzymes that can reduce this ROS damage to the endothelium. These enzymes include 
Catalases (CAT), Glutathione peroxidases (GPx), superoxide dismutase (SOD), Heme 
oxygenase (HO) and periredoxins. We therefore proposed that exposing endothelial cells to 
oxidative stress (40% O2) would lead to an increase in gene expression of these antioxidative 
genes. As shown earlier, our results indicated that there was an up regulation of PGC-1 alpha 
expression in ECFCs and HUVEC grown in hyperoxia (40% O2). We therefore investigated 
the time points when this up regulation begins and alongside PGC-1 alpha is there any 
change in level of expression of these anti oxidative genes. We chose two antioxidative genes 
namely CAT and GPx-1 that encode respective antioxidant enzymes catalase and glutathione 
peroxidase. CAT gene encodes catalase which is an important antioxidant enzyme that 
prevents the body against reactive oxygen species by degrading hydrogen peroxide to oxygen 
and water. Catalase overexpression has been shown to have positive effects in cardiovascular 
system and has been shown to play a role against atherosclerosis and angiotensin induced 
hypertrophy of the aortic wall (Zhang et al., 2005; Li et al., 2013).  
GPx-1 has been shown to play a protective role in preventing oxidative damage to the 
endothelium by reducing both lipid peroxides and hydrogen peroxide (Raes et al., 1987; 
Maiorino et al., 1995). Vascular injury has been demonstrated to be linked with a reduction in 
GPx-1 activity and atherosclerotic plaques isolated from carotid arteries have shown 
decreased expression of GPx-1 (Lapenna et al., 1998).  
Mature endothelial cells HUVEC at P0 were grown in normoxia and were split once the cells 
became confluent. 1 million cells were plated and cells were passaged till P2 and then the 
cells were exposed to hyperoxic conditions. Cells were not split till day 17 and cells were 
frozen down at specific time points as shown in figure 5.6. Cells were frozen down and RNA 
was extracted followed by gene expression analysis of PGC-1 alpha and antioxidative genes 
that we proposed would be up regulated in these cells. There was an up regulation of 
antioxidative genes CAT and GPx-1 in HUVEC when exposed to hyperoxia as shown in 
figure 5.6 B and C suggesting that HUVEC have responded to this exposure to stress 
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Figure 5.6.  Hyperoxia time point experiment showing up regulation of PGC-1 alpha and anti-oxidative genes 
in HUVEC grown in 40% Oxygen (n=1). Figure showing an increase in the level of expression of antioxidative 
genes in HUVEC. PGC-1 alpha showed a significant increase in expression of HUVEC grown in hyperoxia. 
Catalase and GPx-1 are two antioxidants and increase in their mRNA level of expression as the incubation 
period of HUVEC exposure to oxidative stress was increased suggests that antioxidative mechanisms are up 
regulated in HUVEC when they are grown in 40% O2. 
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5.3 Discussion 
Peroxisome proliferator -activated receptor γ coactivator-1α (PGC-1 α) is a transcriptional 
coactivator that is considered to be a master regulator of mitochondrial biogenesis and also 
known to suppress reactive oxygen species (ROS), thus combating oxidative stress (St-Pierre 
et al., 2006). Cell senescence has been shown to be linked with oxidative stress and 
associated telomere and mitochondrial dysfunction. Therefore, it is more than likely that there 
exists a relationship between all these factors promoting senescence and PGC-1 alpha plays 
an important role in preventing this by centrally coordinating all these processes (Xiong et 
al., 2013). It has been shown recently, that PGC-1 alpha deletion leads to increased 
mitochondrial reactive oxygen species (ROS) production as a consequence of vascular 
inflammation and dysfunctioning (Kröller-Schön et al., 2013). It was therefore important to 
find this link and investigate the effect that oxidative stress can have on ECFCs and HUVEC 
in terms of PGC-1 alpha gene expression and associated telomere dysfunction. 
Telomeres are complex DNA-protein structures located at each end of the chromosomes. 
They are shortened with each cycle of cell replication, and can be a predictor of organismal 
age (Blackburn, 2001). Telomere preservation requires intact telomerase enzyme activity and 
maintenance of telomere length itself (Edo and Andrés, 2005). Recently, it has been shown 
that critically shortened telomeres are linked to age-related cardiovascular diseases and 
promote apoptosis and cellular senescence (Samani et al., 2001; Brouilette et al., 2003; 
Brouilette et al., 2008; De Meyer et al., 2008; Samani and Van Der Harst, 2008; Butt et al., 
2010; Aviv, 2012). Similarly, it has been proposed that endothelial cells within an 
atherosclerotic plaque show signs of cell senescence, whether this is linked to shortening of 
telomere length and does this differ between endothelial progenitor cells and mature 
endothelial cells remains to be seen. As shown in figure 5.2, we measured the telomerase 
activity of ECFCs and HUVEC grown in normoxia across passages (early to late passage) 
and there was no significant change in telomerase activity. We exposed the mature 
endothelial cells oxidative stress but still there was no significant increase in telomerase 
activity that could be observed using this sensitive TRAP assay. Similarly for ECFCs as 
shown in figure 5.2, there was no statistically significant difference seen in telomerase 
activity when these cells were exposed to 40% O2. These results suggested that may be this 
stress has not induced telomere dysfunction in either ECFCs or HUVEC and there was no 
telomere shortening and as a consequence of that no concomitant increase in telomerase 
activity. 
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This now is well established that there exists a correlation between oxidative stress and 
inflammation, and several pathological conditions showing signs of both oxidative stress  and 
chronic inflammation are characterized by low EPC count and activity (Guzik et al., 2003; 
Tousoulis et al., 2008; Hulsmans et al., 2011). It has been shown that early EPCs including 
CACs and late EPCs (ECFCs) are more resistant to oxidative stress in comparison to mature 
endothelial cells (HUVEC), due to the expression of high levels of antioxidant enzymes 
(Dernbach et al., 2004; Cai et al., 2006; He et al., 2009). Recent studies have shown that 
there exists a strong interplay between EPCs, reactive oxygen species (ROS) and 
inflammation, and it has been suggested that these endothelial progenitor cells can be used as 
a tool to repair the vasculature in these atherogenic conditions (Rabelink et al., 2004; 
Tousoulis et al., 2008; Badimon et al., 2011).  
Our initial results indicated that endothelial progenitor cells (ECFCs) could be grown for a 
longer period of time and grow at a faster rate in comparison to mature endothelial cells 
(HUVEC) in conditions of oxidative stress (40% O2). It has already been shown that chronic 
oxidative stress leads to telomere dysfunctioning and promotes cell senescence in human 
endothelial cells (Kurz et al., 2004). We therefore proposed that ECFCs are better equipped 
to counteract this ROS mechanism and might have been the cells that take part in repairing 
damaged endothelium and as shown in figure 5.1, the growth kinetics of ECFCs and HUVEC 
confirms that ECFCs are much more resistant to oxidative stress. 
We had hypothesized that oxidative stress would lead to telomere dysfunction and a decrease 
in the level of PGC-1α as shown in mice recently (Sahin et al. 2011), but again instead of 
decreasing the levels of PGC-1α  mRNA transcripts were increased as shown in figure 5.5. 
We also investigated two downstream targets of PGC-1α that included ESSRA gene that 
encodes  ERR- α which is involved in angiogenesis and G6-Phosphatase gene that encodes 
the protein which is part of gluconeogenesis.  
Estrogen- related receptor alpha (ERR-α) also referred to as NR3B1 is an orphan nuclear 
receptor that has no endogenous ligand identified till date. In humans it is encoded by ESSRA 
(Estrogen related receptor alpha) gene which was initially cloned due to DNA sequence 
homology to estrogen receptor alpha but has been confirmed that  it is not regulated by 
estrogens (Giguere et al., 1988; Deblois and Giguère, 2011). This gene is involved in the 
regulation of mitochondrial biogenesis, oxidative phosphorylation and glucose and fatty acid 
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metabolism and is activated by transcriptional coactivator PGC-1 alpha (Wu et al., 1999; 
Yoon et al., 2001; Huss et al., 2004; Mootha et al., 2004).  
Glucose 6- phosphatase dehydrogenase (G6Pase) encodes an enzyme that belongs to the 
catalytic sub family of proteins involved in hydrolysis of glucose-6 phosphate which is an 
important step in gluconeogenesis and glycolysis and essential for regulation of glucose 
levels in blood. PGC-1 alpha is known to promote insulin resistance and is involved in 
inducing gluconeogenic genes including G6Pase (Yoon et al., 2003). PGC-1- deficient mice 
have reduced fasting glucose levels and reduced mRNA expression of genes encoding for 
gluconeogenic enzymes including glucose 6-phosphatase (G6Pase) and phospheonolpyruvate 
carboxy kinase (PEPCK) (Koo et al., 2004). Similarly, telomere dysfunction induced 
repression of PGC-1 alpha and its downstream targets lead to reduced expression of genes 
involved in gluconeogenesis including G6Pase (Sahin et al., 2011). 
The results showed a slight but insignificant increase in gene expression of both these 
downstream targets of PGC-1 alpha at mRNA level in ECFCs and as shown in figure 5.5C 
and D they were consistent with the previous findings in other cell types but this has not been 
shown before in ECFCs. This further confirmed that the hypothesis as it worked in mice was 
not followed in human cells and as seen in figure 5.5B, exposing the cells to 40% O2 did not 
lead to a repression in PGC-1 alpha mRNA level of expression in both ECFCs and HUVEC 
when compared with cells grown in normoxia, although the difference was statistically 
insignificant. Also, both ERR-α and G6Pase mRNA level expression was increased although 
the difference found was not statistically significant. 
It has been proposed and shown that oxidative stress that leads to an increase in reactive 
oxygen species (ROS) production and a decrease in antioxidant enzyme expression can 
promote vascular senescence. Oxidative stress has been implicated in a wide range of 
vascular disorders leading to DNA damage, decreased nitric oxide (NO) availability and 
change in redox state as a result of increased ROS production (Sugamura and Keaney Jr, 
2011; Higgins et al., 2012). This oxidative damage can be linked to vascular aging, as this 
cellular damage due to increased aging can reduce EPC function resulting in an increased risk 
of vascular pathologies. It has been shown that both early and late EPCs are more resistant to 
this oxidative stress than mature endothelial cells (HUVEC) as they express higher level of 
antioxidant enzymes (Dernbach et al., 2004; He et al., 2004a; Cai et al., 2006). This 
suggested that these EPCs can be more efficient cells involved in vascular repair as a result of 
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an ischemic insult, owing to this improved resistance to oxidative stress. However, it has 
been shown recently that early EPCs or circulating angiogenic cells (CACs) are cells of 
myeloid origin and express certain monocyte-macrophage lineage markers including CD45, 
CD14 and CD115 and are proangiogenic but do not take part in vascular repair directly, 
whereas late EPCs or endothelial colony forming cells (ECFCs) have been shown to the 
EPCs involved in vascular repair although they themselves are not shown to be completely 
resistant to oxidative stress, but are better suited to these conditions as compared to mature 
endothelial cells (Ingram et al., 2007; Yoder et al., 2007). However, this antioxidative 
capacity of EPCs  has been shown to diminish with aging, and early EPCs isolated from 
young subjects have shown higher levels of antioxidant enzyme glutathione peroxidase (GPx-
1) as compared to old ones (He et al., 2009) and were found to be more resistant to stress 
induced apoptosis. Glutathione peroxidase 1 (GPx-1) is another important protein involved in 
redox signalling that plays a role in vascular homeostasis. More importantly, over expression 
lead to restoration of endothelial function in endothelial cells treated with high levels of 
homocysteine (Weiss et al., 2001). Several mice studies have demonstrated that loss of GPx-
1 is implicated in endothelial dysfunction and several other vascular abnormalities and 
renders them vulnerable to ischemic insult (Forgione et al., 2002a; Forgione et al., 2002b). 
As shown in figure 5.6, there was an up regulation of both the antioxidative genes CAT and 
GPx-1 in HUVEC and suggested that by exposing these endothelial cells to 40% O2 meant 
that they were subjected to oxidative stress and these genes were up regulated to counteract 
this stress. 
In conclusion, we found endothelial progenitor cells (ECFCs) to be more resistant to 
oxidative stress as compared to mature endothelial cells (HUVEC) and they could be grown 
at a faster rate and over longer periods when exposed to hyperoxic conditions (40% O2).  
Exposing both these cell types to oxidative stress did not lead to telomere dysfunction and as 
we had proposed that a shortening of telomere length would be compensated by an increase 
in telomerase activity in these cells. We measured telomere lengths for both ECFCs and 
HUVEC across passages (early and late passage cells) using flow FISH which has not been 
shown before using this technique and found that the telomere length goes down for HUVEC 
(n=3) but the difference was detected at very late passage (P16). ECFCs as we expected were 
not stem cells and they were not able to preserve their telomere length and it was shortened as 
well as cells grew older (late passage P16) but this was done with one sample (n=1) and no 
statistical analysis could be carried out. There was no reduction in PGC-1 alpha gene 
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expression and instead there was an up regulation along with an increase in mRNA level 
expression for both of its downstream targets when grown in hyperoxia. There was 
statistically significant difference seen in PGC-1 alpha expression in early EPCs as compared 
to ECFCs and the former showed high level of PGC-1 alpha expression. We investigated the 
expression levels of antioxidative genes CAT and GPx-1 in cells grown in hyperoxia so that 
we could confirm that exposing cells to 40% O2 can lead to oxidative stress and an up 
regulation of these genes after 2 weeks of culture confirmed that this much time period is 
required for these endothelial cells to get affected by stress.  
The results in this section indicate that the hypothesis which we had proposed that oxidative 
stress would lead to telomere dysfunction and as a result of that repression of PGC-1 network 
has not worked in ECFCs and mature endothelial cells (HUVEC). The work done by Sahin et 
al., 2011 was done in mice and telomere dysfunction was induced by producing mice that 
were null for either telomerase reverse transcriptase (Tert) or telomerase RNA component 
(Terc) genes. This resulted in an activation of p53 in the nucleus causing a decrease in PGC-1 
alpha expression and subsequent reduced mitochondrial biogenesis, decreased 
gluconeogenesis and increased reactive oxygen species. The activation of p53 resulted in 
cellular growth arrest, apoptosis and senescence. Our results showed that there was no 
increase in telomerase activity which we proposed that would occur due to telomere 
dysfunction induced due to exposure to hyperoxia. As shown later in figure 6.14 there was 
insignificant decrease in expression of p53 in ECFCs grown in hyperoxia. Although, there 
was a significant increase in p53 expression in HUVEC grown in hyperoxia and this suggests 
that may be HUVEC could show signs of senescence and apoptosis due to its activation. In 
summary, the results suggest that exposure to 40% O2 did not lead to telomere dysfunction in 
these cells and as a result of that there was no concomitant increase in telomerase activity. 
PGC-1 alpha levels were not decreased and this could be further confirmed by functional 
assays evaluating cell senescence and measurement of extracellular ROS. 
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Chapter 6. Investigating the effect of oxidative stress on genes 
involved in mitochondrial biogenesis, oxidative metabolism and 
angiogenesis in ECFCs and HUVEC 
 
6.1 Introduction 
Vascular endothelium is the key that maintains vascular homeostasis and endothelial 
dysfunction or injury is the first step towards the progression of atherosclerosis (Chen et al., 
2006b; Lin et al., 2009; Egido et al., 2011; Liu et al., 2012). Several recent studies have 
shown that endothelial progenitor cells constitute an important endogenous mechanism that is 
instrumental in maintaining endothelial integrity and vascular homeostasis (Urbich and 
Dimmeler, 2004). In most forms of cardiovascular diseases, inflammation acts as a mediator 
of oxidative stress, endothelial dysfunction and endothelial cell senescence and inappropriate 
homage of EPCs to the site of vascular injury promotes the progression of vascular diseases 
(Imanishi et al., 2005; Mikirova et al., 2009; Ribeiro et al., 2010; Ungvari et al., 2010). As 
reendothelialization is considered to be a proinflammatory process, it has been proposed that 
it works independently and it has been shown more recently that this occurs exclusively in 
response to oxidative stress mainly due to a localized or a systemic inflammatory response 
(Reinders et al., 2006; Case et al., 2008; Watson et al., 2008).  This response is aided by and 
involves vascular and immune systems as well as several signaling mechanisms, mediators 
and various cell types. This cascade of events can initiate due to changes in microcirculation, 
starting from vessel impairment to endothelial migration of leukocytes, endothelial 
dysfunction and changes in vascular permeability finally leading to new blood vessel 
formation, a process known as angiogenesis. We, therefore proposed that in this in vitro 
system where endothelial progenitor cells (ECFCs) and mature endothelial cells (HUVEC) 
are grown in normal conditions, will be exposed to mild oxidative stress (40% O2), and this 
stress would lead to an inflammatory response in these cells and we would be able to study 
the response of these two cell types under stress conditions.  
Mitochondria are considered to be the power houses of the cell and are involved in energy 
production mainly in the form of ATP. Although, endothelial cells are mainly glycolytic and 
do not use oxidative phosphorylation as a main source of  ATP production, we proposed that 
oxidative stress (40% O2) would lead to an increase in oxidative phosphorylation and as a 
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result of that, an increase in expression level of genes involved in electron transport chain 
(ETC).  
A link between mitochondrial dysfunction leading to endothelial damage and initiating the 
process of atherosclerosis is now an emerging area of research and there is enough evidence 
that suggest that mitochondrial damage plays an important role in the progression of vascular 
diseases including atherosclerosis (Madamanchi and Runge, 2007; Victor et al., 2009; 
Harrison et al., 2011; Hulsmans et al., 2012; Xiong et al., 2013; Yu et al., 2013). PGC-1 
alpha has been shown to be a master regulator of mitochondrial biogenesis and along with 
PPAR gamma, which is transcriptionally co activated by PGC-1 alpha plays a role in 
maintaining energy metabolism (Liu and Lin, 2011). cAMP response element binding 
proteins (CREB) and Nuclear respiratory factor (NRF-1 and 2) are also involved in this 
regulation of mitochondrial biogenesis in response to an external stimuli (Jones et al., 2012). 
Reactive oxygen species (ROS) are continuously produced by mitochondria and are balanced 
by cellular defense mechanism in the form of antioxidative enzymes including catalase, 
glutathione peroxidase, superoxide dismutase and peroxiredoxins present throughout the cell. 
If this balance between ROS and antioxidative defense system is disrupted, it results in the 
production of oxidative stress.  
The significance of mitochondrial ROS production in endothelial cells is difficult to assess 
because ROS is also produced by other sources as well as other cell types within the 
myocardium. Although, it has been shown that superoxide is produced at both complex I and 
III in mitochondria obtained from bovine  aortic endothelial cells (O'Malley et al., 2006), this 
needs further investigation. Similarly, how does oxidative stress affect the pathways that 
utilizes ROS as a signal transducers, still remains to be seen in endothelial cells. 
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6.2Results 
6.2.1 Gene expression analysis of ECFCs and HUVEC grown in normoxia using low density 
array (LDA) 
 
In order to carryout gene expression analysis of ECFCs and HUVEC, cells were isolated 
from umbilical cord blood and cord of the same donor. ECFCs were isolated from 
differentiation of cord blood mononuclear cells (day 0 MNCs) in endothelial specific media. 
An endothelial colony was observed at around 3 weeks of culture that was picked and grown 
separately. This culture was grown for a period of around 4-6 weeks and cells were regularly 
passaged. Cells were grown till passage 5 (P5) and then cells were frozen down for RNA 
extraction. RNA extraction was followed by cDNA synthesis and low density array was 
performed. HUVEC were isolated from the cord of the same donor and cells were grown till 
passage 5 (P5). Both ECFCs and HUVEC were grown in normoxic conditions (20% O2). As 
shown in figure 6.1 a comparison was carried out between ECFCs and HUVEC grown in 
normoxia in terms of gene expression analysis. The data were normalized to three 
housekeeping genes individually that included TBP, HPRT1 and 18s RNA. As shown in 
figure 6.1B, ECFCs showed a down regulation of certain genes in comparison to HUVEC. 
These included genes involved in angiogenesis like VEGF A and C, PDGFRB, FGF2 and 
TGF. Genes showing down regulation in ECFCs also included antioxidative gene SOD2 
which mainly combats against oxidative stress. As shown in figure 6.1B there have been 
several genes that showed an up regulation in ECFCs in comparison to HUVEC. These 
included pro inflammatory markers IL1A and CXCL12 and cell surface markers like 
PECAM1, KDR and KIT. There was also an up regulation of PON1 and BRCA1that was 
found in HUVEC when grown in normoxia in comparison to ECFCs grown in normoxic 
conditions. For the purpose of having a better comparison both ECFCs and HUVEC were 
derived from the same donor and cells at same passage (P5) were used.  
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Figure 6.1. An overall representation of the gene expression analysis carried out using low density 
array. ECFCs were isolated from cord blood obtained from the umbilical vein and HUVEC were 
isolated from the walls of the umbilical vein of the same donor. The comparison is carried out 
between ECFCs and HUVEC grown in normoxia conditions (20% O2). Gene expression is plotted 
relative to MNCs. The data were normalized to three housekeeping genes 18s RNA, TBP and HGPRT1. 
n=2 (ECFC 20% and 40% O2, HUVEC 40% O2) and n=3 (HUVEC 20% O2).  
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6.2.2 Gene expression analysis of ECFCs grown in normoxia and comparison with cells 
grown in hyperoxia 
 
After the gene expression analysis of ECFCs and HUVEC grown in normoxia, the next step 
was to analyse the expression pattern in ECFCs grown in normoxia to ECFCs incubated in 
hyperoxic conditions (40% O2). ECFCs were obtained from cord blood and derived by the 
differentiation of cord blood mononuclear cells. ECFCs were isolated from an endothelial 
colony that was observed and picked at around 3 weeks of growing the cells in endothelial 
specific media. The cells were cultured in normoxic conditions (20% O2) for several passages 
and grown till P5 to get the cells required for ECFCs normoxia. For the array analysis, the 
comparison was made between ECFCs grown in normoxia till P5 and in order to get 
hyperoxic cells, ECFCs were grown in normoxia till P2 and then the cells were split using 
trypsin-EDTA and 1 million cells were plated in hyperoxic conditions (40%O2). These cells 
were grown in hyperoxia till P3 and then frozen down for RNA extractions. This was 
followed by cDNA synthesis and low density array was carried out. As shown in figure 6.2B 
there have been several genes that showed down regulation in ECFCs when grown in 
hyperoxia. These included some genes that are involved in angiogenesis like ANG2, NOS3, 
CXCR4 and endoglin (CD105). The results showed a decrease in expression of several cell 
surface markers including PECAM1 (CD31), CDH5 (CD144), MCAM (CD146) and vWF 
when ECFCs were grown in hyperoxia. UCP2 showed a reduced expression when cells were 
grown in 40% O2. There have been some markers that showed higher expression when 
ECFCs were grown in hyperoxia and these included PGC-1α that showed significant up 
regulation in ECFCs grown in hyperoxic conditions. It is interesting to note that as cells were 
exposed to hyperoxia till P3 there was a significant increase in PGC-1 alpha expression in 
ECFCs whereas earlier data showed no statistically significant difference when cells were 
exposed to hyperoxia till P1. Other markers showing an increase in expression when ECFCs 
were grown in hyperoxia included angiogenic markers ANG1, FGF2, VEGF A and C, 
CXCL12, ACTA2 and PDGFRA and B.  
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Figure 6.2. An overall representation of the gene expression analysis carried out using low density 
array. ECFCs were obtained from the cord blood. The comparison is made between ECFCs grown in 
normoxia (20% O2) to the ECFCs grown in hyperoxia (40% O2). Gene expression is plotted relative to 
MNCs. The data were normalized to three housekeeping genes 18s RNA, TBP and HGPRT1. n=2 (ECFC 
20% and 40% O2, HUVEC 40% O2) and n=3 (HUVEC 20% O2).  
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6.2.3 Gene expression analysis of HUVEC grown in normoxia and comparison with HUVEC 
grown in hyperoxia using low density array (LDA) 
 
In order to compare the expression analysis of HUVEC grown in normoxia with HUVEC 
cultured in hyperoxia, HUVEC were obtained from the umbilical cord. Cells were grown in 
normoxic conditions for several passages and regularly washed and split using PBS and 
trypsin-EDTA respectively. Cells were frozen down at passage 5 (P5) and RNA extraction 
was carried out. Cells were passaged at P2 and split into two cultures. 1 million cells were 
plated and cells were incubated and grown in hyperoxic conditions (40% O2). The 
comparative analysis was carried out between HUVEC grown in normoxia and HUVEC 
grown in hyperoxia. As shown in figure 6.3, there have been some genes that are down 
regulated in HUVEC grown in hyperoxia and mainly include mitochondrial genes that form 
part of electron transport chain namely MTCO1, MTND3, MTCYB, MTCO3 and MTATP6. 
There have been some genes that are involved in angiogenesis which are down regulated and 
included ANG1, VEGFB, NOS3, TGF and PDGFRB. As shown in figure 6.3, there were 
several genes that showed an up regulation in HUVEC grown in hyperoxia. These included 
mitochondrial genes PGC-1 alpha, SIRT4 and PON1. Cell surface markers including PROM1 
and CD34 showed an up regulation in HUVEC grown in hyperoxia. Genes involved in 
angiogenesis like ANG2 and FLT4 were also up regulated in HUVEC exposed to hyperoxia.   
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Figure 6.3. An overall representation of the gene expression analysis carried out using low density 
array. HUVEC were derived from the umbilical vein. The comparison is made between HUVEC grown 
in normoxia (20% O2) to the HUVEC grown under hyperoxic conditions. Gene expression is plotted 
relative to MNCs. The data were normalized to 18s RNA, TBP and HGPRT1. n=2 (ECFC 20% and 40% 
O2, HUVEC 40% O2) and n=3 (HUVEC 20% O2).  
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6.2.4 Gene expression analysis and qPCR validation of genes involved in mitochondrial 
biogenesis, oxidative metabolism and angiogenesis in ECFCs and HUVEC grown in 
normoxia  
After analysing low density array (LDA) data, the next step was to validate the genes that 
showed statistically significant difference in ECFCs and HUVEC grown in normoxic and 
hyperoxic conditions. The validation was carried out on different samples and ECFCs were 
obtained from cord blood and HUVEC from the umbilical cord of the same donor. ECFCs 
were derived from an endothelial colony which was picked after 3 weeks of culture of cord 
blood mononuclear cells (HUCBC) in endothelial specific media. Once a colony was 
isolated, it was grown in normoxia for 4-6 weeks and the cells were termed as endothelial 
colony forming cells (ECFCs). Cells were passaged regularly till P5 and at this stage cells 
were frozen down for carrying out RNA extractions. HUVEC were isolated from the 
umbilical cord of the same donor and cells were grown in normoxic conditions and regularly 
passaged as soon as they reach around 80% confluence. This was followed by RNA 
extractions of frozen down HUVEC samples at P5. Validation was done using qPCR. As 
shown in figure 6.4, the comparative analysis was carried out between ECFCs and HUVEC 
grown in normoxia (20% O2). All data were normalized to three housekeeping genes namely 
18s RNA, HPRT1 and TBP. LDA and qPCR data were analysed together. Cells at same 
passage were used for the comparison (P5). There have been several genes that showed down 
regulation in HUVEC as compared to ECFCs grown in normoxia. These included angiogenic 
genes like ANG2, NOS3 and CDH5. Other genes showing decreased expression were 
PECAM1, PROX1, KIT and NRP2. There were genes that showed up regulation in HUVEC 
grown in normoxia in comparison with ECFCs and they included genes involved in 
angiogenesis like ANG1, TGFα, VEGFA and C, FGF2 and PDGFRB. Other genes showing 
up regulation included PCK2, PPARG and TEK. 
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Figure 6.4. Gene expression analysis of qPCR validation done on LDA genes showing significant up 
regulation or a decrease in expression. ECFCs and HUVEC were obtained from the cord blood and 
umbilical vein of the same donor. Comparative analysis is carried out on ECFCs and HUVEC grown in 
normoxia conditions (20% O2). Gene expression is plotted relative to MNCs. The data were normalized 
to 18s RNA, TBP and HGPRT1. n=4 (ECFC 20% and 40%O2) and n=5 (HUVEC 20% and 40% O2). 
 
 
 
 
 151 
 
6.2.5 Gene expression analysis and qPCR validation of genes involved in mitochondrial 
biogenesis, oxidative metabolism and angiogenesis in ECFCs grown in normoxia and 
hyperoxia  
In order to validate the array results qPCR validation was carried out. ECFCs were derived 
from cord blood by differentiation of cord blood mononuclear cells grown in endothelial 
specific media. An endothelial colony was observed at around 3weeks of culture that was 
picked and grown separately. The cells derived from the colony were named as endothelial 
colony forming cells (ECFCs) and were allowed to grow for 4-6 weeks in endothelial specific 
media. The cells were grown in normoxia and regularly passaged till P5 and then the cells 
were frozen down for RNA extractions. Cells were also required to be grown in hyperoxia 
and to do so, cells were cultured in normoxic conditions till P2 and then cells were split and 1 
million cells were plated in hyperoxia (40% O2) and cells were grown in these conditions for 
three additional passages (P3) so that they are compared with normoxic cells at P5. As shown 
in figure 6.5, the comparison was carried out between ECFCs grown in normoxia to ECFCs 
grown in hyperoxic conditions and cells at same passage were used for RNA extractions. 
This was followed by cDNA synthesis and qPCR. As shown in figure 6.5, all the data were 
normalized to three housekeeping genes including 18s RNA, HPRT1 and TBP. The LDA and 
qPCR data were analysed together. There were several genes that showed down regulation in 
ECFCs grown in hyperoxia and included cells surface markers PECAM1, CDH5, KDR and 
KIT. Several angiogenic genes also showed down regulation in ECFCs cultured in hyperoxia 
included ANG2, NOS3, FLT1 and TP53. As shown in figure 6.5, there have been many 
genes that showed an up regulation in ECFCs grown in hyperoxia and mainly included 
mitochondrial genes involved in electron transport chain like MT-CYB, MT-ND3, MT-
CO1and other mitochondrial genes mainly PGC-1 alpha, PPARG and SIRT4. There were 
several angiogenic genes that showed up regulation in ECFCs cultured in hyperoxia and 
included ANG1, VEGF A and C, CXCL12, ACTA 2, PDGFR A and B and FGF2.   
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Figure 6.5. Gene expression analysis of qPCR validation done on LDA genes that showed significant 
difference in expression. ECFCs were derived from the cord blood. Comparative analysis was carried 
out between ECFCs grown in normoxia to the ECFCs grown in hyperoxic conditions. Gene expression 
is plotted relative to MNCs. The data were normalized to 18s RNA, TBP and HGPRT1. n=4 (ECFC 20% 
and 40% O2) and n=5 (HUVEC 20% O2 and HUVEC 40% O2). 
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6.2.6 Gene expression analysis and qPCR validation of genes involved in mitochondrial 
biogenesis, oxidative metabolism and angiogenesis in HUVEC grown in normoxia and 
hyperoxia 
After the low density array (LDA) analysis the next step was to validate the genes that 
showed significant difference in HUVEC grown in hyperoxia. HUVEC were isolated from 
the umbilical cord and cells were grown in normoxia. The cells were regularly passaged 
when around 80% confluent. Cells were grown till passage 2 (P2) and then culture was split 
in to two. 1 million cells were allowed to grow in normoxia and 1 million cells were 
incubated in hyperoxic conditions. The cells were allowed to grow till passage 5 (P5). As 
shown in figure 6.6 the comparative analysis was done between HUVEC grown in normoxia 
and hyperoxia. All the data were normalized to three housekeeping genes. Both LDA and 
qPCR data were analysed together. As shown in figure 6.6 there have been several genes that 
showed down regulation in HUVEC grown in hyperoxic conditions and mainly included 
mitochondrial genes that are part of electron transport chain namely, MT-CYB, MT-ND3, 
MTCO1 and MT-ATP8. Genes showing down regulation also included angiogenic markers 
ANG1 and VEGFC. As shown in figure 6.6, there were several genes that showed up 
regulation in HUVEC grown in hyperoxia and included mitochondrial genes SIRT4, PCK2 
and PGC-1 alpha. Other genes showing up regulation included cell surface markers and genes 
involved in angiogenesis including ACTA2, CDH5, NOS3, KDR, TGFα, PDK4, PECAM1, 
ANG2, CXCL12, PDGFR A and B and IL1A. 
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Figure 6.6. Gene expression analysis of qPCR validation done on LDA genes that showed significant 
difference in expression. HUVEC were isolated from the umbilical vein. Gene expression is plotted 
relative to MNCs. The comparison is made between HUVEC grown in normoxia to the HUVEC grown in 
hyperoxic conditions. The data were normalized to three housekeeping genes 18s RNA, TBP and 
HGPRT1. n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% O2 and HUVEC 40% O2). 
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6.2.7 Gene expression analysis of genes involved in regulating mitochondrial biogenesis 
and comparing ECFCs and HUVEC grown in normoxia and hyperoxia 
PGC-1 alpha belongs to a family of transcriptional coactivators that are involved in 
mitochondrial biogenesis, gluconeogenesis and angiogenesis. We therefore wanted to 
investigate what effect oxidative stress can have on the gene expression levels of PGC-1 
alpha and other related mitochondrial genes. Peroxisome proliferator receptor gamma 
(PPARG) is known to be activated by PGC-1 alpha in brown fat and cardiomyocytes where it 
promotes fatty acid oxidation, so we investigated the effect in endothelial cells. The cells 
were cultured till passage 5 (P5) in normal oxygen conditions (20% O2). Cells were frozen 
down and RNA extraction was performed. To compare the gene expression analysis these 
cells were also grown in conditions of oxidative stress. RNA was isolated from these cells 
and quantitative PCR analysis was carried out. The results as shown in figure 6.7 showed that 
there was a significant up regulation of PGC-1 alpha levels in ECFCs when grown in 
hyperoxia and the difference was found to be statistically significant. There was an increase 
in PPARG expression in ECFCs when exposed to oxidative stress and this could be due to 
PGC-1 alpha co activation. In HUVEC, PGC-1 alpha levels did not show any significant 
change in expression when grown in hyperoxia. It also shows interestingly that there was no 
significant change in expression of PPARG in HUVEC and this suggests that in ECFCs the 
up regulation of PPARG was due to co activation by PGC-1 alpha. This shows that these two 
cell types namely endothelial progenitor cells (ECFCs) and mature endothelial cells 
(HUVEC) respond and behave differently when exposed to oxidative stress. 
PROX -1gene encodes prospero homeobox protein 1. PROX 1 is a transcription factor which 
is involved in the development of various tissues (Wigle and Oliver, 1999; Sosa-Pineda et al., 
2000; Dyer et al., 2003). It plays an important role in the development of lymphatic 
endothelial cells and it has been shown before that prox-1 null embryos failed to form 
lymphatic vasculature and died in utero (Johnson et al., 2008). PROX-1 is known to regulate 
activity of nuclear receptors including estrogen related receptor (ERRα) and interact with 
PGC-1 α, influencing its transcriptional activity (Charest-Marcotte et al., 2010).  PROX 1 has 
also been shown to interact with hepatocyte nuclear factor 4α (HNFα) and human liver 
receptor homolog-1 (LHR-1) and reducing the transcription of the cholesterol 7-alpha-
hydroxylase gene, suggesting its role in fatty acid oxidation and gluconeogenesis in liver (Qin 
et al., 2004; Song et al., 2006). As shown in figure 6.7D, there was a down regulation of 
around 200 fold in the mRNA expression level of PROX1 when ECFCs were grown in 
hyperoxia and as it is known to interact with PGC-1 alpha it could be possible that activation 
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of PGC-1 alpha has led to this decrease in expression of PROX1. HUVEC did not show a 
significant decrease in expression of PROX1.  
PRDX5 is a protein which in humans is encoded by mitochondrial gene PRDX5. It belongs to 
peroxiredoxins family of antioxidant enzyme whose main function is to reduce hydrogen 
peroxide (Yamashita et al., 1999). It is known to play a protective antioxidative role in tissues 
during normal and also inflammatory conditions (Knoops et al., 1999). As shown in figure 
6.7C there was no statistically significant change in mRNA expression level of PRDX5 in 
either ECFCs or HUVEC when grown in hyperoxic conditions. 
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Figure 6.7. Gene expression analysis of genes involved in mitochondrial gene regulation and fatty acid and 
glucose metabolism. Endothelial colony forming cells (ECFCs) were derived from cord blood and mature 
endothelial cells (HUVEC) were derived from the umbilical cord of the same donor. Both ECFCs and HUVEC 
were grown in conditions of normoxia (20% O2) and hyperoxia (40% O2). Figure A and B shows an up regulation 
of PPARGC1A and PPARG genes in ECFCs when grown in hyperoxia and the difference was found to be 
statistically significant. Figure C and D shows down regulation of antioxidative gene PRDX5 in ECFCs although 
the difference was not statistically significant. The data were normalized to 18s rRNA, HPRT1 and TBP which 
were used as endogenous controls. Gene expression is plotted relative to cord blood mononuclear cells. 
Statistical analysis was carried out using two way ANOVA followed by Bonferroni posttests. All values are 
calculated as ± SEM. n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% and 40% O2). * P < .05, ** P < .01, ***P 
< .001 and ns stands for not significant.  
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6.2.8 Gene expression analysis of electron transport chain genes involved in oxidative 
phosphorylation (OXPHOS) and comparison between ECFCs and HUVEC grown in 
normoxia and hyperoxia 
We investigated one protein-coding gene from each of the steps involved in ETC of oxidative 
phosphorylation. MT-ND3 belongs to a group of genes that encode for NADH 
dehydrogenase enzyme complex also known as complex I which is the largest component of 
the mitochondrial respiratory chain. MT-CYB is a mitochondrially encoded gene that 
encodes  cytochrome b protein which forms part of coenzyme Q- cytochrome c reductase also 
known as complex III which is involved in biochemical production of ATP (oxidative 
phosphorylation). MT-CO1 also known as cytochrome c oxidase 1(COX1) encodes a protein 
that forms part of mitochondrial DNA (mtDNA) encoded enzyme subunit of respiratory 
complex IV which is the final enzyme of the ETC of oxidative phosphorylation. MT-ATP8 
encodes a protein that forms a subunit of enzyme mitochondrial ATP synthase and important 
enzyme required for ATP generation. We cultured the cells till passage 5 (P5) under normal 
oxygen conditions (20% O2). Cells were frozen down and RNA extraction was carried out. 
The cells were grown in hyperoxia till passage 3 (P3) and RNA was isolated from them. 
RNA extraction was followed by quantitative PCR. The results as shown in figure 6.8 
indicate that as a result of exposure to oxidative stress there was an increase in gene 
expression level of the genes involved in ETC of oxidative phosphorylation in ECFCs when 
grown in hyperoxia and the difference was found to be statistically significant. The 
expression level of ETC genes in mature endothelial cells (HUVEC) either remained same or 
there was a down regulation, although the difference was not found to be statistically 
significant. This suggests that endothelial progenitor cells and mature endothelial cell behave 
differently when exposed to oxidative stress. 
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Figure 6.8. Gene expression analysis of human mitochondrial genes which are part of the electron transport 
chain and are involved in oxidative phosphorylation. Endothelial colony forming cells (ECFCs) were derived 
from cord blood and mature endothelial cells (HUVEC) were derived from the umbilical cord of the same 
donor. Both ECFC and HUVEC were grown in conditions of normoxia (20% O2) and hyperoxia (40% O2). Figure 
shows an up regulation of the mitochondrial genes in ECFCs grown in hyperoxia, and the difference was found 
to be statistically significant. HUVEC showed down regulation of these genes under hyperoxic conditions 
although the difference was not found to be statistically significant. The data were normalized to 18s rRNA, 
HPRT1 and TBP which were used as endogenous controls. Gene expression is plotted relative to cord blood 
mononuclear cells. Statistical analysis was carried out using two way ANOVA followed by Bonferroni posttests. 
All values are calculated as ± SEM. n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% and 40% O2). * P < .05, 
**P < .01, ***P < .001 and ns stands for not significant. 
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6.2.9 Gene expression analysis of mitochondrial genes involved in antioxidative 
mechanisms and oxidative metabolism and comparing ECFCs and HUVEC grown in 
normoxia and hyperoxia 
Phospheonolpyruvate carboxykinase also known as PEPCK or PCK2 is a human 
mitochondrial gene that encodes a protein that acts as an enzyme involved in a rate limiting 
step in gluconeogenesis. PEPCK gene transcription is induced by glucagon, retinoic acid and 
cAMP and is down regulated by insulin (O'Brien et al., 1990). 
SIRT 4 is a mitochondrial gene which encodes a member of sirtuins family of proteins that 
function as intracellular regulatory proteins and belong to a group of nicotinamide adenine 
dinucleotide (NAD) - dependent enzymes which are involved in stress responses, longevity 
and metabolism. SIRT4 is known to be involved in regulation of mitochondrial gene 
expression and fatty acid oxidation in muscle and liver cells (Nasrin et al., 2010). It has been 
shown that SIRT4 inhibits mitochondrial glutamate dehydrogenase activity resulting in a 
decrease in insulin secretion (Haigis et al., 2006). It has been shown recently that mTORc1 
pathway is involved in regulation of amino acid glutamine metabolism and it does that by 
repressing SIRT4 transcription resulting in an increase in glutamine metabolism (Csibi et al., 
2013). Both PCK2 and SIRT4 mRNA expression did not show any statistically significant 
difference in ECFCs grown in normoxia and hyperoxia. As shown in figures 6.9A and C, 
there was an increase in gene expression level of mitochondrial genes PCK2 and SIRT 4 in 
HUVEC grown in hyperoxia, and the difference was found to be statistically significant. This 
suggests that oxidative stress lead to an increase in fatty acid oxidation in mature endothelial 
cells.  
Pyruvate dehydrogenase lipoamide kinase isozyme 4 is a mitochondrial enzyme, which in 
humans is encoded by PDK4 gene. PDK4 has been shown to contribute towards regulation of 
glucose metabolism by inhibiting pyruvate dehydrogenase complex. The gene is induced by 
retinoic acid, insulin and glucocorticoids and is activated in response to fasting in muscle and 
liver (Wu et al., 1999; Pilegaard et al., 2000; Hildebrandt et al., 2003). It has been shown that 
PGC-1 α regulates the expression of PDK4 by coactivation of ERR α and PPARα and also 
directly induces PDK4 gene expression in skeletal muscle (Wu et al., 2001; Wende et al., 
2005). This leads to increased mitochondrial fatty acid oxidation and a simultaneous decrease 
in glucose oxidation. As shown in figure 6.9D there was a 4 fold increase in mRNA 
expression level of PDK4 in HUVEC grown in hyperoxia suggesting that it could be due to 
PGC-1 alpha activation and hyperoxia leads to increased mitochondrial fatty acid oxidation. 
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Glutathione peroxidase 4, also known as GPx4 is an enzyme which is encoded by GPX4 gene 
in humans. It is a phospholipid peroxidase and protects cells against lipid peroxidation. It 
protects the cells against oxidative stress by catalyzing the reduction of hydrogen peroxide at 
the expense of glutathione and is essential for embryonic development (Yant et al., 2003; 
Muller et al., 2007). As shown in figure 6.9B, there was a 10 fold decrease in the expression 
of GPX4 in ECFCs grown in hyperoxia and the difference was found to be statistically 
significant. 
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Figure 6.9. Gene expression analysis of human mitochondrial genes which are part of fatty acid and glucose 
metabolism and antioxidative mechanism. Endothelial colony forming cells (ECFCs) were derived from cord 
blood and mature endothelial cells (HUVEC) were derived from the umbilical cord of the same donor. Both 
ECFC and HUVEC are grown in conditions of normoxia (20% O2) and hyperoxia (40% O2). Figure shows an up 
regulation of the mitochondrial genes in ECFCs grown in hyperoxia, and the difference was found to be 
statistically significant. HUVEC showed down regulation of these genes under hyperoxic conditions although 
the difference was not found to be statistically significant. The data were normalized to 18s rRNA, HPRT1 and 
TBP which were used as endogenous controls. Gene expression is plotted relative to cord blood mononuclear 
cells. Statistical analysis was carried out using two way ANOVA followed by Bonferroni posttests. All values are 
calculated as ± SEM. n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% and 40% O2). * P < .05, **P < .01, ***P 
< .001 and ns stands for not significant. 
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6.2.10 Gene expression analysis of cell surface endothelial markers involved in 
angiogenesis and comparison between changes in expression in ECFCs and HUVEC grown 
in normoxia and hyperoxia 
Von willibrand factor (vWF) is a plasma glycoprotein encoded by vWF gene which is  
involved in adhesion of platelets and plays an important role in maintaining haemostasis 
(Cheresh, 1987). It acts as a carrier for coagulation factor VIII and its deficiency can lead to 
von Willibrand disease, which is a common congenital bleeding disorder  (Huang et al., 
2009). Endothelial vWF has been shown to regulate inflammation via an  independent 
mechanisms including leukocyte adhesion and increased levels of vWF are implicated in 
acute coronary thrombosis and is considered to be a clinical marker of atherosclerotic 
progression (Spiel et al., 2008). As shown in figure 6.10, there was no significant change in 
expression of vWF in ECFCs when grown in normoxia and hyperoxia. Whereas, there was a  
significant increase in expression of vWF in HUVEC and this suggests that oxidative stress 
lead to an increase in this expression and this  can resemble an inflammatory and pro 
atherosclerotic environment.    
VE-Cadherin is a type of cadherin also known as CD144, and encoded in humans by CDH5 
gene. It has been shown to be involved in the maintenance of newly formed blood vessels and 
is essential for endothelial permeability. CD144 deficiency has shown to induce haemorrhage 
in vivo and increased monolayer permeability in an in vitro culture system (Carmeliet et al., 
1999; Corada et al., 2002; Crosby et al., 2005). As shown in figure 6.10, there was several 
thousand fold decrease in the expression of CDH5 in ECFCs grown in hyperoxia suggesting 
it is playing its role in angiogenesis. HUVEC did not show any significant change in 
expression of CDH5, although it showed an up regulation. 
Platelet cell adhesion molecule 1(PECAM-1) also called CD31 is a protein which in humans 
is encoded by PECAM-1gene. It is involved in removing aged neutrophils, leukocyte 
migration and angiogenesis (Newman et al., 1990; Gumina et al., 1996; Xie and Muller, 
1996). CD31 is mainly expressed in endothelial cells and forms part of intercellular junctions. 
It has shown the expression in several vascular tumours. As shown in figure 6.10 there was a 
statistically significant difference in the expression of CD31 in ECFCs grown in hyperoxia 
and showed more than 5 fold change in mRNA expression level. HUVEC showed an increase 
in expression but the difference was not found to be statistically significant. 
PROM1 is a glycoprotein also known as CD133 or AC133. It is mainly expressed in 
hematopoietic stem cells, early endothelial progenitor cells and glial stem cells (Horn et al., 
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1999; Corbeil et al., 2000; Sanai et al., 2005). As shown in figure 6.10 there was an increase 
in expression of PROM1 in HUVEC grown in hyperoxia. ECFCs did not show a significant 
change in expression. 
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Figure 6.10. Gene expression analysis of endothelial cell surface markers. Endothelial colony forming cells 
(ECFCs) were derived from cord blood and mature endothelial cells (HUVEC) were derived from the umbilical 
cord of the same donor. Both ECFCs and HUVEC were grown in conditions of normoxia (20% O2) and hyperoxia 
(40% O2). Figure shows down regulation of endothelial markers PECAM 1 and CDH5 (VE-cadherin) in ECFCs 
grown in hyperoxia, and the difference was found to be statistically significant. HUVEC showed an increase in 
expression of endothelial marker vWF and an up regulation of PROM 1.  The data were normalized to 18s 
rRNA, HPRT1 and TBP which were used as endogenous controls. Gene expression is plotted relative to cord 
blood mononuclear cells. Statistical analysis was carried out using two way ANOVA followed by Bonferroni 
posttests. All values are calculated as ± SEM. n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% and 40% O2). * 
P < .05, ** P < .01, ***P < .001 and ns stands for not significant. 
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6.2.11 Gene expression analysis of angiogenic factors involved in promoting angiogenesis 
and comparison between changes in expression in ECFCs and HUVEC grown in normoxia 
and hyperoxia 
VEGFA gene encodes the protein vascular endothelial growth factor A in humans. The gene 
is a member of PDGF/VEGF family and has been studied in detail in vascular endothelium. 
VEGFA has been known to play many important functions in angiogenesis involving 
migration and mitosis of endothelial cells and creation of blood vessel lumen (Creuzet et al., 
2002; Stockmann et al., 2008; Mackenzie and Ruhrberg, 2012). As shown in figure 6.11 
there was more than 2 fold increase in mRNA level of expression of VEGFA in ECFCs that 
were cultured in hyperoxic conditions. This shows that ECFCs promote angiogenesis when 
they are exposed to oxidative stress. HUVEC showed no significant change in expression of 
VEGFA when grown in hyperoxia.   
VEGF C encodes vascular endothelial growth factor C in humans. VEGFC belongs to the 
PDGF/VEGF family of proteins and is involved in several important functions including 
angiogenesis, endothelial growth, blood vessel permeability and lymphangiogenesis 
(Paavonen et al., 1996; Schoppmann et al., 2002).  As shown in figure 6.11 there was several 
thousand fold increase in the expression of VEGFC in ECFCs grown in hyperoxia as 
compared to cells grown in normoxia. HUVEC showed a decrease in expression and the 
difference was found to be statistically significant. This suggests that HUVEC do not take 
part in angiogenesis when they are exposed to hyperoxia. 
Vascular endothelial growth factor (VEGF) is a key signaling protein which is involved in 
both vasculogenesis and angiogenesis. There are three main types of receptors to which 
VEGF binds which are all tyrosine kinase receptors. Two main receptors include VEGFR1 
also known as FLT-1 and VEGFR2 which is also known as FLK-1 or KDR (Holmes et al., 
2007; Stuttfeld and Ballmer-Hofer, 2009). VEGFA binds to both FLT-1 and KDR receptors 
but mainly KDR receptor mediates the cellular responses (Fujita et al., 2008). VEGFC binds 
mainly to KDR. As shown in figure 6.11 both FLT-1 and KDR showed several fold decrease 
in expression when ECFCs were exposed to oxidative stress. This could be due to receptor 
filling as both VEGFA and C showed higher expression in ECFCs grown in hyperoxia.  
HUVEC did not show any significant change in mRNA level of expression of any of these 
receptors again suggesting that these cells do not take part in angiogenesis as opposed to 
ECFCs which show up regulation of angiogenic genes when grown in hyperoxic conditions. 
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Figure 6.11. Gene expression analysis of angiogenic growth factors and angiogenesis inhibitor FLT1. 
Endothelial colony forming cells (ECFCs) were derived from cord blood and mature endothelial cells (HUVEC) 
were derived from the umbilical cord of the same donor. Both ECFC and HUVEC were grown in conditions of 
normoxia (20% O2) and hyperoxia (40% O2). Figure A and B showing an increase in expression of angiogenic 
growth factors VEGF A and C in ECFCs when exposed to hyperoxia and HUVEC showed no significant difference 
in gene expression. Figure C and D showing down regulation of angiogenic inhibitor FLT1 gene in ECFCs in 
hyperoxia, and the difference was found to be statistically significant. There was no significant difference seen 
in HUVEC for VEGF A expression, but VEGF C expression decreased under hyperoxia and the difference was 
found to be statistically significant. The data were normalized to 18s rRNA, HPRT1 and TBP which were used as 
endogenous controls. Gene expression is plotted relative to cord blood mononuclear cells. Statistical analysis 
was carried out using two way ANOVA followed by Bonferroni posttests. All values are calculated as ± SEM. 
n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% and 40% O2). * P < .05, ** P < .01, ***P < .001 and ns stands 
for not significant. 
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6.2.12 Gene expression analysis of pro-angiogenic factors and angiogenic targets 
involved in angiogenesis and comparison between changes in expression in ECFCs and 
HUVEC grown in normoxia and hyperoxia 
As shown in figure 6.12, we investigated the genes that we thought would be involved in an 
inflammatory response. This included as shown in figure 6.12 A, a cytokine belonging to 
chemokine family, CXCL12 also known as stromal cell-derived factor-1(SDF-1). This gene 
is involved in hematopoietic stem cell migration and blood vessel formation during early 
embryogenesis. It has recently been shown to be involved in EPC recruitment from bone 
marrow via CXCR4 which is its binding receptor, thus contributing towards blood vessel 
formation (Zheng et al., 2007). CXCL12 gene has been shown to be a pro-inflammatory 
genetic marker associated with atherosclerosis and encodes a chemokine which is involved in 
vascular repair (Linsel-Nitschke et al., 2010; Mehta et al., 2011). The results showed that 
ECFCs when exposed to hyperoxia show an up regulation of CXCL12 gene suggesting that 
these cells are responding to this stress environment and could be the cells involved in vessel 
repair. The difference between ECFCs grown in normoxia and hyperoxia was found to be 
statistically significant. As shown in figure 6.12 A, the mature endothelial cells HUVEC did 
not show any significant change in CXCL12 gene expression.  
Fibroblast growth factor 2 (FGF2) is a potent angiogenic growth factor involved in blood 
vessel formation, which is dependent on heparin sulphate (HS) (Ferreras et al., 2012). HS 
degrading enzymes activate FGF2 during wound healing and tumorigenesis. As shown in 
figure 6.12 B, ECFCs grown in hyperoxia show a 200 fold increase in gene expression of 
FGF2. This suggests that these cells are responding to oxidative stress and promoting 
angiogenesis. The difference was found to be statistically significant. Mature endothelial cells 
(HUVEC) did not show any significant change in expression of FGF2, when grown in 
hyperoxia. 
PDGFRA gene encodes a protein in humans which is known as alpha platelet derived growth 
factor receptor (PDGFRA). It encodes cell surface tyrosine kinase receptors for PDGF family 
of proteins. It has shown interactions with PDGFRB and both of them have been involved in 
growth and maturation being mitogens for cells of mesenchymal origin (Seifert et al., 1989; 
Rupp et al., 1994). As shown in figure 6.12 both genes showed more than 5 fold increase in 
mRNA expression level in ECFCs grown in hyperoxia. This suggests that hyperoxia 
environment provided an atherosclerotic and proinflammatory condition and ECFCs respond 
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by up regulation of angiogenic markers. HUVEC did not show any significant change in 
expression of either of these genes.  
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Figure 6.12. Gene expression analysis of angiogenesis target genes. Endothelial colony forming cells (ECFCs) 
were derived from cord blood and mature endothelial cells (HUVEC) were derived from the umbilical cord of 
the same donor. Both ECFC and HUVEC were grown in conditions of normoxia (20% O2) and hyperoxia (40% 
O2). Figure shows an up regulation of these genes in ECFCs in hyperoxia, and the difference was found to be 
statistically significant. The data were normalized to 18s rRNA, HPRT1 and TBP which were used as 
endogenous controls. Gene expression is plotted relative to cord blood mononuclear cells. Statistical analysis 
was carried out using two way ANOVA followed by Bonferroni posttests. All values are calculated as ± SEM. 
n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% and 40% O2). * P < .05, ** P < .01, ***P < .001 and ns stands 
for not significant. 
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6.2.13 Gene expression analysis of angiogenic factors involved in promoting angiogenesis 
and comparison between changes in expression in ECFCs and HUVEC grown in normoxia 
and hyperoxia. 
Endothelial nitric oxide (eNOS) is the main source of NO, which plays an important role in 
maintaining vasodilation and vasoconstriction by regulating smooth muscle cells activation 
(Ignarro et al., 1987). More importantly, NO is a competitive inhibitor of electron transport 
chain at complex IV (Moncada and Erusalimsky, 2002), thus altering the rate of oxidative 
metabolism in both cardiomyocytes and endothelial cells (Clementi et al., 1999), which is 
suggested to be inversely related to oxygen levels. As shown in figure 6.13 there was a 20 
fold down regulation in mRNA expression level of NOS3 when ECFCs were exposed to 
hyperoxic conditions and suggests that this is ECFCs response to oxidative stress.  
Alpha -actin-2 which also known as alpha smooth muscle actin is a protein that in humans is 
encoded by ACTA2 gene. It is considered to be a highly conserved protein and is involved in 
cell motility, integrity and shaping of cell structure. It forms the bulk of cells contractile 
machinery and has also been used as a marker of myoblast formation and known to be 
activated by p53 (Tomasselli et al., 1991; Comer et al., 1998). As shown in figure 6.13 there 
was a 40 fold increase in expression of ACTA 2 in ECFCs exposed to oxidative stress 
suggesting this environment promotes angiogenesis in ECFCs. HUVEC showed no 
significant change in expression of ACTA2.  
Angiopoeitin1is a protein that is encoded by ANGPT1 gene in humans. It is an important 
growth factor that plays a vital role in promoting angiogenesis and vascular development. It 
binds to and interacts with endothelial specific TEK tyrosine kinase receptor and is known to 
be involved in maintaining blood vessel maturity and stability (Maisonpierre et al., 1997). 
 ANGPT2 is a gene which encodes angiopoeitin 2 proteins in humans. It mainly acts as an 
antagonist to ANG1 and TEK tyrosine kinase and is mainly expressed at vascular 
remodelling sites (Maisonpierre et al., 1997; Cheung et al., 1998; Sato et al., 1998; Fiedler et 
al., 2003). As shown in figure 6.13 ANG1 mRNA expression level was increased 40 fold and 
as ANG2 acts as an antagonist to ANG1, its level of expression was found to be several 
thousand fold decreased in ECFCs that were exposed to oxidative stress. This shows that 
during hyperoxia angiogenesis is activated and ECFCs take part in this vascular repair. 
HUVEC did not show a significant change in expression of these angiogenic genes. 
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Figure 6.13. Gene expression analysis of pro angiogenic target genes and genes involved in regulation of 
blood vessel formation. Endothelial colony forming cells (ECFCs) were derived from cord blood and mature 
endothelial cells (HUVEC) were derived from the umbilical cord of the same donor. Both ECFC and HUVEC were 
grown in conditions of normoxia (20% O2) and hyperoxia (40% O2). Figure shows an up regulation of these 
proangiogenic genes in ECFCs grown in hyperoxia, and the difference was found to be statistically significant. 
Figure shows reduced expression of ANGPT2 and endothelial NO (eNOS) in ECFCs grown in hyperoxia and the 
difference was found to be statistically significant. HUVEC did not show any statistically significant change in 
expression of these angiogenic markers. The data were normalized to 18s rRNA, HPRT1 and TBP which were 
used as endogenous controls. Gene expression is plotted relative to cord blood mononuclear cells. Statistical 
analysis was carried out using two way ANOVA followed by Bonferroni posttests. All values are calculated as ± 
SEM. n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% and 40% O2). * P < .05, ** P< .01, ***P < .001 and ns 
stands for not significant. 
 171 
 
6.2.14 Gene expression analysis of angiogenic and anti angiogenic factors involved in 
regulating angiogenesis and comparison between changes in expression in ECFCs and 
HUVEC grown in normoxia and hyperoxia 
Transforming growth factor alpha (TGF-α) is a marker that has been found to be up regulated 
in several cancers and is mainly produced by macrophages and keratinocytes and known to 
take part in the development of epithelium. It has shown to be involved in neural cell 
development in cases of adult brain injury (Fallon et al., 2000). ECFCs showed the 
expression of TGF- α and the expression level decreased when cells were grown in 
hyperoxia, but the difference was not statistically significant as shown in figure 6.14. 
HUVEC on the other hand, showed statistically significant increase in the expression of TGF- 
α when grown in conditions of oxidative stress.  
TEK tyrosine kinase also known as angiopoeitin 1-receptor is a protein which in humans is 
encoded by TEK gene. It is exclusively expressed in endothelial cells and is known to interact 
with both ANG1 and ANG2 (Davis et al., 1996; Sato et al., 1998; Fiedler et al., 2003). As 
shown in figure 6.14 TEK levels did not show a significant change in expression of either 
ECFCs or HUVEC when these cells were exposed to oxidative stress.  
TP53 is a tumor suppressor protein in humans and is encoded by TP53 gene (Isobe et al., 
1986; Kern et al., 1991). It has been known to play key anticancer roles and is involved in 
apoptosis and inhibition of angiogenesis (Teodoro et al., 2006; Assadian et al., 2012). It is 
known to be activated by oxidative stress and DNA damage. As shown in figure 6.14 there 
was a down regulation of the mRNA expression level of the gene in ECFCs grown in 
hyperoxia, as these cells promote angiogenesis when exposed to oxidative stress. HUVEC 
showed a statistically significant increase in the expression of TP53. This again suggests that 
HUVEC do not take part in vascular repair when exposed to oxidative stress. 
NRP2 is a gene which in humans encode for neuropilin-2 protein. It plays a role in 
cardiovascular development and is known to interact with VEGF (Chen et al., 1997; Soker et 
al., 1998). As shown in figure 6.14 there was a decrease in expression of NRP2 in ECFCs 
grown in hyperoxia, but the difference was not found to be significant. HUVEC also did not 
show any significant change in expression of the gene.  
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Figure 6.14. Gene expression analysis of angiogenic growth factors and target genes. Endothelial colony 
forming cells (ECFCs) were derived from cord blood and mature endothelial cells (HUVEC) were derived from 
the umbilical cord of the same donor. Both ECFC and HUVEC were grown in conditions of normoxia (20% O2) 
and hyperoxia (40% O2). Figure shows reduced expression of these proangiogenic genes in ECFCs grown in 
hyperoxia, but the difference was not found to be statistically significant. HUVEC showed an up regulation of 
some of these angiogenic growth factors and the difference was found to be statistically significant. The data 
were normalized to 18s rRNA, HPRT1 and TBP which were used as endogenous controls. Gene expression is 
plotted relative to cord blood mononuclear cells. Statistical analysis was carried out using two way ANOVA 
followed by Bonferroni posttests. All values are calculated as ± SEM. n=4 (ECFC 20% and 40% O2) and n=5 
(HUVEC 20% and 40% O2). * P < .05, ** P< .01, ***P < .001 and ns stands for not significant. 
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6.2.15 Gene expression analysis of factors involved in proinflammatory response for 
angiogenesis and comparison between changes in expression in ECFCs and HUVEC grown 
in normoxia and hyperoxia 
Interleukin -1alpha (IL-1α) is an inflammatory cytokine that in humans is encoded by IL1A 
gene. It is known to play a central role in the regulation of immune response and is produced 
mainly by macrophages and endothelial cells (March et al., 1985). It binds to interleukin-1 
receptor and has shown to activate tumor necrosis factor (TNF- α) in endothelial cells 
(Bankers-Fulbright et al., 1996; Hu et al., 2003). As shown in figure 6.15 HUVEC showed a 
20 fold increase in mRNA level expression of IL1A and shows that exposing cells to 
hyperoxia can activate pro inflammatory markers. ECFCs showed a decrease in expression 
that was found to be statistically significant.  
c-kit or Stem cell factor receptor (SCFR) also known as CD117 is a protein which in humans 
is encoded by KIT gene (Andre et al., 1997). It is a proto-oncogene mainly expressed in 
hematopoietic stem cells and myeloid progenitors and bind to stem cell factor playing a role 
in cell survival and proliferation (Anzai et al., 2002). There was a 20 fold decrease in 
expression of KIT in ECFCs grown in hyperoxic conditions as shown in figure 6.15. HUVEC 
showed no significant change in expression. 
ABCG2 is a gene that in human encodes the protein ATP- binding cassette subfamily G 
receptor 2 also known as ABCG2 (CD338). This protein belongs to a family of ATP- binding 
cassette (ABC) transporters, which are mainly involved in transport of substances across cell 
membranes by using energy derive from ATP hydrolysis. ABCG2 has been shown to be a 
marker of progenitor cells and unique amongst this family of transporters to have this 
expression pattern. It also shows expression (mRNA and protein) in cancer stem cells, 
epithelial cells, placenta, blood brain barrier and many other organs including liver, lung and 
brain (Gutmann et al., 2005; Visvader and Lindeman, 2008). This gene has been shown to be 
suppressed during DNA methylation (Turner et al., 2006). As shown in figure 6.15 ECFCs 
when cultured in hyperoxic conditions showed more than 5 fold decrease in expression of the 
gene suggesting that oxidative stress induced this change in expression. 
The ITPKB gene in humans encodes the protein inositol –triphosphate 3-kinase B which is an 
enzyme that regulates inositol metabolism by phosphorylation and mediates cell signaling 
(Erneux et al., 1992). The gene is involved in immune cell function and promotes T and B 
cell maturation (Sauer and Cooke, 2010). As shown in figure 6.15 there was statistically 
 174 
 
significant difference in mRNA level expression of ITPKB gene in ECFCs. HUVEC showed 
no significant change in expression of the gene.   
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Figure 6.15. Gene expression analysis of proinflammatory and immunoregulatory markers and angiogenesis 
target genes. Endothelial colony forming cells (ECFCs) were derived from cord blood and mature endothelial 
cells (HUVEC) were derived from the umbilical cord of the same donor. Both ECFC and HUVEC were grown in 
conditions of normoxia (20% O2) and hyperoxia (40% O2). Figure shows down regulation of these 
proangiogenic genes in ECFCs grown in hyperoxia, and the difference was found to be statistically significant. 
HUVEC did not show any statistically significant change in expression of these markers. The data were 
normalized to 18s rRNA, HPRT1 and TBP which were used as endogenous controls. Gene expression is plotted 
relative to cord blood mononuclear cells. Statistical analysis was carried out using two way ANOVA followed by 
Bonferroni posttests. All values are calculated as ± SEM. n=4 (ECFC 20% and 40% O2) and n=5 (HUVEC 20% and 
40% O2). * P < .05, ** P< .01, ***P < .001 and ns stands for not significant. 
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6.3. Discussion 
We carried out gene expression analysis of mitochondrial, antioxidative, proangiogenic and 
proinflammatory genes and those involved in DNA damage due to oxidative stress. In order 
to understand the role of PGC-1 alpha in ECFCs and HUVEC we also analysed several 
downstream targets of PGC-1 alpha so that we could study the pathways PGC-1 alpha 
monitors when cells are grown in conditions of oxidative stress. We proposed that exposing 
cells to 40 % O2 would lead to oxidative stress, and endothelial damage will lead to an 
atherosclerotic and inflammatory environment in an in vitro system. Inflammation refers to a 
series of complex but well conserved processes that forms part of an organism‟s response to a 
harmful stimulus, including cell damage and irritants and leads to repair mechanisms 
following this tissue injury.  It has been shown recently that there exists an interplay between 
oxidative stress and inflammation which results in the initiation and progression of 
cardiovascular diseases and this combination of oxidative stress and inflammation leads to 
mobilization of EPCs (Stenvinkel et al., 2003; Haubitz and Woywodt, 2004).  
Endothelial cells mainly derive their energy from anaerobic glycolysis and it has been shown 
that more than 70 % of ATP synthesis occurs via glycolysis in porcine aortic endothelial cells 
(Spahr et al., 1989; Culic et al., 1997; Quintero et al., 2006). Endothelial mitochondria are 
thought to be involved in regulating interplay between ROS, NO and calcium ions. This is 
suggested to be important in maintaining endothelial function, and a disruption to endothelial 
mitochondria can progress towards endothelial dysfunction leading to atherosclerosis. 
An important endothelial marker Von Willibrand factor (vWF) was investigated in order to 
differentiate between endothelial progenitors and mature endothelial cells. vWF has recently 
been shown to play a regulatory role in angiogenesis in endothelial cells (Starke et al., 2011). 
Angiogenic factors mainly, Angiopoeitins (Ang) and vascular endothelial growth factor 
(VEGF) mediate cell signaling pathways involved in endothelial cell proliferation and 
migration leading to blood vessel formation. VEGF- A is known to be a key player involved 
in angiogenesis (Grothey and Galanis, 2009) and acts mainly on Kinase insert domain 
receptor (KDR) also known as the VEGFR-2 (CD309/FLK1), which is a type 3 tyrosine 
kinase receptor (Petrova et al., 1999). This leads to endothelial cell proliferation, migration 
and early angiogenic sprouting (Gerhardt, 2008). Vascular endothelial growth factor C also 
known as VEGF- C has been known to be involved in endothelial cell proliferation and 
angiogenesis (Meyer et al., 1999). It is also involved in lymphangiogenesis and mediates its 
signaling through both VEGFR-2 (KDR) and VEGFR-3 (FLT4) receptors (Joukov et al., 
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1996; Dias et al., 2002). Angiopoeitins play an important role in advanced stages of blood 
vessel formation. ANG-1 and ANG-2 binding to endothelial TEK receptor (Tie2) maintain 
vascular maturity and intact endothelium (Thomas and Augustin, 2009). It was initially 
considered that ANG-1 and ANG-2 act as antagonists. ANG-1 playing a role in vessel wall 
maturation and promoting endothelial cell migration and adhesion and ANG-2 breaking the 
links between perivascular cells and endothelium and leading to vascular regression and 
permeability (Suri et al., 1996; Lobov et al., 2002).  
Endothelial cells mediate ROS production in the form of superoxide and hydrogen peroxide 
which acting as messengers lead to a growth factor -dependent response promoting 
angiogenesis (Case et al., 2008). NADPH oxidase is considered to be the most important 
source of ROS in vasculature (Griendling et al., 2000; Lassègue et al., 2012). NADPH 
oxidase (NOX) derived ROS has been shown to be implicated in several cardiovascular 
diseases and increased ROS levels have been found in both human and animal models (Lacy 
et al., 2000; Touyz and Schiffrin, 2001; Álvarez et al., 2008; Brandes et al., 2010; Lassègue 
and Griendling, 2010). 
Reactive oxygen species (ROS) are substances produced as a result of cellular metabolism, 
and are chemically active molecules that contain oxygen. ROS produced at normal levels, as 
a byproduct of oxygen metabolism are involved in maintaining homeostasis and cell 
signaling mechanisms (Dickinson and Chang, 2011). An increase in ROS production can lead 
to significant cell damage causing oxidative stress (Mancardi et al., 2004). In order to 
counteract this ROS damage, cells defend themselves by activating certain enzymatic and 
nonenzymatic pathways leading to up regulation of anti-ROS genes (Lomri, 2008). The 
effects of oxidative stress on endothelial progenitor cells are well known and it has been 
shown that oxidative stress affects EPC activity and mobilization. ROS has been shown to 
directly damage the vascular endothelium, suggesting that it plays a role in the progression of 
atherosclerosis (Griendling and FitzGerald, 2003b; Torsney et al., 2005; Tigges et al., 2013).  
Reduced EPC levels and impaired EPC function have been implicated with increased 
superoxide production (Thum et al., 2007; Qiao et al., 2010). It has been shown that 
oxidative stress leads to increased ROS production which in turn causes Nitric oxide (eNOS) 
inactivation and DNA damage resulting in altered redox state (Laufs et al., 2004; Fike et al., 
2013). EPC migration is an essential step during angiogenesis following vascular injury or 
endothelial dysfunction. Cell migration occurs in response to chemotactic stimuli, and there is 
strong evidence to show that proangiogenic factors including VEGF and Angiopoeitin- 1are 
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involved in directing cell migration in response to ROS production (Yamaoka-Tojo et al., 
2004; Chen et al., 2006a; Kim et al., 2006; Xia et al., 2007). 
Nitric oxide is considered to be an important regulator of mitochondrial dynamics and also 
promoter of oxidant production, although its effects are dependent upon the availability of 
oxygen and associated redox cellular state (Erusalimsky and Moncada, 2007). NO is known 
to be an inhibitor of cytochrome c oxidase (complex IV) of the electron transport chain and 
competes at oxygen binding site and results in reduction of mitochondrial respiration leading 
to an increase in ROS signaling (Dranka et al., 2010; Widlansky and Gutterman, 2011). In 
conditions of oxidative stress NO inhibits complex I that further blocks mitochondrial ROS 
production (MacMillan-Crow et al., 1998). Acute inflammatory response leads to an increase 
in NO levels that shows that the capacity of endothelial cells to respond to cellular stress has 
diminished. It is therefore proposed that conditions that reduce endothelial nitric oxide 
(eNOS) bioavailability can promote mitochondrial ROS production (Doughan et al., 2008). 
This reduction in availability of endothelial NO results in the formation of peroxynitrite that 
affects complex I and III in such a way that it promotes ROS production and also inhibits 
antioxidants like MnSOD causing further mitochondrial damage (Wang et al., 2012).  
Mitochondrial ROS production and understanding the mechanisms regulating their activity 
has gained immense importance recently, as they play an important role in cell signaling and 
pathogenesis of vascular diseases (Sena and Chandel, 2012). As has been shown before the 
bulk of oxygen consumption occurs at complex IV (cytochrome c oxidase) of the electron 
transport chain and complex I and III contribute to less than 2% of the total consumption, 
although these analysis are based on studies in isolated mitochondria and an in vivo analysis 
of ROS production in endothelial cell still remains to be seen (Chance et al., 1979; Murphy, 
2009; Widlansky and Gutterman, 2011). In addition to that there are several other 
mitochondrial ROS sources that have been identified in endothelial cells and include 
nicotinamide adenine dinucleotide phosphate oxidase (NOX4) which shows high expression 
in endothelial cells, but mitochondrial localization is still uncertain whereas in most other 
tissues it is mainly present in mitochondria (Chen et al., 2012). NOX4 serves as an important 
regulator of ROS signaling mechanisms in endothelial cells and has been shown to play a 
vital role in contributing towards endothelial cell senescence, angiogenesis and migration and 
combating inflammatory response as a result of oxidative stress and hypoxia (Lassègue et al., 
2012).  
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An important indicator of increased mitochondrial ROS production is an altered 
mitochondrial membrane potential. It has been shown that a decrease in membrane 
depolarization can increase the activity of complexes I and III of the ETC leading to an 
increase in ROS production (Freed and Gutterman, 2013). Mitochondrial membrane 
hyperpolarization can also lead to an increase in ROS mainly in metabolic states where there 
is nutrient excess and no more ATP synthesis is required. This causes an increase in 
NADH/NAD+ ratio resulting in a decrease in electron flow leading to accumulation of 
reactive metabolites at complexes I and III of the electron transport chain causing reduction 
of oxygen and superoxide ions. Several metabolic disorders including diabetes mellitus and 
obesity that are characterized by increased glucose and fatty acid levels have been shown to 
use this mechanism resulting in increased production of mitochondrial ROS (Brownlee, 
2001).  
As shown before, availability of excess nutrients in cardiac myocytes results in alteration of 
mitochondrial metabolism and can lead to heart failure, but in endothelial cells where energy 
demands are not as higher this excess nutrient supply provides  a signal that increases 
mitochondrial ROS production that leads to a change in phenotype of endothelial cells 
(Lopaschuk et al., 2010; Algahim et al., 2012). Endothelial cells when exposed to high 
glucose or fatty acid levels leads to a decrease in eNOS activity, resulting in activation of 
transcription factor NFκB and protein kinase c (Nishikawa et al., 2000; Brownlee, 2001). 
This up regulation requires counteractive mechanisms which includes over expression of 
uncoupling protein (UCP1), mitochondrial membrane depolarization and inhibition of 
electron transport chain which bring membrane potential to lower limits (Nishikawa et al., 
2000).  
Vascular diseases are characterized in most cases by ROS- induced damage to mitochondrial 
membrane and mtDNA, lipid and proteins which further alleviate ROS damage (Algahim et 
al., 2012; Hill et al., 2012). Mitochondrial DNA (mtDNA) damage in particular has long 
term consequences as it causes either a decrease in the expression of ETC components or 
results in the production of defective components generating more ROS (Ballinger et al., 
2000). It is interesting to note that all the important risk factors that eventually progress 
towards cardiovascular diseases including smoking, hypertension, hyperglycaemia and 
hypercholesterolemia are associated with mitochondrial DNA damage (Knight-Lozano et al., 
2002). More importantly, it has been shown in several studies both in mice an in human 
tissues that the severity of atherosclerosis is directly proportional to the associated mtDNA 
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damage (Ballinger et al., 2002). A recent study has shown that glycation of mitochondrial 
proteins can increase ROS production in diabetic patients (Pun and Murphy, 2012).  
Mitochondrial antioxidant enzymes are instrumental in combating oxidative stress and there 
have been several of these that are involved in this counteracting mechanism. Manganese 
superoxide dismutase (MnSOD) is considered to be the most potent antioxidant against 
mitochondrial superoxide and takes part in conversion of superoxide ion to hydrogen 
peroxide. This antioxidative enzyme is known to play a protective role in endothelium and 
MnSOD
+/−
 mice has shown to have impaired vasodilation (Brown et al., 2007). In addition to 
that, mice with double knockout of apolipoprotein E along with MnSOD
+/− 
has been shown to 
have more mitochondrial DNA damage and as a consequence of that more severe 
atherosclerosis in comparison with same double knockout mice with MnSOD
+/+ 
, suggesting a 
vital role of MnSOD in maintaining the integrity of the endothelium (Ballinger et al., 2002). 
Catalase (CAT) along with other cytosolic peroxidases including glutaredoxin-2, 
peroxiredoxins-3and thioredoxin-2 is involved in maintaining the levels of hydrogen peroxide 
within normal limits. Glutathione peroxidase (GPx-1) is present in cytosol as well as 
mitochondria in the endothelial cells (Griendling and FitzGerald, 2003a). PGC-1 alpha 
regulates this antioxidative response and sends this signal as soon as oxidative stress in the 
form of hydrogen peroxide or as we proposed by exposure to 40% oxygen affects the 
endothelial cells. These antioxidative genes are up regulated and in turn promotes the 
translation of antioxidant proteins to protect the endothelium against these form of stress 
(Valle et al., 2005; Schulz et al., 2008). In several studies performed in mice and other 
experimental models it has been shown that loss of any of these antioxidant enzymes can 
make the endothelium vulnerable to various forms of stress leaving the endothelium prone to 
injury and progression to atherosclerosis with associated mitochondrial damage (Forgione et 
al., 2002a; Brown et al., 2007). On the other hand, overexpression of these antioxidant 
enzymes have shown to have a protective role against forms of vascular diseases (Widder et 
al., 2009).     
Uncoupling proteins (mainly UCP1 and UCP2) are localized inside inner mitochondrial 
membrane and play an important role in ROS production. The main function of UCPs is to 
promote the uncoupling of electron transport chain leading to reduction of mitochondrial 
membrane potential and ATP production (Duval et al., 2002; Mailloux and Harper, 2011). 
UCP1 is mainly expressed in brown fat, whereas UCP2 is the main endothelial isoform that 
regulates the mitochondrial membrane potential when they get activated by oxidative stress in 
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the form of superoxide ion and function to reduce the ROS (Echtay et al., 2002; Echtay et al., 
2003). There is strong epidemiological evidence that UCP2 is related to human 
cardiovascular pathologies. 866 G > A variant is linked with overexpression of UCP2 causing 
a reduction in cardiovascular disease occurrence, and a polymorphism at this locus has been 
shown to be linked with carotid artery atherosclerosis (Oberkofler et al., 2005; Cheurfa et al., 
2008). There has been no study so far that has examined the role of UCP2 in the regulation of 
endothelium-dependent vasodilation in humans, but several experimental studies have 
confirmed the importance of UCP2 in endothelial cells. UCP2 overexpression has been 
shown to decrease mitochondrial ROS and inhibit inflammatory response in cultured 
endothelial cells and improved vasodilation in rat aorta (Lee et al., 2005). UCP2 expression is 
regulated by PGC-1 alpha and AMPK mediated stress response which up regulates several 
other anti-ROS genes  (Valle et al., 2005). It has been reported that UCP2 null mice has 
shown to have impaired and defective vasodilation and increased incidence of atherosclerosis 
(Moukdar et al., 2009; Haines et al., 2010; Tian et al., 2012).  
Sirtuins are involved in longevity and regulation of metabolism with control over 
mitochondrial function mainly through PGC-1 alpha deacetylation, and have been studied 
recently as potential therapeutic targets (Abdellatif, 2012; Nogueiras et al., 2012). Sirtuins are 
NAD
+
 dependent deacetylases and mainly regulate gene expression through this activity. 
Mammals have seven sirtuins 1-7. SIRT 3,4 and 5 are mitochondrial, SIRT 1,6 and 7 are 
nuclear and SIRT 2 is cytoplasmic (Guarente, 2013). Sirtuin 1 (SIRT1) deacetylates PGC-1 
alpha affecting glucose and fatty acid metabolism along with the expression of several 
important mitochondrial genes (Vega et al., 2000; Rodgers et al., 2005; Gerhart-Hines et al., 
2007; Abdellatif, 2012). Sirtuin 3 (SIRT3) is a mitochondrial sirtuin which is specifically 
expressed in mitochondrial matrix and involved in regulation of mitochondrial function by 
deacetylating mitochondrial enzymes and importantly MnSOD, thereby decreasing 
superoxide levels in mitochondria and contributing towards antioxidative mechanisms 
(Onyango et al., 2002; Tao et al., 2010). Sirtuins have been known to play an important role 
in cardiovascular system. SIRT1 has been shown to prevent ischemic heart injury and 
hypertrophy of cardiac muscle and promotes angiogenesis by deacetylating and activating 
eNOS in the endothelium (Mattagajasingh et al., 2007; Potente et al., 2007).  It has been 
interesting to note that endothelial SIRT1 expression was found to be decreased in older 
subjects progressing towards aging and was correlated with reduced endothelium dependent 
vasodilation (Donato et al., 2011). SIRT1has been shown to regulate glucose metabolism by 
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controlling insulin secretion, gluconeogenesis and glycolysis (Abdellatif, 2012). It inhibits 
the transcription of uncoupling protein 2 (UCP2) thus regulating insulin secretion from 
pancreatic β -cells (Moynihan et al., 2005; Bordone et al., 2006).  SIRT3 is a recently 
identified downstream target of PGC-1 alpha and although no studies on humans or animal 
models have so far examined the role of SIRT3 activation on endothelial phenotype, there 
have been reports that up regulation of SIRT3 is found in vascular tissues where inhibition of 
transcription factor NFκB has shown to reduce inflammatory activity and improved 
mitochondrial biogenesis and life span (Hasegawa et al., 2012). In our study, we investigated 
for the mitochondrial SIRT, SIRT4 and found that it showed expression in ECFCs as well as 
HUVEC. ECFCs did not show a significant change in its expression when cells were grown 
in hyperoxia, whereas HUVEC showed a significant change in its expression when grown in 
hyperoxic conditions. This suggests that SIRT4 is activated in HUVEC and these cells 
undergo fatty acid oxidation in response to oxidative stress.  
In conclusion, the results obtained in this section showed that ECFCs and HUVEC behaved 
differently when exposed to oxidative stress and as shown by the gene expression analysis, 
different genes are activated in ECFCs as compared to HUVEC. As shown in figure 6.7, 
PGC-1 alpha showed a significant increase in expression in ECFCs when exposed to 
hyperoxia, whereas HUVEC did not show a significant change in expression. This suggests 
that HUVEC use a different pathway to combat stress conditions. PPARG has been shown to 
be co-activated by PGC-1 alpha in cardiomyocytes and here we show that in ECFCs there 
was a significant up regulation of PPARG in ECFCs that could be linked to the activation of 
PGC-1 alpha. HUVEC did not show a significant change and it could be due to no significant 
change in PGC-1 alpha expression in HUVEC grown in hyperoxia. PROX1 has been shown 
to be playing a role in the development of lymphatic endothelial cells and is known to be a 
negative modulator of ERR-α/PGC-1 alpha pathway. Our results showed that there was a 
down regulation of PROX1 gene in ECFCs grown in hyperoxia and this suggests that this 
could be related to an increase in PGC-1 alpha gene expression. HUVEC did not show a 
significant change in expression. PRDX5 is a mitochondrial gene that has been shown to be 
involved in reduction of hydrogen peroxide playing a role in antioxidative mechanisms. Our 
results did not show any significant change in expression of this gene in either ECFCs or 
HUVEC suggesting this gene is not activated in oxidative stress in these cells.  
As shown in figure 6.8, we investigated the genes involved in electron transport chain of 
oxidative phosphorylation. We checked for a gene from each step of this process and the 
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results showed that there was an up regulation of all these oxidative genes namely MT-ND3, 
MT-CYB, MT-CO1 and MT-ATP8 in ECFCs grown in hyperoxia. This suggests that this 
could be due to the activation of PGC-1 alpha causing an increase in mitochondrial 
biogenesis and oxidative phosphorylation. HUVEC showed an insignificant decrease in 
expression of all these genes suggesting they are not activating electron transport chain of 
oxidative phosphorylation. 
As shown in figure 6.9, we investigated several mitochondrial genes that are involved in fatty 
acid oxidation and gluconeogenesis in liver and muscle cells namely SIRT4 and PCK2. We 
found that there was significant up regulation of these genes in HUVEC that were exposed to 
hyperoxia suggesting that these cells activate metabolic pathways in stress conditions. ECFCs 
did not show a significant change in expression of these genes. Our results showed that there 
was an up regulation of PDK4 gene in HUVEC grown in hyperoxia. This gene is involved in 
glucose metabolism and did not show a significant change in ECFCs grown in hyperoxia. 
GPX4 gene is involved in protecting cells against oxidative stress by the reduction of 
hydrogen peroxide. We found a down regulation of this gene in ECFCs exposed to hyperoxia 
suggesting that may be other isoforms of GPX are activated in response to oxidative stress in 
ECFCs. HUVEC did not show a significant change in expression. 
As shown in figure 6.10, we investigated the effect of oxidative stress on several cell surface 
markers. This included vWF which as shown earlier showed high expression in HUVEC and 
is involved in platelet adhesion. High endothelial vWF expression suggests atherosclerotic 
progression and as seen in the figure HUVEC showed significant increase in its expression 
when grown in hyperoxic conditions. ECFCs did not show any significant change in 
expression. CD144 is involved in maintaining vascular permeability and shows decreased 
expression in early stages of angiogenesis which is in correlation with increased vascular 
permeability observed in angiogenesis (Corada et al., 2001). As shown in the figure, ECFCs 
showed a significant decrease in its expression when exposed to hyperoxia suggesting that 
these cells are angiogenic and exposure to oxidative stress leads to inflammatory and 
atherosclerotic environment promoting vascular repair. HUVEC did not show a significant 
change in the expression. CD31 mainly shows expression in endothelial cells and as shown in 
figure 6.10 there was a down regulation of its expression seen in ECFCs grown in hyperoxia. 
HUVEC did not show a significant change in expression of CD31. CD133 is mainly 
expressed early endothelial progenitors and hematopoietic stem cells. ECFCs showed 
insignificant change in its expression when grown in hyperoxia. HUVEC showed a 
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statistically significant change in CD133 expression and this could be further investigated as 
till now the function of CD133 is not known. 
As shown in figure 6.11, we investigated several genes that encode growth factors involved 
in promoting angiogenesis. These included VEGF A and C that are known to be involved in 
angiogenesis, mitosis of endothelial cells and their migration. The results showed that there 
was a significant increase in the expression of both VEGFA and C in ECFCs exposed to 
hyperoxia suggesting that these cells become angiogenic when exposed to oxidative stress. 
HUVEC did not show a significant change in expression of VEGFA but showed a significant 
decrease in VEGFC expression suggesting that these cells do not promote angiogenesis. 
FLT1 and KDR are VEGF receptors and both showed a significant decrease in expression in 
ECFCs grown in hyperoxia and it could be due to the filling of receptors as both VEGFA and 
C showed a significant increase in expression. HUVEC did not show any significant change 
in expression of either FLT1 or KDR. 
As shown in figure 6.12, we investigated some genes involved in proinflammatory response 
including  CXCL12 (SDF-1) that has been shown to be a proinflammatory genetic marker 
that is up regulated in atherosclerosis (Linsel-Nitschke et al., 2010). Our results showed that 
there was a significant increase in expression CXCL12 in ECFCs grown in hyperoxia 
suggesting that oxidative stress has led to an atherosclerotic environment. HUVEC did not 
show any significant change in expression. FGF2, PDGFRA and PDGFRB were the other 
genes that we investigated and the results showed that there was an up regulation of all these 
markers in ECFCs grown in hyperoxia suggesting that these cells promote angiogenesis when 
exposed to oxidative stress. HUVEC did not show any significant change in expression. 
As shown in figure 6.13, we investigated several pro angiogenic target genes involved in 
blood vessel formation. This included ANGPT1which encodes a growth factor involved in 
vascular development. ECFCs showed a significant increase in its expression when grown in 
hyperoxia suggesting that these cells are promoting angiogenesis. HUVEC did not show any 
significant change in expression. ANPT2 acts as an antagonist to ANGPT1 and shown in 
figure ECFCs showed a significant decrease in its expression when grown in hyperoxia. This 
suggests that the oxidative stress has led to an atherosclerotic environment and ECFCs are 
promoting vascular repair as shown by up regulation of ANGPT1 and down regulation of 
ANGPT2.  We also investigated for ACTA2 which is involved cell motility and forms the 
contractile machinery of the cell. ECFCs showed a significant increase in its expression and 
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HUVEC did show any significant change in expression. NOS3 is considered to be the main 
source of NO which is involved in smooth muscle regulation. It is also an inhibitor of 
electron transport chain at complex IV which is inversely related to oxygen levels. Our 
results showed that exposing cells to hyperoxia resulted in decreased NOS3 expression in 
ECFCs. HUVEC did not show a significant change in expression. 
As shown in figure 6.14, we checked for the gene expression of transforming growth factor 
alpha (TGF-α) and the results showed no significant change in expression in ECFCs grown in 
hyperoxia. HUVEC showed a significant increase in its expression when exposed to 
hyperoxia. This requires further investigation as TGF alpha is known to be up regulated in 
several cancers. TP53 showed an insignificant decrease in ECFCs grown in hyperoxia but 
showed a significant up regulation in HUVEC exposed to hyperoxia. This gene is up 
regulated in oxidative stress and DNA damage and inhibits angiogenesis. Up regulation in 
HUVEC again confirm that HUVEC do not take part in angiogenesis when exposed to 
oxidative stress. TEK encodes angiopoeitin 1 receptor. It is mainly expressed in endothelial 
cells but both ECFCs and HUVEC did not show any significant change in the expression of 
this gene when grown in hyperoxia. NRP2 is known to interact with VEGF and is known to 
play a role in cardiovascular development. Our results showed that both ECFCs and HUVEC 
showed insignificant change in expression of this gene.  
As shown in figure 6.15, we checked for the gene expression of IL-1alpha which encodes an 
inflammatory cytokine mainly produced by endothelial cells. ECFCs showed a significant 
decrease in its expression and HUVEC showed statistically significant increase in the 
expression of IL-1 alpha. This again suggests that both ECFCs and HUVEC behave 
differently when exposed to oxidative stress. KIT is a proto-oncogene expressed in 
hematopoietic stem cells and myeloid progenitors and our results showed that ECFCs 
expressed KIT but it was down regulated when these cells were exposed to oxidative stress. 
This suggests that may be ECFCs grown in hyperoxia were differentiated towards a more 
mature lineage and lost their stem cell characteristics. As expected, HUVEC did not show the 
expression of KIT gene and there was no significant change in expression when grown in 
hyperoxia. ABGC2 (CD338) has been shown to be suppressed during DNA methylation and 
ECFCs showed significant down regulation in ECFCs grown in hyperoxia. This could be the 
effect of oxidative stress on these cells. HUVEC did not show any significant change in 
expression. ITPKB gene is involved in immune cell functions and our results indicate that 
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there was a significant down regulation seen in ECFCs grown in hyperoxia. HUVEC did not 
show any significant change in expression. 
The results in this section clearly indicate that ECFCs and HUVEC behave differently when 
exposed to oxidative stress. ECFCs mainly promote angiogenesis and up regulate angiogenic 
markers suggesting that this stress environment resembles that of inflammatory and pro 
atherosclerotic conditions that promotes these cells to become angiogenic. HUVEC did not 
show up regulation of angiogenic markers suggesting that these cells do not become 
angiogenic on exposure to oxidative stress and do not take part in vascular repair. 
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Chapter 7. General discussion and limitations 
The research work carried out in the study includes successful isolation of mononuclear cells 
(day 0 MNCs) from umbilical cord blood also known as human umbilical cord mononuclear 
cells (HUCBC), based on ficoll based separation referred to as lymphoprep (n >15). These 
MNCs were used in subsequent experiments including qPCR and FACS analysis. They were 
used as a calibrator or reference sample for low density array and validation experiments. We 
have been able to isolate early EPCs or CACs both from peripheral blood and umbilical cord 
blood from more than 15 samples. Macrophages have been successfully isolated from both 
peripheral blood and cord blood n >10. Endothelial colony forming cells (ECFCs or late 
EPCs) have been successfully derived from umbilical cord blood (n >10) by differentiating 
cord blood mononuclear cells (day 0 MNCs) in an in vitro system. Mature endothelial cells 
(HUVEC) have been successfully isolated from over 15 human umbilical vein samples. We 
have successfully attempted the isolation of all the cell populations from the same donor. 
Cord blood mononuclear cells (day 0 MNCs), early EPCs (proangiogenic cells), ECFCs 
(endothelial colony forming cells) and macrophages all were derived from the umbilical cord 
blood of the donor whose umbilical cord was used for the isolation of mature endothelial 
cells (HUVEC) from the umbilical vein n=6. This has therefore provided us with a 
longitudinal comparison of the m RNA expression of hematopoietic stem cell and endothelial 
cell surface markers from mononuclear cells (day 0 MNCs) through to mature endothelial 
cells of the same donor for the first time. It was difficult to get an endothelial colony from 
each cord blood isolation and the success ratio was less than 50%. There could be different 
reasons to explain this low success rate and include  age of the donor, anaesthetics used in the 
delivery, circadian influences, (early morning births or night deliveries), nutritional 
influences, fasting, caffeine levels, vitamin D status; ethnicity of donor and many more. We 
have carried out the molecular profiling of these cells based on the expression of cell surface 
markers including hematopoietic stem cell, macrophage specific and endothelial markers. 
The results showed that early EPCs can easily be distinguished from ECFCs and mature 
endothelial cells (HUVEC). The difference found was statistically significant. Early EPCs 
were found to be related to monocyte-macrophage lineage and showed expression of 
macrophage specific markers. These findings have been confirmed at both RNA and protein 
level and were consistent with the previous findings as shown in earlier studies. Our results 
further showed that endothelial colony forming cells (ECFCs) derived from cord blood and 
mature endothelial cells (HUVEC) derived from the umbilical vein of the same donor can 
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also be distinguished on the basis of expression of cell surface markers namely CD144, 
CD105 and vWF, and the difference was found to be statistically significant (n=3-5). The 
difference was investigated further at protein level, and we performed direct 
immunofluorescence analysis with vWF antibody as it is an internal marker. The results 
confirmed that ECFCs and HUVEC derived from the same donor showed statistically 
significant difference (n=3) in terms of number of vWF positive cells when compared at same 
passages (P5 for both ECFCs and HUVEC and P15 for both ECFCs and HUVEC). FACS 
analysis was carried out for cell surface marker including CD144, CD146, CD14 and CD34. 
This way protein expression was confirmed and compared in MNCs to the expression in 
ECFCs and HUVEC based on the percentage of positive cells. This comparison at mRNA 
and protein level clearly distinguished early and late EPCs and we narrowed down our 
approach to use of late EPCs (ECFCs) which have been used for vascular repair and 
compared with mature endothelial cells. The early EPCs were distinguished from ECFCs at 
mRNA and protein level and addition of a functional assay like in vitro matrigel assay could 
have further validated the results.  
The second part of the study involved studying the behavior of these late EPCs (ECFCs) and 
mature endothelial cells (HUVEC) under hyperoxic conditions (40% O2) which has been 
shown to be a model of  mild oxidative stress. We proposed that oxidative stress would lead 
to telomere dysfunction and as a result of that a decrease in the expression of PGC-1α that 
has been shown recently in mice cells. We proposed that PGC-1 alpha being a key metabolic 
regulator would be involved in mitochondrial biogenesis and oxidative metabolism in 
endothelial cells, and a decrease in its expression would lead to an impairment of 
mitochondrial activity in these cells. This would in turn lead to a decrease in the angiogenic 
potential of these cells. We first studied the growth kinetics of these two cell types in 
conditions of normoxia and hyperoxia. The results showed that ECFCs were found to be 
much more resistant to stress conditions as compared to mature endothelial cells (HUVEC). 
They grew at a faster rate and were able to survive in oxidative stress conditions (40% O2) for 
longer period of times. The next step was to investigate the mRNA level expression of PGC-1 
alpha and its downstream targets in both ECFCs and HUVEC under normoxic and hyperoxic 
conditions. The results showed that instead of going down PGC-1 alpha levels increased in 
both ECFCs and HUVEC and also there was an increase in expression of its downstream 
targets G6- phosphatase and ERR-alpha which are known to be involved in glucose 
metabolism and angiogenesis respectively. The difference found was not statistically 
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significant (n=3-5). This suggested that oxidative stress has led to an increase in PGC-1 alpha 
expression and this in turn would activate antioxidative mechanisms by upregulting 
antioxidant genes. The next step was to confirm if oxidative stress has resulted in telomere 
dysfunction in these cells. The cells were grown till late passages in an in vitro system and 
were regularly split so that they are not overgrown. We first measured the telomerase activity 
in ECFCs and HUVEC using a sensitive TRAP assay no significant difference was found in 
either ECFCs or HUVEC as cells grew older and progressed towards aging. We expected to 
have a higher telomerase activity in these cells under conditions of oxidative stress, but again 
the difference found was not statistically significant. This was done to see if there was a 
concomitant increase in telomerase activity as a result of telomere shortening that could be 
the result of exposure of these endothelial cells to oxidative stress. In order to see the effect of 
aging on telomere length of ECFCs and HUVEC cells were grown till late passages (P2-P16) 
and as expected it was observed that telomere length was shortened as a result of growing 
these cells for long-term. The telomere length was measured using flow-FISH analysis which 
is an extremely sensitive and one of the most accurate methods of measuring the telomere 
lengths. This is a newly developed technique and we have used this assay to measure 
telomere lengths in these cells ECFCs and HUVEC for the first time as it has mostly been 
used to measure lengths of fresh blood cells mainly leukocytes. The results indicate that flow-
FISH can be used as a technique to measure telomere lengths of frozen cells and cells that are 
old and aged and have been cultured for a longer period of time in an in vitro system.  
The results obtained clearly showed that true endothelial progenitor cells have been isolated. 
They are easily distinguished from early EPCs on the basis of expression of macrophage 
marker CD14 and leukocyte marker CD45. This was important as the EPCs isolated and 
cultured were not a mixture of monocyte-macrophage lineage cells as these cells are resistant 
to oxidative stress and would have made it difficult to analyse the results. The results also 
indicated that ECFCs are better equipped to combat oxidative stress as compared to mature 
endothelial cells and could be grown for longer periods. On the basis of these findings we 
designed a low density gene array that could differentiate these cells further on the basis of 
expression of angiogenic or antioxidative markers or genes that are involved in DNA damage 
repair and electron transport chain complexes so that we can conclude on the basis of 
expression these gene if these two cell types behave differently under conditions of oxidative 
stress and perform different functions when exposed to stress. 
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The array results confirmed that these endothelial progenitors which are known to take part in 
vascular repair are much more resistant to stress environment as they home in to the sites of 
vascular injury and take part in vessel repair. There are several antioxidative genes that are up 
regulated in ECFCs when exposed to stress conditions and increased ROS production as 
evident from up regulation of genes involved in electron transport chain (ETC). ECFCs show 
increased mRNA expression of several genes that are involved in angiogenesis, including 
several growth factors that are important in initiating and maintaining new blood vessel 
formation. Similarly, in terms of metabolism ECFCs and HUVEC show differential gene 
expression analysis when compared with normoxic conditions. The overall results further 
validate our earlier findings that these are two different cell types that behave differently 
under conditions of oxidative stress. This is confirmed at both levels with functional assay 
including the growth kinetics and gene expression analysis at mRNA level using LDA and 
protein analysis using immunofluorescence and FACS. 
Limitations of the study: 
The main part of the research study was carried out in cells that were derived from the same 
donor. This provided a better comparison, so that the mononuclear cells (MNCs) from the 
same donor were differentiated in to early EPCs and macrophages by growing in different 
media but under same culture conditions. The ECFCs were isolated once a colony was 
observed which normally takes around 3 weeks to appear and in certain cases there was no 
colony formation from the culture so the results were excluded from the final analysis and 
only those cultures were included in which all cell types were isolated from the same donor. 
This reduced the sample size to around n=3-6 as all the mRNA gene expression level 
experiments were carried out as same donor analysis.  
Similarly, for a comparison between early and late passage cells for telomerase activity and 
telomere length measurements the cells were grown for a period of around 2-3 months in 
order to achieve significant results. This again was time consuming but was inevitable. 
In the earlier qPCR experiments, the data were normalized to one housekeeping gene (TBP) 
but later on for the LDA and array validation experiments this was compensated by data 
normalization to three housekeeping genes (18s RNA, TBP and HGPRT). 
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In direct immunofluorescence analysis with vWF (FITC) antibody, isotype matched control 
was used but that was not tagged with a fluorochrome. The negative control used was human 
IgG (normal) which was a good control, but a better control would have been IgG (FITC). 
There was lack of senescence assay to evaluate endothelial cell senescence and SA-β-gal 
staining or crystal violet staining could have been done to see if hyperoxia has led to vascular 
aging and senescence. 
The characterization of early and late EPCs was done at mRNA and protein level but the 
addition of in vitro tube forming assays and in vivo matrigel plug assays for evaluating in 
vivo angiogenesis would have differentiated both types of EPCs and would have added 
strength to the gene expression studies. 
 
8. Future work 
In my opinion, ECFCs are one of the best candidates for regenerative vascular therapy. At the 
first place, they have this capacity to differentiate in to endothelial cell progeny and secondly 
they are highly proliferative cells. Human ECFCs have been successfully injected into 
immunodeficient mice that took part in blood vessel formation (Au et al., 2008a; Melero-
Martin et al., 2008). More importantly, ECFCs have been shown to incorporate in damaged 
vasculature in vivo in various animal models including rabbit carotid artery injury, hind limb 
ischemia, murine retinal ischemia and porcine myocardial infarction (He et al., 2004b; Hur et 
al., 2004; Dubois et al., 2010; Medina et al., 2010a). This makes it more important to design 
and develop preclinical methods to study and evaluate the angiogenic and vasculogenic 
potential of these ECFCs. A detailed study of experimental models of revascularization can 
become a better tool to further define these cells and the pathological conditions that can be 
explored with this. Recent studies have shown the involvement of ECFCs in various 
pathological diseases including vonwillibrand disease and myeloproliferative disorders. 
ECFCs obtained from vonwillibrand disease patients have shown to have increased 
angiogenic activity (Starke et al., 2011).  There is a growing need for improving the methods 
to culture these ECFCs, as so far one of the limitations in autologous usage of these cells is 
their paucity in peripheral blood. More studies are required focusing on in vitro growth of 
these ECFCs and co-culturing them with other cell types mainly mesenchymal stem cells.  
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Endothelial senescence is an important feature of vascular aging and contributes to the 
vascular dysfunction, therefore, SA-β-gal and crystal violet staining can be performed to 
evaluate cellular senescence and proliferation in these cells under hyperoxia and that can be 
compared with mature endothelial cells. 
Western blot analysis for SIRT1 and PGC-1α, from early to late passages, specifically 
enhancement of SIRT1 phosphorylation has been shown in senescent cells. 
Measurement of telomere length under oxidative stress in ECFCs and HUVEC using flow-
FISH can be done to establish if there is a difference between these two cell types. 
Telomerase activity (TERT/TERC subunit) of ECFCs and HUVEC can be measured under 
oxidative stress. 
Another downstream organelle of PGC-1α, the mitochondria, can be assessed under oxidative 
stress by quantifying mitochondrial activity and measurement of ROS production. The 
measurement of extracellular ROS production in an in vitro culture of ECFCs can be 
achieved by the use of compounds such as luminol and lucigenin using techniques such as 
electron spin resonance spectroscopy and liquid scintillation counting. 
Cellular ATP production can be measured under conditions of oxidative stress by ELISA and 
mitochondrial membrane potential can be measured by flow cytometry using JC-1. 
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